CUA 2012 : Final Programme

GENERAL INFORMATION

Message from the Co-chairs of the Local Organizing Committee . . . . . . . 1Message from the CUA President . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2CUA Executive & Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6Continuing Professional Development . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Future CUA Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9Floor Plan of the Fairmont The Banff Springs Hotel . . . . . . . . . . . . . . . . 10Social Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11CUASF Fun Run/Walk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14Companions' Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Kids' Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

RENSEIGNEMENTS GÉNÉRAUX

Mot de bienvenue des co-présidents du Comité organisateur local . . . . 17Mot de bienvenue du Président de l'AUC . . . . . . . . . . . . . . . . . . . . . . . . 18Membres de l'Éxécutive et Comités de l'AUC . . . . . . . . . . . . . . . . . . . . . 19Renseignements généraux . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22Développement professionnel continu . . . . . . . . . . . . . . . . . . . . . . . . . . 24Congrès futurs de l'AUC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25Plan du Fairmont Banff Springs Hotel . . . . . . . . . . . . . . . . . . . . . . . . . . 26Programme Social . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27Course et marche amicale au profit de la FBAUC . . . . . . . . . . . . . . . . . . 30Programme des accompagnateurs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31Programme Jeunesse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

SPONSORS AND EXHIBITORS / COMMANDITAIRES ET EXPOSANTS

CUA Sponsors 2012 / Commanditaires de l’AUC 2012 . . . . . . . . . . . . . . 33CUASF 2012 Sponsors / Commanditaires de la FBAUC 2012 . . . . . . . . . 34Sponsored Sessions / Séances commanditées . . . . . . . . . . . . . . . . . . . 35Exhibit Information / Renseignements sur l'Exposition . . . . . . . . . . . . . . 36Exhibit Floor Plan / Plan de l'exposition . . . . . . . . . . . . . . . . . . . . . . . . . 37Exhibitor Listing / Liste des exposants . . . . . . . . . . . . . . . . . . . . . . . . . . 38Exhibit Directory / Répertoire des exposants . . . . . . . . . . . . . . . . . . . . . 39

TABLE OF CONTENTS / TABLE DES MATIÈRES

CUA 2012 BANFF 1

2 CUA 2012 BANFF

SCIENTIFIC PROGRAM / PROGRAMME SCIENTIFIQUE

Invited Faculty / Conférenciers invités . . . . . . . . . . . . . . . . . . . . . . . . . . 63CUA Prize Essays / Travaux primés de l'AUC . . . . . . . . . . . . . . . . . . . . . 64CUA and Affiliated Meetings / Réunions des sociétés affiliées et des comités de l'AUC . . . . . . . . . . . . 65Canadian Academy Of Urological Surgeons (CAUS) Banff 2012 . . . . . . . 68

DETAILED PROGRAM / PROGRAMME DÉTAILLÉS

Friday / Vendredi - June 22 juin . . . . . . . . . . . . . . . . . . . . . . 69Saturday / Samedi - June 23 juin . . . . . . . . . . . . . . . . . . . . . 70Sunday / Dimanche - June 24 juin . . . . . . . . . . . . . . . . . . . . 73Monday / Lundi - June 25 juin . . . . . . . . . . . . . . . . . . . . . . . 83Tuesday / Mardi - June 26 juin . . . . . . . . . . . . . . . . . . . . . . . 93Unmoderated Posters / Posters non-modérés . . . . . . . . . . . 127

Disclosures / Divulgations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xxx

INDEX

Invited Speakers Index / Index des conférenciers invités . . . . . . . . . . . . xxPresenters Index / Index des présentateurs . . . . . . . . . . . . . . . . . . . . . . xx

TABLE OF CONTENTS / TABLE DES MATIÈRES

CUA 2012 BANFF 1

Well it is finally upon us…CUA 2012. Welcome to Banff!

As we have been promising all year we have quite a meeting in store for you. The academic sessions are filled with many educational opportunities and the nightsare filled with things that will provide an opportunity for relaxation and enjoyment. I expect you may hear the mountains and meadows calling to you from the meeting,so be sure to answer, because it is a world of wonder out there. Come and learn lots,get involved, and catch up with old friends and new. But most of all HAVE FUN!

Marty & HowardCo-chairs, CUA 2012 Local Organizing Committee

MESSAGE FROM THE CO-CHAIRS OF THE LOCAL ORGANIZING COMMITTEE

2 CUA 2012 BANFF

Welcome to the 67th Annual Meeting CUA Meeting in beautiful Banff Alberta, the crown jewel of the Canadian Rocky’s.

Our host hotel is the historic Fairmont Banff Springs Hotel. It’s castle like designnestled along the banks of the Bow River is stunning and will provide the perfectvenue for our gathering

Drs. Jay Lee and Trevor Schuler and their Scientific Committee have planned the scientific portion of the meeting with a superb list of speakers and engaging educational fora.

Drs. Howard Evans and Marty Duffy, Chairs of the Local Organizing Committee (LOC),have worked hard to create an entertaining social program for us to enjoy after a“hard day at the office”.

As President of the CUA, it is my pleasure to welcome you to Banff and to wish you a wonderful and productive CUA Annual Meeting.

Michael ChetnerPresident, CUA

MESSAGE FROM THE CUA PRESIDENT

CUA 2012 BANFF 3

EXECUTIVE COMMITTEE

President Michael ChetnerPresident-Elect Joseph ChinPast-President Sender HerschornVice-President Peter AndersonTreasurer Anne Marie

HouleSecretary Denis LavoieSecretary-Elect Karen PsooyVP Education Gerald BrockMembers-at-LargeGreg Bailly

British ColumbiaJohn DushinskiPrairiesVladimir KurganskyOntarioChristopher MorashQuébecAndrew McNeillyAtlantic

ANNUAL MEETINGPLANNING COMMITTEE

Gerald Brock, ChairArmen AprikianFrançois BénardIan BrownSerge CarrierMichael ChetnerJoseph ChinMarty DuffyHoward EvansDianne HeritzJonathan IzawaAnil KapoorDenis LavoieJay LeeTiffany PizioliNadia PaceTrevor Schuler

AWARDS COMMITTEE

Peter Anderson, ChairJohn-Paul CapolicchioMichael ChetnerDenis LavoieJohn Mahoney

BY-LAWS COMMITTEE

Joseph Chin, ChairMichael ChetnerSender HerschornDenis Lavoie

CONTINUING PROFESSIONALDEVELOPMENT COMMITTEE

François Bénard, ChairKevin CarlsonMarc Anthony FischerScott MurrayThomas Whelan

ENDORSEMENT COMMITTEE

Sender Herschorn, ChairPeter AndersonGerald BrockMichael ChetnerJoseph ChinAnne-Marie HouleDenis Lavoie

CUA EXECUTIVE AND COMMITTEES

4 CUA 2012 BANFF

FINANCE COMMITTEE

Anne-Marie Houle, ChairGerald BrockIan BrownMichael ChetnerJoseph ChinMarty DuffyHoward EvansDenis LavoieRob Siemens

GUIDELINES COMMITTEE

Antonio Finelli, ChairGreg BaillyJohn DushinskiVladimir KurganskyChristopher MorashAndrew MacNeily

HISTORIAN

Vacant

INFORMATION TECHNOLOGY COMMITTEE

Christopher Nguan, ChairMike Leveridge

LOCAL ORGANIZING COMMITTEE

Marty Duffy and Howard Evans, Co-Chairs

NOMINATING COMMITTEE

Sender Herschorn, ChairPeter BlackJohn-Paul CapolicchioJoe ChinJay LeeDawn MacLellanYves Fradet

PATIENT INFORMATIONCOMMITTEE

Ben Chew, ChairNafisa DharamsiSamer HannaJay Lee Rob Siemens Troy Sitland Thomas Whelan

PRIZE ESSAY COMMITTEE

Jay Lee and Trevor Schuler, Co-ChairsArmen AprikianFrançois BénardJonathan IzawaAnil KapoorDawn MacLellanRyan Paterson


CUA 2012 BANFF 5

POST-GRADUATE TRAINING COMMITTEE

Joseph Chin, ChairTurki Al-EssawiGreg BaillyDiego BarrierasGerald BrockBill GourlayAnil KapoorWassim KassoufYves PonsotKeith RourkeRob SiemensRob StewartFrederic SoucyJim Watterson

SCIENTIFIC COMMITTEE


SOCIO-ECONOMIC COMMITTEE

Darrel Drachenberg, ChairLorne AaronScott BagnellJack BarkinGreg KozakAlan So

CUASF EXECUTIVE COMMITTEE

Michael Chetner, ChairAnne-Marie HouleDenis LavoieRicardo RendonRobert Siemens

CUASF ADMINISTRATIVECOMMITTEE

Robert Siemens, ChairAnne-Marie HouleJun KawakamiChris MorashPaul Whelan

CUASF SCIENTIFIC COUNCIL

Ricardo Rendon, ChairLuis GuerraWassim KassoufPatrick LukeRon MooreAlan So

CUA/ASTELLAS GRANT PROGRAM, SCIENTIFIC COUNCIL

Peter BlackLeslie CarrSerge CarrierJonathan IzawaJay LeeAndrew MacNeillyBobby Shayegan


6 CUA 2012 BANFF

VENUE

The Fairmont Banff Springs Hotel is the CUA Annual Meeting headquarter hotel and meeting venue. All scientific programactivities listed take place at the hotel, unless otherwise indicated.

The Fairmont Banff Springs Hotel 405 Spray AvenueBanff, AB, T1L 1J4(403) 762-6866

ADMISSION POLICIES

Name badges are required to gain access to all meeting functions. Tickets must be presented at social events and optional events.

Registration categories are indicated by thecolour band of the badge holder included inthe registration package. Tickets for socialand optional activities are included in thepackage.

Upon claiming your registration material,please ensure that all of the activities youpurchased have been included, and that yourbadge holder correctly corresponds to the legend below:Full Program (Scientific & Social) . . . . BlueScientific Program Only . . . . . . . . . . . RedIndustry . . . . . . . . . . . . . . . . . . . . . . GreenCompanion . . . . . . . . . . . . . . . . . . . YellowMedia . . . . . . . . . . . . . . . . . . . . . . . . Black

Full Program delegates and companionshave access to the Opening Brunch, FunNight, President’s Reception and Banquet.

Registered companions are entitled to dailybreakfast in the Companions’ Lounge.

Registered teens and children have accessto the Opening Brunch as well as the following activities and meals:

1 Activities, snacks and dinner on Sundayat the Kids'lounge (from 14:00)

2 Breakfast on Monday and Tuesday at the Kid's lounge

3 Activities, snacks and lunch, on Mondayand Tuesday at the Banff SpringsHotel Kids' Club (8:45 to 16:30)

4 Monday night dinner and activities at the Kids' lounge

Delegates registered for the Scientific Program Only may purchase tickets to the social optional events in the main registration area.

BOOK OF ABSTRACTS

The book of abstracts is included in the delegate bag. It is published by the CanadianUrological Association Journal (CUAJ).

CERTIFICATE OF ATTENDANCE

A personalized certificate of attendance willbe available via email after the event. Thiscertificate can be used to claim CPD credits.

EXHIBIT HALL

The Canadian Urological Association and theLocal Organizing Committee wish to expresstheir gratitude to the companies who havegiven their support to this meeting by takingpart in the Exhibit. We invite you to visit ourIndustry partners and gain valuable, up-to-date knowledge of their products and services. Please refer to theSponsors/Exhibitors section of this Program for a complete list and floor plan.

The Exhibit Hall is located in Van Horne BCand will be open during the following hours:Sunday, June 24. . . . . . . . . . . . 0800-1700Monday, June 25 . . . . . . . . . . . 0800-1530

GENERAL INFORMATION

CUA 2012 BANFF 7

INTERNET

Wireless Internet is available on the convention level of the hotel. Please verifythe housekeeping notes for the password.

LIABILITY

The CUA Banff 2012 Annual Meeting and theSecretariat IS Event Solutions cannot acceptresponsibility for any accidents, injuries orillness that may occur during the AnnualMeeting.

LOST AND FOUND

Found items should be handed in promptlyto staff at the Registration Desk.

PHOTOGRAPHS

Souvenir photographs taken at the AnnualMeeting will be posted online after theevent.

REGISTRATION DESK

The Registration Desk is located in the Hotel’s Convention Center, across the streetfrom the Hotel’s main building. Hours of operation are as follows:Saturday, June 23 . . . . . . . . . . 1100-1800Sunday, June 24. . . . . . . . . . . . 0630-1700Monday, June 25 . . . . . . . . . . . 0630-1800Tuesday, June 26 . . . . . . . . . . . 0630-1630

SPEAKER READY ROOM Room: NR Crump

All podium, moderated video, moderatedposter, educational fora and invited lecturepresenters with PowerPoint slides andvideos are asked to check in at the SpeakerReady Room, located in the NR Crump room,24 hours before their scheduled talk.Saturday, June 23 . . . . . . . . . . 1300-1800Sunday, June 24. . . . . . . . . . . . 0630-1730Monday, June 25 . . . . . . . . . . . 0630-1700Tuesday, June 26 . . . . . . . . . . . 0630-1600

A technician will be at the speaker’s disposal to assist with any audio-visualqueries. Speakers are asked to bring theirfiles on portable media devices (USB stick,flashcard, CD, etc.). The use of individual laptop computers is prohibited.

UNMODERATEDPOSTER DISPLAYS

Unmoderated e-poster stations will be available in the President’s Hall Foyer from 0930 on Sunday, June 24, until Tuesday,June 26, at 1400.

5-STAR POSTERS

The moderators of each Moderated Postersession will select 5-star posters. The 5-starposter presenters will be announced in the Closing Session at 1600 on Tuesday,June 26.

GENERAL INFORMATION

8 CUA 2012 BANFF

GOAL

The goal of this program is to provide a forum to identify and discuss "state-of- the-art" information concerning urologicaldiseases, including the prevention diagnosisand treatments, and to support basic science and clinical research by urologistsand other healthcare professionals.

LEARNING OBJECTIVES AND CANMEDS ROLE COMPETENCIES OBJECTIVES1 To Identify modifications in SWL treatment

protocols designed to maximize efficacy anddecrease morbidity

2 To Identify techniques to optimize preoperativeplanning and intraoperative implementation ofpercutaneous renal access

3 To discuss relevant epidemiologic studies onpatient safety

4 To review complications of medical manage-ment of kidney stone disease including medication interactions and side effects

5 To understand the methodology of analysis regarding the literature supported recommen-dations presented on urethral reconstruction

6 Gain an appreciation for the treatment ofpelvic fracture urethral distraction defects(PFUDD)

7 Discuss the diagnosis and treatment of common genital injuries

8 To better understand the Regional Differences in Practice Patterns and Outcomes after Radical Cystectomy

9 To identify long term side effects of testis cancer chemotherapy

10 To conduct a critical evaluation of the treatment strategies for superficial Bladder cancer

11 To better understand the Understand the morbidity of cystectomy and the alternativesto this this surgery in bladder cancer

12 To discuss rules and regulations regarding diet and supplement for men's health

13 To discuss clinical studies that support or doe not support recommending specific dietary changes and supplements to your patients

14 To understand how potential risks (side effects /complications) of medical andsurgical intervention for benign prostatic enlargement drives patient decision making

15 To gain an awareness of how to prevent the development of LUTS through lifestylemanagement

16 To learn that long term financial implicationsof medical and surgical management for benign prostatic enlargement does not play arole in current decision making

17 To understand the future health problems formen with infertility (higher risk of cancer etc.)

18 To Appreciate the technical aspects of current sling procedures that can be incorporated into surgical armamentarium

19 Formulate a rational and effective plan for the evaluation and treatment of elderly patients with OAB symptoms

20 To correlate clinical findings of VUR with itsgenetic basis

21 To review the evidence for and against the use of 5-ARI in prostate cancer prevention

22 To better understand Need for Intervention andSurvival in a Cohort of Patients on Active Sur-veillance (AS) for Low-risk Prostate Cancer

23 To Assess state-of-the-art management of CRCP, both in terms of guidelines as well as novel agents that will be available inthe near future

24 To assess the existing scientific support foruse of PDE5i's in BPH/LUTS

25 To discuss ethics in surgery and professional applications of these concepts

MoCert CREDITS

This program has been accredited by theCUA as a Section 1 Group Learning Activityas defined by the Maintenance of Certifica-tion Program of the Royal College of Physi-cians and Surgeons of Canada. For the spe-cialist, this activity qualifies for 1 credit perhour of participation as articulated in Section1 of the Maintenance of Certification Pro-gram of the Royal College of Physicians andSurgeons of Canada for a maximum of 22credits. Participants should only claim thecredit corresponding to their attendance.

CONTINUING PROFESSIONAL DEVELOPMENT

CUA 2012 BANFF 9

2013 JUNE 23-25

68th CUANiagara Falls, ONSheraton on the Falls Hotel

2014 JUNE 29-JULY 1

69th CUASt. John’s, NLDelta St. John’s Hotel & Conference Center

2015 JUNE 28-30

70th CUAOttawa, ONThe Westin Ottawa Hotel

2016 JUNE 26-28

71st CUAVancouver, BCThe Westin Bayshore Hotel

2017 JUNE 25-27

72nd CUAToronto, ONWestin Harbour Castle

Hote

FUTURE CUA MEETINGS

2015 OTTAWA

2013 NIAGARA FALLS

2014 ST. JOHN’S

2017 TORONTO

2016 VANCOUVER

10 CUA 2012 BANFF

FLOOR PLAN OF THE FAIRMONT BANFF SPRINGS HOTEL

CUA 2012 BANFF 11

SOCIAL PROGRAM GRID

TIME SOCIAL PROGRAMCOMPANION'S

PROGRAMKID'S PROGRAM

SUNDAY, JUNE 24

0800-1100Breakfast & Privateconcierge Services

Companion's Lounge: Oak room

1130-1230 Opening Brunch VanHorne BC

1400-2200Fun Activities, Dinner

& EntertainementKid's lounge: Norquay room

1900-2230FUN NIGHT Rockies & RailThe Fairmont Banff Springs Hotel

Riverview Lounge, Alberta & New-Brunswick rooms

MONDAY, JUNE 25

0700-0845 BreakfastKid's Lounge: Norquay room



0845-1630 Fun ActivitiesBanff Springs Kid's Club

1630-2300Fun Activities, Dinner

& EntertainementKid's lounge: Norquay room

1900-2300

President's Reception & BanquetFire & Ice Ball / Cocktail at 18:30The Fairmont Banff Springs Hotel

Alberta room

TUESDAY, JUNE 26

0630-0730CUASF Fun Run/Walk

Lobby The Fairmont Banff SpringsHotel

0700-0845 BreakfastKid's Lounge: Norquay room

0800-1100Breakfast & Privateconcierge Services:


0845-1630 Fun ActivitiesBanff Springs Kid's Club

12 CUA 2012 BANFF

All Social Events are by ticket admission/ registration badge only. Additional Social Event tickets are available forpurchase at the Registration Desk.

SUNDAY, JUNE 24

1130-1230 Opening BrunchExhibit Hall – Van Horne BC

Included for all registered participants

After a session-filled morning, CUA2012 officially kicks off with a meet-and-greet brunch in the Exhibit Hall.Catch up with friends you haven't seensince the last CUA meeting in Montrealand prepare yourself for 3 full days ofexciting scientific updates.

An assigned CUA concierge will be ableto make restaurant reservations for youduring the day on Sunday, June 24.

1900-2230 CUA Fun Night –Rockies & RailThe Fairmont Banff Springs HotelRiverview Lounge, Alberta & New Brunswick Room

Included for Full Program delegates and registered companions.Cost of additional ticket: $125, plus tax

All aboard! For the first-time in CUA history, the Fun Night will take place on Sundayevening, once the exhibit hall closes andthe sessions are over. You can expect afull house filled with CUA members andpartners in industry.

Eat, dance and relive the Golden Age ofthe Canadian Rockies at the grandioseBanff Springs Hotel, while the Livin’ inSwing band takes you back in time! This six-piece band will have attendeeson their feet and dancing the nightaway. Playing Swing music as well as a variety of other tunes, this ensemble’slively flair also has an extensiverepertoire of sing along melodies.

Let yourself be taken back in time in afashionable décor and savor the manyflavors of the Great-Canadian-West withBuffalo mini-burgers, beef tenderloinpies, cedar planked salmon… just toname a few. The night is sure to makeCUA Fun Night history as we have amultitude of surprises planned whichwill keep you on the edge of your seat!

SOCIAL PROGRAM

CUA 2012 BANFF 13

M O N D AY , J U N E 2 5

1900-2300 President's Reception and Banquet – The CUA Fire & Ice Ball(Cocktails at 1830)Alberta & New Brunswick room The Fairmont Banff Springs Hotel

Included for Full Program delegates and registered companions.Cost of additional ticket: $150, plus tax

The LOC Chairs have planned an eventthat will incorporate some of nature’selements; let your senses take over and expect the unexpected!

Join us to salute and to pay tribute to the Local Organizing Chairs, the Scientific Committee and CUA Presi-dent, Dr. Michael Chetner, and to wel-come the new CUA 2013 cast who are enthusiastically preparing to greet you in Niagara Falls!

This year’s President’s Reception andBanquet featuring a tantalizing 4-coursedinner will bring you to a world whereFire & Ice create an explosion of dazzling beauty and refinement.

Gentlemen, pull out your tuxedos and ladies, wear THAT stunning dressthat will surprise and astonish! With themeeting drawing to an end, take sometime to reflect on the previous 3 days ofsessions and start looking forward tonext year's meeting.

SOCIAL PROGRAM

14 CUA 2012 BANFF

T U E S D AY , J U N E 2 6

0630-0730 CUASF Charity Run/Walk

*A fee of $50 applies (non-taxable)

CUA will hold a Charity Run & Walk to support the Canadian Urological Association Scholarship Fund (CUASF)for a third time. The objective of theCUASF is to provide financial support forurologic research to be conducted inCanada.

Participants can choose a 2km walk or a 5km fun-run through the streets of Banff. Strike up some friendly competition as we band together tosupport this important CUA initiative!

All proceeds will be donated to theCUASF.

CUASF FUN RUN/WALK

CUA 2012 BANFF 15

Registration for companions includes:1 Welcome gift2 Access to Exhibit Hall3 Daily breakfast in

Companions’ Lounge4 Exhibit Opening and Opening

Brunch (Sunday)5 Fun Night (Sunday) 6 President’s Reception & Banquet

(Monday)

COMPANIONS’ LOUNGE

Companions are invited to use theLounge at the Fairmont Banff SpringsHotel to meet friends and enjoy the daily continental breakfast. The Loungewill be open Sunday, Monday & Tuesday,from 08:00-11:00. A private CUAconcierge is posted in the Loungeduring opening hours on Sunday,Monday and Tuesday to assist you inmaking your stay a memorable one.

Information & Tour booking will be available on-site.

If you are interested in visiting the Fairmont Banff Springs Hotelinternationally acclaimed Willow Stream Spa, please contact the hotel Concierge desk, located in the hotel lobby.

TUESDAY, JUNE 26

0630-0730 CUASF Charity Run/Walk

*A fee of $50 applies (non-taxable) See page 18 for details.

COMPANIONS’ PROGRAM

16 CUA 2012 BANFF

KIDS’ LOUNGE

The 2012 CUA Kids’ Program will be extra-special as the Fairmont BanffSprings features a fantastic kids’ clubwhich will be open for CUA’s kids onMonday and Tuesday.

The Banff Springs Kid’s Club, the hotel’sactivity hub for kids, will be the star attraction for our young guests betweenthe ages of 6 and 16 years old. TheKid’s Club offers supervised activitieswith enthusiastic camp leaders. Everyday is a new adventure and each childreceives a complimentary Banff SpringsKids Club ball cap, nametag, and lan-yard on their first visit.

Outdoor activities will focus on learningnew wilderness skills like navigation,emergency survival and cooking over anopen fire. Inside, the centre has plentyof great games, crafts and activities tokeep kids entertained.

Registration for Kids’ Program includes:1 Welcome kit

2 Activities from 14:00 on Sunday atthe Kids’ Lounge

3 Breakfast in Kids’ Lounge on Monday& Tuesday

4 Bowling & pizza on Sunday evening

5 Dinner and movie night on Monday

6 Two full-days of activities on Mondayand Tuesday indoor and outdoor atthe hotel’s Kids’ Club

7 Lunch and snacks on Monday andTuesday at the hotel’s Kids’ Club.

KIDS’ PROGRAM HOURS

Sunday, June 24Fun Activities in Kids’ Lounge......................14:00-23:00

Monday, June 25 Breakfast in Kids’ Lounge ..07:00-08:45 Activities at the Banff Springs Kids’ Club..............08:45-16:30 Dinner & Entertainment......16:30-23:00

Tuesday, June 26 Breakfast in Kids’ Lounge ..07:00-08:45 Activities at the Banff Springs Kids’ Club..............08:45-16:30

BABYSITTING

A babysitting service is available starting from 16$/hour for up to 2 children, and a minimum of 4 hours. The caregiver can look after the childrenin the room or take them to different hotel activities (swimming, bowling,movie theatre, etc...)

Advance reservations are required andmay be made through the concierge at [email protected] 24-hour cancellation policy applies to all reservations.

KIDS’ PROGRAM

CUA 2012 BANFF 17

Finalement, nous y voilà...AUC 2012. Bienvenue à Banff!

Comme nous vous l'avions promis toute l'année, nous avons tout un congrès enréserve pour vous, en passant par un programme scientifique des plus complet,vous permettant de saisir de nombreuses opportunités éducatives de qualités,jusqu'à nos célèbres soirées remplies comme toujours de moments mémorables!

Comme nous sommes certains que vous entendrez l'appel des montagnesrocheuses et de leurs prés verdoyants, nous vous suggérons fortement d'être prêt à y répondre sans faute, car vous êtes entourés d'un monde de merveilles à découvrir...ou à redécouvrir. Apprenez, découvrez, épaulez et revoyez d'anciennesconnaissances ainsi qu'à vous en faire de nouvelles. Mais surtout, surtout, amusez-vous!'

Marty & HowardCo présidents, CUA 2012 Comité scientifique

MOT DE BIENVENUE DES CO-PRÉSIDENTS DU COMITÉ ORGANISATEUR LOCAL

18 CUA 2012 BANFF

Bienvenue au 67e Congrès annuel de l’AUC, dans la magnifique ville de Banff en Alberta, le joyau des Rocheuses canadiennes.

Notre hôte est l’hôtel historique Fairmont Banff Springs. Son architecture semblableà celle d’un château blotti sur la rive de la rivière Bow est tout à fait impressionnanteet offre un lieu de réunion idéal.

Les docteurs Jay Lee et Trevor Schuler, ainsi que les membres de leur comité scientifique ont préparé dans le cadre de ce congrès un programme scientifique quiprévoit une liste impressionnante de conférenciers ainsi qu’un forum éducatif desplus intéressants.

Les docteurs Howard Evans et Marty Duffy, présidents du comité local d’organisationont déployé tous les efforts pour mettre sur pied un programme social à notre intention, après ‘une dure journée de travail’.

En qualité de président de l’AUC, je suis très heureux de vous souhaiter la bienvenue à Banff et je vous souhaite un magnifique congrès annuel de l’AUC, intéressant et fructueux.

Michael ChetnerPrésident, CUA

MOT DE BIENVENUE DU PRÉSIDENT DE L'AUC

CUA 2012 BANFF 19

COMITÉ EXÉCUTIF

Président Michael ChetnerPrésident désigné Joseph ChinPrésident Sortant Sender HerschornVice-président Peter AndersonTrésorier Anne Marie HouleSecrétaire Denis LavoieSecrétaire désigné Karen PsooyVice-président Education

Gerald BrockExécutifs extraordinaires

Greg BaillyColombie-BritanniqueJohn DushinskiLes PrairiesVladimir KurganskyOntarioChristopher MorashQuébecAndrew McNellyAtlantic

COMITÉ DE PLANIFICATIONDU CONGRÈS ANNUEL

Gerald Brock, ChairArmen AprikianFrançois BénardIan BrownSerge CarrierMichael ChetnerJoseph ChinMarty DuffyHoward EvansDianne HeritzJonathan IzawaAnil KapoorDenis LavoieJay LeeTiffany PizioliNadia PaceTrevor Schuler

COMITÉ DES PRIX

Peter Anderson, ChairJohn-Paul CapolicchioMichael ChetnerDenis LavoieJohn Mahoney

COMITÉ DES RÉGLEMENTS

Joseph Chin, ChairMichael ChetnerSender HerschornDenis Lavoie

COMITÉ DU DÉVELOPPEMENTPROFESSIONNEL CONTINU

François Bénard, ChairKevin CarlsonMarc Anthony FischerScott MurrayThomas Whelan

COMITÉ DES APPROBATIONS

Sender Herschorn, ChairPeter AndersonGerald BrockMichael ChetnerJoseph ChinAnne-Marie HouleDenis Lavoie

MEMBRES DE L'EXÉCUTIF ET COMITÉS DE L'AUC

20 CUA 2012 BANFF

COMITÉ DES DES FINANCES

Anne-Marie Houle, ChairGerald BrockIan BrownMichael ChetnerJoseph ChinMarty DuffyHoward EvansDenis LavoieRob Siemens

COMITÉ DES GUIDES DE PRATIQUE

Antonio Finelli, ChairGreg BaillyJohn DushinskiVladimir KurganskyChristopher MorashAndrew MacNeily

HISTORIEN

Vacant

COMITÉ DES TECHNOLOGIES DE L'INFORMATION

Christopher Nguan, ChairMike Leveridge

COMITÉ ORGANISATEUR LOCAL

Marty Duffy and Howard Evans, Co-Chairs

COMITÉ DES NOMINATIONS

Sender Herschorn, ChairPeter BlackJohn-Paul CapolicchioJoe ChinJay LeeDawn MacLellanYves Fradet

COMITÉ INFO-PATIENTS

Ben Chew, ChairNafisa DharamsiSamer HannaJay Lee Rob Siemens Troy Sitland Thomas Whelan

COMITÉ DES TRAVAUX PRIMÉS



CUA 2012 BANFF 21

COMITÉ DES AFFAIRES DES RÉSIDENTS

Joseph Chin, ChairTurki Al-EssawiGreg BaillyDiego BarrierasGerald BrockBill GourlayAnil KapoorWassim KassoufYves PonsotKeith RourkeRob SiemensRob StewartFrederic SoucyJim Watterson

COMITÉ SCIENTIFIQUE


COMITÉ SOCIOÉCONOMIQUE

Darrel Drachenberg, ChairLorne AaronScott BagnellJack BarkinGreg KozakAlan So

COMITÉ EXÉCUTIF DE LA FBAUC

Michael Chetner, ChairAnne-Marie HouleDenis LavoieRicardo RendonRobert Siemens

CONSEIL D'ADMINISTRATION DE LA FBAUC

Robert Siemens, ChairAnne-Marie HouleJun KawakamiChris MorashPaul Whelan

CONSEIL SCIENTIFIQUE DE LA FBAUC

Ricardo Rendon, ChairLuis GuerraWassim KassoufPatrick LukeRon MooreAlan So

CUA/ASTELLAS GRANT PROGRAM, SCIENTIFIC COUNCIL

Peter BlackLeslie CarrSerge CarrierJonathan IzawaJay LeeAndrew MacNeillyBobby Shayegan


22 CUA 2012 BANFF

SIÈGE DU CONGRÈS

Toutes les activités du programme scien-tifique ci-dessous s'y déroulent, à moinsd'indication contraire.

Le Fairmont Banff Springs Hotel 405, Spray AvenueBanff, AB, TIL 2J4(403) 762-6866

ADMISSION

Vous devez porter votre badge pour entrerau congrès. Vous devez présenter votre billetlors des événements sociaux facultatifs.La catégorie d'inscriptions se reconnaît à lacouleur de la cocarde comprise dans votretrousse d'inscription. Les billets pour lesévénement sociaux et facultatifs se retrou-vent également dans la trousse.

Lorsque vous récupérerez vore matérield'inscription, veuillez vous assurer quetoutes les activités que vous avez payéessont bien indiquées et que la couleur devotre badge correspond à la légende ci-dessous:Programme complet (scientifique et social) : . . . . . . . . . .BleuProgramme scientifiqueseulement : . . . . . . . . . . . . . . . . . . .RougeIndustrie : . . . . . . . . . . . . . . . . . . . .VertAccompagnateur : . . . . . . . . . . . . .JauneMédia : . . . . . . . . . . . . . . . . . . . . . .Noir

Les délégués inscrits à tout le programmeainsi que les accompagnateurs ont accès auBrunch de bienvenue, à la Grande soirée del'AUC et au Banquet présidentiel.

Les accompagnateurs inscrits peuventégalement prendre leur petit-déjeuner dans le Salon des accompagnateurs.

Les enfants et adolescents inscrits ont accès au Brunch de bienvenue ainsi qu'aux activités et repas suivants:1 Activités, collation et souper le dimanche

au salon des enfants (à partir de 14h00)2 Petits déjeuners les lundi et mardi au

salon des enfants3 Activités, collations et lunch, les lundis

et mardis au Club des enfants du BanffSprings Hotel (8h45 à 16h30)

4 Souper et activités du lundi soir au salondes enfants

Les délégués inscrits au Programme scientifique seulement peuvent acheter des billets pour les activités sociales et facultatives au bureau d'inscription.

RECUEIL DES RÉSUMÉS

Un recueil des résumés présentés, publiépar le Journal de l'Association des urologuesdu Canada, est inclus dans la trousse desdélégués.

ATTESTATION DE PARTICIPATION

Une attestation de participation vous seraenvoyée par courriel, sur demande, aprèsl'événement. Cette attestation peut être utilisée pour réclamer vos crédits de DPC.

HALL D'EXPOSITION

L'Association des urologues du Canada etleur Comité organisateur désirent exprimerleur reconnaissance envers les compagniesqui ont prêté leur soutien à ce congrès enparticipant à cette exposition. Nous vous in-vitons à rendre visite à nos partenaires del'industrie et à vous mettre à jour sur leursproduits et services. Veuillez vous reporter à la section Commanditaires/ Exposants dece livret pour consulter le répertoire des exposants et la plan de la salle.


CUA 2012 BANFF 23

L'exposition se tiendra dans le salon Van Horne BC selon l'horaire suivant:Dimanche 24 juin: . . . . . . . . . . 0800-1700Lundi 25 juin: . . . . . . . . . . . . . 0800-1530

INTERNET

Un accès internet sans fil gratuit estdisponible au niveau de Centre des Congrèsde l'hôtel. Le mot de passe sera affiché surles écrans LCD.

RESPONSABILITÉ

Le congrès annuel de l'AUC 2012 et le Secrétariat du congrès IS Event Solutions ne peuvent être tenus responsables de tout accident, blessure ou maladie survenant lors du congrès.

OBJETS TROUVÉS

Les objets trouvés devraient être remis rapidement au personnel du bureau d'inscription.

PHOTOGRAPHIES

Des photographies seront prises lors duCongrès annuel et seront affichées en ligne après l'événement.

BUREAU D'INSCRIPTION

Le bureau d'inscription est situé dans lefoyer President's Hall, au centre des congrèsde l'hôtel. Ce dernier est situé en face dubâtiment principal de l'hôtel. Les heuresd'ouverture sont les suivantes:Samedi 23 juin: . . . . . . . . . . . . 1100-1800Dimanche 24 juin: . . . . . . . . . . 0630-1700Lundi 25 juin: . . . . . . . . . . . . . 0630-1800Mardi 26 juin: . . . . . . . . . . . . . 0630-1630

SALON DES CONFÉRENCIERS Salle : NR Crump

Tous les présentateurs ayant diapositives ou vidéos doivent se présenter au Salon des conférenciers, 24 heures avant leurprésentation.Samedi 23 juin . . . . . . . . . . . . . 1300-1800Dimanche 24 juin. . . . . . . . . . . 0630-1730Lundi 25 juin . . . . . . . . . . . . . . 0630-1700Mardi 26 juin . . . . . . . . . . . . . . 0630-1600

Les conférenciers sont priés d'apporter leurs fichiers sur des dispositifs courant de stockage de données (clés USB, cartemémoire flash, DC, etc.) au moins 24 heuresavant leur présentation. Un technicien serasur place en tout temps. L'utilisation duportable personnel est interdit.

POSTERS NON-MODÉRÉS

Cette année, les posters non-modérésseront présentés en format ''en-ligne''.Plusieurs stations seront disponibles dans le foyer du Président's Hall à partir du 0930,dimanche le 24 juin , jusqu'au mardi 26 juin 1400.

POSTERS 5-ÉTOILES

Les modérateurs des séances de postersmodérés sélectionneront des affiches 5-étoiles de chaque session de postersmodérés. Les présentateurs d'affiches 5-étoiles seront annoncés dans la séance de clôture à 1600, mardi le 26 juin.


24 CUA 2012 BANFF

OBJECTIFL’objectif du programme est d’offrir un forumd’échange qui permette d’identifier les toutesdernières données sur les maladies urologiques,notamment sur le diagnostic et les traitementspréventifs, et de s’assurer que les urologues etd’autres professionnels de la santé soutiennent la science fondamentale et la recherche clinique.

OBJECTIFS D’APPRENTISSAGEET RÔLE, COMPÉTENCES ET OBJECTIFS DE CanMEDS1 Identifier les modifications aux protocoles de

traitement par ondes de choc SWL afin d’enmaximiser l’efficacité et de réduire la morbidité.

2 Déterminer les techniques destinées à optimiser la planification préopératoire et l’accès rénal percutané peropératoire.

3 Discuter des études épidémiologiques pertinentes sur la sécurité des patients.

4 Examiner les complications liées à la gestiondes services médicaux dans le cas d’unenéphrite, notamment les interactions médicamenteuses et les effets secondaires.

5 Comprendre la méthodologie utilisée pouranalyser la documentation étayant les recommandations de reconstruction urétrale.

6 Mieux comprendre le traitement des problèmes de distraction urétrale d’une fracture du bassin (PFUDD).

7 Discuter du diagnostic et du traitement des lésions génitales communes.

8 Mieux comprendre les différences régionalesdans les modèles de pratiques et les résultatsd’une cystectomie radicale.

9 Déterminer les effets secondaires à long termede la chimiothérapie pour le cancer des testicules.

10 Effectuer une évaluation critique des stratégiesde traitement du cancer superficiel de la vessie.

11Mieux comprendre la morbidité relative à lacystectomie et les solutions autres que lachirurgie pour traiter le cancer de la vessie.

12 Discuter des règles et modes d’application concernant l’alimentation et les supplémentspour les hommes.

13 Discuter des études cliniques qui appuient ounon les recommandations prônant un changement de régime alimentaire et l’apportde suppléments pour les patients.

14 Comprendre comment les risques éventuels(effets secondaires ou complications) d’une in-tervention médicale et chirurgicale dans le cas

d’une hypertrophie bénigne de la prostate permettent au patient de prendre une décision.

15Mieux connaître la façon de prévenir les infections des voies urinaires inférieures (LUTS)par une meilleure hygiène de vie.

16 Savoir que les incidences financières à longterme de la gestion médicale et chirurgicaled’une hypertrophie bénigne de la prostate n’influent pas sur les décisions actuelles.

17 Comprendre les problèmes de santé dont souffriront plus tard les hommes présentantune infertilité (risque plus élevé de cancer, etc.)

18 Connaître les aspects techniques des interven-tions de fronde qui peuvent être intégrées àl’arsenal chirurgical.

19 Élaborer un plan rationnel et efficace d’évaluation et de traitement des patients plusâgés souffrant de symptômes associés à unehyperactivité vésicale (OAB).

20 Corréler les résultats cliniques du reflux urinaire vésico-urétéral (VUR) à sa base génétique.

21 Examiner les preuves en faveur ou contre l’utilisation du 5-ARI pour prévenir le cancer de la prostate.

22Mieux comprendre la nécessité d’intervenir et la survie d’une cohorte de patients sous surveillance active en raison d’un cancer de la prostate à faible risque

23 Évaluer la gestion de pointe du CRCP, à la foisses lignes directrices et les nouveaux agentsqui seront disponibles dans un avenir rapproché.

24 Évaluer le soutien scientifique actuel concernant l’utilisation des PDE5i dans le casde BPH/LUTS.

25Discuter de questions d’éthique dans l’application de ces concepts au niveau chirurgical et professionnel.

CRÉDITS DE FORMATION MDCCe programme est agréé par la AUC en tantqu'activité de la section 1 (formation collective)comme défini par le Programme de maintien du certificat du Collège royal des médecins etchirurgiens du Canada. Pour un médecin spécial-iste, cette activité lui permet d'obtenir un (1) créditpar heure de participation, comme défini dans lasection 1 du Programme de maintien du certificatdu Collège royal des médecins et chirurgiens duCanada, jusqu'à un maximum de 22 crédits. Lesparticipants ne doivent réclamer que les créditscorrespondant à leur participation.

DÉVELOPPEMENT PROFESSIONNEL CONTINU

CUA 2012 BANFF 25

2013 23-25 JUIN

68e AUCNiagara Falls, ONHôtel Sheraton on the Falls

2014 29 JUIN-1 JUILLET

69e AUCSt. John’s, NLDelta St. John’s Hotel & Conference Center

2015 28-30 JUIN

70e AUCOttawa, ONThe Westin Ottawa Hotel

2016 26-28 JUIN

71e AUCVancouver, BCThe Westin Bayshore Hotel

2017 25-27 JUIN

72e AUCToronto, ONWestin Harbour Castle Hotel

CONGRÈS FUTURS DE L'AUC

2015 OTTAWA

2013 NIAGARA FALLS

2014 ST. JOHN’S

2017 TORONTO

2016 VANCOUVER

26 CUA 2012 BANFF

PLAN DU FAIRMONT BANFF SPRINGS HOTEL

CUA 2012 BANFF 27

GRILLE DU PROGRAMME SOCIAL

HEURESPROGRAMME

SOCIALPROGRAMME DES

ACCOMPAGNATEURSPROGRAMME

JEUNESSE

SUNDAY, JUNE 24

0800-1100

Petit-déjeuner & Service de concierge privé

Salon des Accompagnateur : Oak room

1130-1230 Brunch de bienvenue VanHorne BC

1400-2200

Activités, souper et divertissementSalon des enfants :

Norquay room

1900-2230GRANDE SOIRÉE DE L'AUC Rails & Rocheuses

Le Fairmont Banff Springs HotelRiverview Lounge, Alberta & New-Brunswick rooms

MONDAY, JUNE 25

0700-0845Petit-DéjeunerSalon des enfants :

Norquay room



0845-1630Activités

Club des Jeunes du Banff Springs Hotel

1630-2300

Activités amusantes,souper et divertissement

Salon des enfants : Norquay room

1900-2300Réception et banquet du Président

Le bal de feu et de glace / RÉCEPTION À 18:30Le Fairmont Banff Springs Hotel / Alberta room

TUESDAY, JUNE 26

0630-0730Course et marche amicale

au profit de la FBAUCLobby The Fairmont Banff Springs Hotel

0700-0845Petit-DéjeunerSalon des enfants :

Norquay room

0800-1100

Petit-déjeuner & Service de concierge privé

Salon des Accompagnateur : Oak room

0845-1630Activités

Club des Jeunes du Banff Springs Hotel

28 CUA 2012 BANFF

Tous les événements sociaux sont parbillet d'admission / badge d'inscriptionseulement. Les billets additionnels pourdes événements sociaux sontdisponibles à l'achat au bureau d'enregistrement.

DIMANCHE 24 JUIN

1130-1230 Brunch de bienvenueSalle d'exposition - VanHorne BC

Compris dans toutes les catégoriesd'inscription

Partez du bon pied en démarrant l'AUC2012 par un brunch de bienvenue dansle hall d'exposition. Retrouvez les amisque vous n'avez pas vu depuis ledernier congrès annuel de l'AUC àMontréal, et préparez-vous à passertrois jours stimulants remplis desdernières nouveautés scientifiques.

1900-2230 Grande Soirée de l'AUC –Rails & RocheusesLe Fairmont Banff Springs HotelRiverview Lounge, salles Alberta & New Brunswick

Inclus dans le programme complet etpour les accompagnateurs inscrits.Prix d'un billet supplémentaire : $125, plus tax

Tout le monde à bord! Pour la première fois dans l’histoire descongrès de l’AUC, la Grande Soirée auralieu le dimanche soir, après la fermeturedu hall des exposants et la fin des

séances scientifiques. Nous prévoyonsque de nombreux membres de l'AUC etpartenaires de l'industrie répondront ànotre invitation.

Festoyez, dansez et revivez l’âge d’or des Rocheuses canadiennes augrandiose hôtel Banff Springs, pendantque l’orchestre Livin’ in Swing vous fera revivre le bon vieux temps! Cetensemble de six musiciens vous feradanser toute la nuit sur des airs deswing et une variété d’autres styles. Ce groupe plein d’entrain comporteaussi à son répertoire un grand nombrede mélodies que vous vous plairez àfredonner.

Laissez-nous vous faire voyager dans le temps dans un décor branché etdélectez-vous des nombreuses saveursde l’Ouest canadien : miniburgers debison, pâtés de filet de bœuf, saumongrillé sur planche de cèdre… pour n’ennommer que quelques-unes. La soiréepassera sans aucun doute à l'histoiredes congrès de l'AUC, car nous avonsen réserve de nombreuses surprises qui vous tiendront en haleine!

PROGRAMME SOCIAL

CUA 2012 BANFF 29

L U N D I L E 2 5 J U I N

1900-2300 Réception et Banquet du Président - Le bal de feu et de glace de l'AUC(Réception à 1830)Salles Alberta & New BrunswickLe Fairmont Banff Springs Hotel

Inclus dans le programme complet et les accompagnateurs inscrits.Prix du billet supplémentaire :$150, plus tax

Les présidents du Comité d'organisationlocale ont mis sur pied un événementqui intégrera certains éléments de lanature. Laissez-vous emporter par vossens et attendez-vous à… l’inattendu!

Joignez-vous à nous pour saluer etféliciter les présidents du Comité d'or-ganisation locale, les membres duComité scientifique et le président del'AUC, le Dr Michael Chetner, et pour ac-cueillir la nouvelle équipe du congrès de2013 qui se prépare avec enthousiasmeà vous recevoir à Niagara Falls!

Cette année, le cocktail et le banquetprésidentiel, qui comprendront un suc-culent repas à quatre services, vousmèneront dans un univers où l’union dufeu et de la glace engendrera une ex-plosion dont la beauté et le raffinementvous éblouiront.

Messieurs, sortez votre smoking! Mesdames, l'heure est arrivée d'acheterLA fabuleuse robe qui vous rendraépoustouflante!

PROGRAMME SOCIAL

30 CUA 2012 BANFF

M A R D I 2 6 J U I N

0630-0730 Course et marche amicale au profit de la FBAUC

*Un tarif de 50$ s'applique(non-taxable)

Levez-vous tôt pour une matinéesportive! Pour la troisième fois l'AUCtiendra une Marche/Course bénéficeafin de soutenir la Fondation desbourses de l'Association des urologuesdu Canada (FBAUC). Son objectif est de fournir un soutien financier pour effectuer de la recherche en urologie auCanada. Les participants peuvent choisird'effectuer une marche de 2 km ou unecourse amusante de 5 km dans les rues de Banff. Lancez la concurrenceamicale dans ce rassemblement poursoutenir cette importante initiative de l'AUC.

Tous les dons seront remis à la FBAUC.

COURSE ET MARCHE AMICALE AU PROFIT DE LA FBAUC

CUA 2012 BANFF 31

Les frais d'inscription pour les accompagnateurs incluent :1 un cadeau de bienvenue2 accès à la salle d'exposition3 petit déjeuner continental le matin

dans le salon des accompagnateurs4 brunch d'ouverture (dimanche)5 la Grande Soirée de l'AUC

(dimanche)6 ainsi que le banquet présidentiel

(lundi)

SALON DES ACCOMPAGNATEURSSalle: Oak

Les accompagnateurs sont invités àutiliser le Salon des accompagnateurssitué au Fairmont Banff Springs pourrencontrer des amis ainsi que pourprofiter du petit déjeuner continentalquotidien.

Le Salon des accompagnateurs seraouvert les dimanche, lundi et mardi de8h à 11h.

Un concierge privé de l'AUC seraprésent pendant ces heures pour vousaider à rendre votre séjour mémorable.

Information et réservation de visitesguidées seront disponibles sur place.

Si vous êtes intéressés à visiter leréputé Willow Stream Spa de l'hôtelFairmont Banff Springs, nous vousinvitons à communiquer avec leconcierge de l'hôtel situé au Lobbyprincipal.

MARDI 26 JUIN

0630-0730 Course et marche amicale au profit de la FBAUC

*Un tarif de 50$ s'applique(non-taxable)Voir page XXX pour détails

PROGRAMME DES ACCOMPAGNATEURS

32 CUA 2012 BANFF

KIDS’ LOUNGE

Le programme pour les jeunes du congrès2012 sera très spécial! En effet, le FairmontBanff Springs comprend un superbe clubdes jeunes qui sera à la disposition des en-fants des membres de l’AUC lundi et mardi.

Le Club des jeunes du Banff Springs, laplaque tournante des activités pour les jeunes à l’hôtel, sera la principale attractionpour nos jeunes de 6 à 16 ans. Le club offredes activités supervisées par des moniteursenthousiastes. Chaque jour sera une nou-velle aventure et les jeunes recevront tousgratuitement une casquette du Club des jeunes du Banff Springs et un porte-nomavec cordon lors de leur première visite.

Les activités extérieures permettront aux enfants d’acquérir de nouvelles habiletéscomme la navigation, la survie en cas d’urgence et la préparation de nourriture sur feu ouvert. Les activités intérieures comprennent une grande variété de jeux,d’activités de bricolage et d'autres activitéspour amuser les jeunes.

L’inscription au programme pour les jeunes comprend : 1 Trousse de bienvenue

2 Activités à partir de 14 h dimanche auSalon des jeunes (Kids’ Lounge)

3 Petit-déjeuner au Salon des jeunes lundi et mardi

4 Partie de quilles et pizza dimanche soir

5 Souper et cinéma lundi soir

6 Deux journées complètes d'activitéslundi et mardi à l’intérieur et à l’extérieurau Club des jeunes de l’hôtel

7 Dîner et collation lundi et mardi au Club des jeunes de l’hôtel

KIDS’ PROGRAM HOURS

Dimanche 24 juinActivités et jeux au Salon des jeunes ...............................14:00-23:00

Le Salon des jeunes comprend des jeux surconsole Wii, des activités de bricolage et desjeux de société. Les activités sont superviséespendant les heures d'ouverture du salon.

Lundi 25 JuinDéjeuner au Salon des jeunes ..07:00-08:45

Activités au Club des jeunes du Banff Springs Hotel ..............08:45-16:30

Souper & divertissement...........16:30-23:00

Mardi 26 JuinDéjeuner au Salon des jeunes...07:00-08:45

Activités au Club des jeunes du Banff Spring.........................08:45-16:30

SERVICE DE GARDE

Les services de gardiennage sont offerts à16 $ l'heure pour un maximum de deux en-fants et pour un minimum de quatre heuresde service. Les gardiens peuvent s'occuperdes enfants dans la chambre ou ils peuventparticiper à différentes activités à l'intérieurde l'hôtel (baignade, quilles, cinéma, etc.) Le service de concierge peut se charger d'effectuer les réservations. La politiqued'annulation pour ce service est de 24heures.

À noter que les prix sont sujets à changement sans préavis. Veuillez réserver ce service en communi-quant avec le concierge de l'hôtel [email protected] ou en vousprésentant au bureau du concierge situé au Lobby principal de l'hôtel.

PROGRAMME JEUNESSE

CUA 2012 BANFF 33

The members of the CUA would like to acknowledge the following organizations for their generous support for the 67th Annual Meeting.

Their outstanding commitment to urological research and education willbenefit urologists and their patients throughout Canada.

Les membres de l’AUC tiennent à souligner le soutien généreux des laboratoires suivants pour la tenue du 67e Congrès annuel. Leur

implication dans le recherche et la formation en urologie fait bénéficier les urologues et leurs patients dans tout le Canada.

PATRON SPONSORS OF THE CUA /GRANDS COMMANDITAIRES DE L’AUC

CUA 2012 ANNUAL MEETING SPONSORS / COMMANDITAIRES DU CONGRÈS ANNUEL 2012

Platinum Pfizer

GoldAllerganGSK

Janssen OrthoSanofi

Silver Bayer Healthcare

CUA SPONSORS 2012 / COMMANDITAIRES DE L’AUC 2012

34 CUA 2012 BANFF

The Canadian Urological Association Scholarship Foundation (CUASF) was estab-lished in 1973 as a means of supporting promising Canadian urological researchers.

More recently, scholarship funding has also been provided to support internationalurologists to visit Canadian centres of excellence. These scholarships would not be

possible without the generous financial support of our Industry sponsors.

The Canadian Urological Association Scholarship Foundation (CUASF) recognizes thefollowing companies for their generous contributions in 2012 and their ongoing

commitment to fostering high-caliber urological research in Canada.

FRENCH TO COME

PATRON SPONSORS OF THE CUA /GRANDS COMMANDITAIRES DE L’AUC

CUASF 2012 SPONSORS / COMMANDITAIRES DE LA FBAUC 2012

CUA 2012 BANFF 35

PLENARY SESSIONS AND EDUCATIONAL FORA ARE SUPPORTED BY OUR CUA PATRON SPONSORS

PODIUM SESSIONS ARE SUPPORTED BY OUR CUA 2012 ANNUAL MEETING PLATINUM SPONSOR

MODERATED POSTER SESSIONS ARE SUPPORTED BY OUR CUA 2012 ANNUAL MEETING GOLD SPONSORS

AllerganGSK

Janssen Orthosanofi

UNMODERATED POSTER SESSIONS ARE SUPPORTED BY OUR CUA 2012 ANNUAL MEETING SILVER SPONSOR

Bayer Healthcare

SPONSORED SESSIONS / SÉANCES COMMANDITÉES

36 CUA 2012 BANFF

EXHIBIT HALL LOCATION

The Exhibit Hall is located in the VanHorne Ballroom BC.

EXHIBIT HOURS

Registered exhibitors with badges, will be allowed into the Exhibit Hall 30 minutes before opening and 30minutes after closing.

Sunday, June 24 . . . . . . . . . 0800-1700Monday, June 25 . . . . . . . . 0800-1530

ACTIVITIES IN THE EXHIBIT HALL

Sunday, June 240940-1010Networking Break

1130-1230Opening Brunch

1430-1500Networking BreakLaparoscopic Skills Competition

Monday, June 250950-1020Networking Break

1150-1300Luncheon

1450-1520Networking Break

EXHIBIT INFORMATION / RENSEIGNEMENTS SUR L’EXPOSITION

CUA 2012 BANFF 37

EXHIBIT FLOOR PLAN / PLAN DE L’EXPOSITION

38 CUA 2012 BANFF

Abbott Laboratories. . . . . . . . . . . . . . 24/25

Allergan Canada . . . . . . . . . . . . . . . . 27/32

American Urological Association (AUA) . 63

American Urological Association (AUA) - Western Section . . . Table in Foyer

Amgen Canada Inc. . . . . . . . . . . . . . . 16/17

AMS Canada Inc. . . . . . . . . . . . . . . . . 10/11

AMT Electrosurgery . . . . . . . . . . . . . . . . 15

Anexxa Medical Technologies Inc. . . . . . . 3

Astellas Pharma Canada Inc. . . . . . . 22/23

Baxter . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

BK Medical . . . . . . . . . . . . . . . . . . . . . . . 42

Bladder Cancer Canada. . . . Table in Foyer

Boston Scientific . . . . . . . . . . . . . . . . 53/54

Bracco Imaging Canada . . . . . . . . . . . . . 34

Calmoseptine, Inc. . . . . . . . . Table in Foyer

CAN-AM HIFU . . . . . . . . . . . . . . . . . . . . . 38

Canadian Urological Association (CUA) - Corporate Office . . . . . . . . . . . . . 62

Canadian Urological Association Journal (CUAJ) . . . . . . . . . . . . . . . . . . . . 62

Clarion Medical Technologies . . . . . . 44/45

Coloplast Canada . . . . . . . . . . . . . . . 30/31

Cook Medical . . . . . . . . . . . . . . . . . . . . 1/2

Covidien . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Ethicon . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Ethicon Endo-Surgery . . . . . . . . . . . . . . 20

European Association of Urology (EAU) . 65

Ferring Pharmaceuticals . . . . . . . . . . . . 41

Fibertech Canada E.R. Inc. . . . . . . . . . . . 26

GlaxoSmithKline . . . . . . . . . . . . . 40/51/52

Jac-Cell Medic Inc. . . . . . . . . . . . . . . . . . 35

Janssen Inc. . . . . . . . . . . . . . . . . . . . . . . 18

Karl Storz Endoscopy Canada . . . . . . 46/47

Kidney Cancer Canada . . . . Table in Foyer

Laborie Medical . . . . . . . . . . . . . . . . . . . 33

Eli Lilly Canada . . . . . . . . . . . . . . . . . 59/60

mdBriefCase Inc. . . . . . . . . . Table in Foyer

Mediwatch USA Inc. . . . . . . . . . . . . . . . . 36

Medtronic of Canada Ltd. . . . . . . . . . . . . 12

Minogue Medical Inc. . . . . . . . . . . . . . . . 39

Novartis Oncology . . . . . . . . . . . . . . . . . 29

Olympus Canada Inc. . . . . . . . . . . . . . . 8/9

Paladin Labs Inc. . . . . . . . . . . . . . . . . . . 4/5

Pendopharm. . . . . . . . . . . . . . . . . . . . . . . 7

Pfizer Canada Inc. . . . . . . . . . . . . . . . 48/50

Prostate Cancer Canada . . . Table in Foyer

Red Leaf Medical Inc. . . . . . . . . . . . . . . . 21

Royal College of Physicians and Surgeons of Canada . . . Table in Foyer

sanofi aventis Canada Inc. . . . . . . . . . . . 43

Science and Medicine . . . . . Table in Foyer

SeeMore Imaging Canada . . . . . . . . . . . 66

Siemens . . . . . . . . . . . . . . . . . . . . . . . . . 13

Société internationale d'urologie (SIU). . 64

Thunder Bay Regional Health Sciences Centre . . . . . . . . . . . . . . . . . . . 67

Triton Pharma Inc . . . . . . . . . . . . . . . . . . 37

Ultramed Inc. . . . . . . . . . . . . . . . . . . . . . 61

Urology Nurses of Canada . . Table in Foyer

Vantage Endoscopy . . . . . . . . . . . . . . . . 14

Warnex Medical Laboratories. . . . . . . . . 56

Watson Pharma Company. . . . . . . . . 57/58

EXHIBITOR LISTING / LISTE DES EXPOSANTS

CUA 2012 BANFF 39

ABBOTT LABORATORIESBooths / Kiosques : 24/25

Contact: Mike Tweedle8401 TransCanada HighwaySt. Laurent, QC, H4S 1Z1T: 705-733-4466F: 514-832-7837E: [email protected]

AndroGel once daily provides provenefficacy for hypogonadism in a clearodourless gel.

Lupron has been helping prostate cancerpatients for 25 years.

AndroGel est un gel transparent et sansodeur qui a l'efficacité éprouvée dansl'hypogonadisme.

Lupron aide les patients atteint de cancerde la prostate depuis 25 ans.

ALLERGAN CANADABooths / Kiosques : 27/32

Contact: Geoff Morrow500-85 Enterprise Blvd.Markham, ON, L6G 0B5T: 905-940-7020F: 416-606-7198E: [email protected]

Allergan Canada is proud to bring Botox(onabotulinumtoxin A) to CanadianUrologists for treatment of UrinaryIncontinence due to Neurogenic DetrusorOveractivity resulting from Neurogenicbladder associated with Multiple Sclerosisor subcervical spinal cord injury in adultswho had an inadequate response to or areintolerant of anticholinergic medications.

AMERICAN UROLOGICAL ASSOCIATION (AUA)

Booth / Kiosque : 63Contact: Caroline Williams1000 Corporate Boulevard Linthicum, MD 21090, United States T: 410-689-3933F: 410-689-3939E: [email protected]

The American Urological Association(AUA), founded in 1902, works towardsthe advancement of urologic patient care,and ensures that its more than 18,000members are current on the latestresearch and practices in urology. TheAUA also pursues its mission of fosteringthe highest standards of urologic care byproviding a wide range of services—including publications, research, theAnnual Meeting, continuing medicaleducation (CME) and the formulation of health policy.

L'Association Urologique Américaine(AUA), fondée en 1902, travaille versl'avancement de soin patient urologique et s’assure que ses plus de 18,000membres sont actuels sur la dernièrerecherche et les pratiques dans l'urologie.L'AUA poursuit aussi sa missiond'encourager les plus hautes normes desoin urologique en fournissant une largegamme de services en incluant despublications, la recherche, la RéunionAnnuelle, l'éducation médicale continuée(CME) et la formulation de politique de santé.

EXHIBIT DIRECTORY / RÉPERTOIRE DES EXPOSANTS

40 CUA 2012 BANFF

AMERICAN UROLOGICAL ASSOCIATION (AUA) - WESTERN SECTION

Table in FoyerContact: Teri Sechler1950 Old Tustin AvenueSanta Ana, CA, 92705, United StatesT: 714-550-9155F: 714-550-9234E: [email protected]

The Western Section AUA invites CUAmembers to join us October 7-12, 2012on the Big Island of Hawaii at themagnificent Hilton Waikoloa Hotel for our88th Annual Meeting. Please visit ourwebsite at 2012meeting.wsaua.org for all the meeting details. We look forward to seeing you in Hawaii!

AMGEN CANADA INC.Booths / Kiosques : 16/17

Contact: James Austin6775 Financial Dr., Suite 100Mississauga, ON, L5N 0A4 T: 905-285-3215F: 905-286-4991 E: [email protected]

Amgen, a biotechnology pioneer,discovers, develops and deliversinnovative human therapeutics. Ourmedicines have helped millions of patientsin the fight against cancer, kidney disease,rheumatoid arthritis and other seriousillnesses. With a deep and broad pipelineof potential new medicines, we continueto advance science to serve patients.

Amgen, pionnière en biotechnologie,découvre, élabore et distribue destraitements novateurs. Nos médicamentsont aidé des millions des patients àcombattre le cancer, les maladies rénales,la polyarthrite rhumatoïde et d’autresmaladies graves. Nantis d’une solidepépinière de produits, nous faisonsavancer la science pour toujours mieuxservir les patients.

AMS CANADA INC.Booths / Kiosques : 10/11

Contact: Lisa Cribb381 Elmira Rd. N., Unit #1 Guelph, ON, N1K 1H3T: 800-265-2611F: 519-821-1356E: [email protected]

AMS is the world's leading independentcompany focused on developing,manufacturing and marketing medicaldevices that restore pelvic health. We arecommitted to serving the increasingnumber of people coping with male andfemale incontinence, erectile dysfunction,prostate disorders, urethral strictures andother pelvic floor conditions includingprolapse.

AMS est le leader mondial pour lafabrication et la mise en marché dedispositifs médicaux pour la SantéPelvienne. Nous sommes engagés à servir le nombre croissant d'hommes etde femmes aux prises avec l'incontinence, la dysfonction érectile, les troubles de laprostate, le rétrécissement urétral et lesautres conditions pelviennes incluant lesprolapsus.


CUA 2012 BANFF 41

AMT ELECTROSURGERYBooth / Kiosque : 15

20 Steckle Place, Unit 16Kitchener, ON, N2E 2C3T: 888-803-6799 F: 519-895-2299E: [email protected]

AMT Electrosurgery is focused onproviding our customers with surgicalsolutions that optimize patient safety,clinical performance, ease of use and cost effectiveness in Electrosurgery,Laparoscopic Surgery and Cyrotherapy.

AMT Electrosurgery vise à fournir à nosclients des solutions chirurgicales quioptimisent la sécurité des patients, laperformance clinique, la facilitéd'utilisation et la rentabilité dans lesdomaines d’électrochirurgie, la chirurgielaparoscopique et cyrothérapierapy.

ANEXXA MEDICAL TECHNOLOGIES INC.

Booth / Kiosque : 3Contact: Jean Catafard13-5115 Harvester Rd. Burlington, ON, L7L 0A3T: 905-333-1557F: 888-234-2063E: [email protected]

Anexxa will showcase new andunprecedented technology at CUA. Zephyr,an Artificial Urinary Sphincter, the firstnew artificial sphincter in over a decade.Axogen creates the first nerve Allograft to the medical area. Medafor, a uniquehemostatic agent and Cuda, a powerfulcordless headlight. Come by and seewhat’s new!

Anexxa présentera des nouvellestechnologies sans précédent à l'AUC.Zephyr, un sphincter urinaire artificiel, le premier depuis plus d’une décennie.AxoGen, une matrice pour la régénerationdes nerfs. Arista, un agent hémostatiqueunique à base de plante et finalementCuda, une lampe frontale sans corde. On vous attends!

ASTELLAS PHARMA CANADA INC.

Booths / Kiosques : 22/23Contact: Neil Sarin675 Cochrane Drive, Suite 500, West TowerMarkham, ON, L3R 0B8T: 905-470-7990F: 905-470-2538E: [email protected]

Astellas Pharma Canada Inc. is committedto improving patient’s lives. In addition tooffering Vesicare (solifenacin succinate)for overactive bladder Astellas continuesits commitment to add value throughresearch, innovation and partnerships in Urology and Uro-Oncology.

Astellas Pharma Canada, Inc. estdéterminée à améliorer la vie despatients. En plus de proposer Vesicare(succinate de solifénacine) pour letraitement de l'hyperactivité vésicale,Astellas poursuit son engagement àapporter une valeur ajoutée par le biais de la recherche, de l'innovation et departenariats tant en urologie qu'en uro-oncologie.


42 CUA 2012 BANFF

BAXTERBooth / Kiosque : 28

Contact: Gordon Blair7125 Mississauga RoadMississauga, ON, L5N 0C2T: 905-369-6791F: 905-659-5398E: [email protected]

In Canada, Baxter BioSurgery provides acomplete portfolio of surgical sealants thatcan be used to achieve haemostasis, sealor glue tissues, and support woundhealing. The core products of theBioSurgery portfolio are TISSEEL VH/SD,Floseal and CoSeal. They have a longtrack record in terms of safety andefficacy and are supported by anextensive number of clinical studies.

La division Biochirurgie de Baxter offre une gamme complète d’agenthémostatique, de scellant, de colle avecdes facteurs de croissance qui favorisentla guérison des plaies. Les principauxproduits de biochirurgie sont Floseal,Tisseel et Coseal. Nous possédons toutesles données cliniques prouvant leurefficacité et la sécurité des produits.

BAYER, INC.Booth / Kiosque : 55

Contact: Jodi Benowski77 Belfield RoadToronto, ON, M9W 1G6T: 416-240-5338F: 416-248-8072E: [email protected]

As an inventor company, Bayer createsinnovative products, breakthroughtreatments and healthier alternatives toimprove the quality of life for people,

animals and communities. We put scienceto work in the vital areas of health,nutrition and high-tech materials, bothacross Canada and around the world.

Entreprise innovatrice, Bayer crée des produits novateurs, traitementsrévolutionnaires et solutions saines quiaméliorent la vie des gens, des animauxet des communautés. Nous mettons lascience à profit dans les domaines de lasanté, de la nutrition et des matériaux dehaute technologie, au Canada et ailleursdans le monde.

BK MEDICALBooth / Kiosque : 42

Contact: Natacha Treskin8 Centennial DrivePeabody, MA 01960, United StatesT: 978-326-1300F: 978-326-1399E: [email protected]

BK Medical’s Flex Focus 800 Ultrasoundsystem featuring Quantum Technology istailored for the Surgical Suite. It islightweight and mobile and supports awide range of sterilizable transducers, and can be battery powered.

Le système à ultrasons, Flex Focus 800 deBK médical est doté de la technologiequantique et est adapté pour les Suites deChirurgie. Il est léger, mobile et prend encharge un large éventail de sondesstérilisables. Le système est autonome,alimenté par piles.


CUA 2012 BANFF 43

BLADDER CANCER CANADATable in Foyer

Contact: David Guttman21 Jason CrescentGeorgetown, ON, L7G 4Z3T: 416-571-0016E: [email protected]

Bladder Cancer Canada is a nationalorganization helping bladder cancerpatients and their support team. We raise awareness of bladder cancer andadvocate for allocation of government and private funds directed to medicalresearch. Canadian Bladder CancerNetwork is our research group comprisedof leading Canadian researchers.

Cancer de la Vessie Canada est unorganisme national qui aide les patientsatteints de cancer de la vessie et leuréquipe de soutien. Nous voulonssensibiliser les gens pour le cancer de la vessie et plaidons pour l’allocation des fonds publics et privés destinés à la recherche médicale dans ce domaine.Réseau canadien du cancer de la vessieest notre groupe de recherche composéd’éminents chercheurs canadiens.

BOSTON SCIENTIFICBooths / Kiosques : 53/54

Contact: Kristin Muzylo500-5060 Spectrum Way Mississauga, ON, L4W 5N5 T: 905-696-1947F: 905-696-1893E: [email protected]

Boston Scientific’s mission: improvequality of patient care and productivity ofhealth care delivery through developmentand advocacy of less-invasive medical

devices and procedures. This isaccomplished through continuingrefinement of existing products andprocedures and investigation anddevelopment of technologies that reduce risk, trauma, cost, procedure time & aftercare.

Notre mission : l’amélioration de la qualitédes soins cliniques et de la productivité del’administration des soins par promotionet la défense de méthodes et dispositifsmédicaux moins invasifs. Tout cela estatteint grâce à un perfectionnementcontinuel des produits et méthodesexistants par recherche ainsi q’te parla de nouvelles technologies réduisant lesrisques, traumatismes, coûts, durée desinterventions et nécessité de suivi.

BRACCO IMAGING CANADABooth / Kiosque : 34

Contact: Hélène Potier 11065 boul. Louis-H. LafontaineAnjou, QC, H1J 2Z4 T: 800-465-5820, x 5308F: 514-807-9499E: [email protected]

BRACCO IMAGING Canada, located inMontréal, is a member of the BraccoGroup, a global leader in the manufactureof contrast agents, medical devices, andinjection systems dedicated to medicalimaging.

At the CUA, BRACCO IMAGING Canada will be presenting Invivo’s DynaCAD forProstate, a digital imaging system with a comprehensive set of advancevisualization tools for performing real-time


44 CUA 2012 BANFF

image analysis of prostate MRI studiesand precise biopsy.

BRACCO IMAGING Canada, situé àMontréal, est un membre du GroupeBracco, un leader mondial dans lafabrication d’agents de contraste,instruments médicaux, et systèmesd’injection dédiés à l’imagerie médicale.Au congrès de l’AUC, BRACCO IMAGINGCanada présentera DynaCAD pourProstate, un système d’imagerie digitalecomportant des outils avancés devisualisation, permettant une analyse entemps réel des images par RésonanceMagnétique de la prostate et des biopsiesprécises.

CALMOSEPTINE, INC.Table in Foyer

Contact: Kim Saeng16602 Burke LaneHuntington Beach, CA 92647, United StatesT: 714-840-3405F: 714-840-9810E: [email protected]

Calmoseptine Inc. promotes CalmoseptineOintment for the prevention and treatmentof skin irritations from moisture such asurinary and fecal incontinence. It is alsoeffective for irritations from perspiration,wound drainage, fecal & vaginal fistulasand feeding tube site leakage.Calmoseptine Ointment temporarilyrelieves discomfort and itching. Free samples at our booth!

Un onguent multifonctionnel agissantcomme barrière contre l'humidité et quiprotège, apaise et aide à favoriser la

guérison de l’irritation de la peau contre:l'urine, la diarrhée, la transpiration, lesécoulements venant d'une fistule ou d'une plaie, l'érythème fessier, les petitesbrulûres, les coupures, les écorchures, les gerçures et les démangeaisons.

CAN-AM HIFUBooth / Kiosque : 38

Contact: Mary Duggan123 Edward St., Suite 1401Toronto, ON, M5G 1E2T: 647-654-1499F: 905-873-1811E: [email protected]

High Intensity Focused Ultrasound (HIFU)is a minimally invasive, outpatientprocedure for men diagnosed withlocalized prostate cancer. The Sonablate®

500 is the medical device that deliversHIFU to the tissues affected by prostatedisease.

CANADIAN UROLOGICAL ASSOCIATION (CUA) - CORPORATE OFFICE

Booth / Kiosque : 62Contact: Raffaella Leroux185 Dorval, Suite 401Dorval, QC, H9S 5J9T: 514-395-0376F: 514-395-1664E: [email protected]

The Canadian Urological Associationrepresents and provides a voice for allCanadian urologists and fostersdedications of all members of theprofession toward ensuring the highestpossible standard of urologic care ofCanadians.


CUA 2012 BANFF 45

La vocation de l’AUC est de représentertous les urologues canadiens et incitertous les membres de la profession à seconsacrer à l’optimisation de la qualitédes soins urologiques offerts au Canada.

CANADIAN UROLOGICAL ASSOCIATION JOURNAL (CUAJ)

Booth / Kiosque : 62Contact: Joesphine Sciortino185 Dorval, Suite 401Dorval, QC, H9S 5J9T: 514-395-0376F: 514-395-1664E: [email protected]

The Canadian Urological AssociationJournal (CUAJ) is a peer reviewed,indexed journal, specializing in originalscientific publications and selected reviewarticles from Canadian and internationalauthors.

Le Journal de L’Association des urologuesdu Canada (JAUC) est une revuescientifique indexé dans le domaine del’urologie et chaque manuscrit est soumisà un examen critique par les pairs. LeJAUC publie aussi des rapports de cas,des articles de résidents et des articlesd’opinion.

CLARION MEDICAL TECHNOLOGIES

Booths / Kiosques : 44/45125 Fleming Drive Cambridge, ON, N1T 2B8 T: 800-668-5236F: 866-320-7287

Clarion Medical Technologies is one of the leading specialty medical technologyproviders in Canada, offering the mostsophisticated and high performancetechnologies including 100W holmium and980 diode laser systems, and specialtyinstruments for urologic and endourologicapplications. The Clarion product portfoliogives office-based physicians andhospitals the ability to treat a wide rangeof conditions.

Clarion Medical Technologies Inc. est le chef de file des fournisseurs detechnologie médicale spécialisée auCanada, offrant les technologies les plusperfectionnées au rendement supérieur,notamment les appareils Laser Holmiumde 100 watts et Diode 980. Le portefeuillede produits spécialisés de Clarion offreaux praticiens en cabinet ainsi qu'auxhôpitaux la capacité de traiter une vastegamme de conditions médicales enUrologie.


46 CUA 2012 BANFF

COLOPLAST CANADABooths / Kiosques : 30/31

Contact: Joe Holloway3300 Ridgeway Drive, Unit #12Mississauga, ON, L5L 5Z9 T: 416-578-0427F: 905-820-8218E: [email protected]

Coloplast develops products that make lifeeasier for people with very personal andprivate medical conditions. Within the fieldof urology, Coloplast offers a wide rangeof devices that help people who sufferfrom urinary incontinence and erectiledysfunction.

Coloplast développe des produits etservices qui simplifient la vie despersonnes aux prises avec des problèmesmédicaux intimes et très personnels. Dansle domaine de l’urologie, Coloplast offreune vaste gamme de dispositifs pour aiderles personnes qui souffrent d’incontinenceurinaire et de dysfonction érectile.

COOK MEDICALBooths / Kiosques : 1/2

Contact: Alex Szabo165 Mostar Street Stouffville, ON, L4A 0Y2 T: 905-640-7110F: 905-640-7408E: [email protected]

Cook Group companies develophealthcare devices. We are at the forefront of medical research and product development in minimallyinvasive medical device technology fordiagnostic and therapeutic procedures.

Les sociétés du Groupe Cook effectuent ledéveloppement des dispositifs médicaux.Nous sommes au premier rang de larecherche médicale et du développementdes produits et de la technologie desdispositifs médicaux à effraction minimaleaux fins des interventions diagnostiqueset thérapeutiques.

COVIDIENBooth / Kiosque : 6

Contact: Caroline Robert7300 TransCanada HighwayPointe-Claire, QC, H9R 1C7T: 514-695-1220F: 514-695-2379E: [email protected]

The V-Loc™ Wound Closure Device familyis a revolutionary technology that supportsoptimal patient outcomes by closingwounds securely without the need to tieknots. It has evenly-spaced unidirectionalbarbs throughout the strand which allowsfor a secure closure of the incision. It alsofeatures premium cutting needles withNuCoat technology. The benefits include:distribution of tension throughout thewound, closing wounds up to 50% fasterthan conventional sutures withcomparable holding strength and apotential to reduce knot-relatedcomplications.

Le dispositif de fermeture de plaiesV-LocMC présente une technologierévolutionnaire qui permet d’obtenir desrésultats optimaux grâce à la fermeturede plaies sans nœud. Le dispositifpossède des crans unidirectionnelsuniformément répartis tout le long du filqui permettent de fermer l’incision de


CUA 2012 BANFF 47

façon sûre. Il est offert avec des aiguillestranchantes de qualité supérieure dotéede la technologie NuCoat. Ses principauxavantages comprennent la répartition dela tension sur toute la longueur de la plaie,la fermeture de plaies 50 % plus rapideque les sutures traditionnelles pour uneforce de maintien comparable et lepotentiel de réduction des complicationsliées aux nœuds.

ETHICONBooth / Kiosque : 19

Contact: Kendal SinghT: 1-800-642-6748E: [email protected] Info: Ethicon, a division ofJohnson & Johnson Medical Companies

For nearly a century products fromJohnson and Johnson’s MedicalCompanies have been in the hands ofhealthcare practitioners, transforming theirwork and restoring the lives of patientsthey serve. As part of the Surgical CareGroup of Johnson & Johnson, ourcommitment to improving and enhancingthe lives of patients is fully realized whenour products are in the hands of ourcustomers. With a legacy of innovation and industry-leading experience, we’vecreated new ways to care for patients. By understanding the complex ways inwhich materials interact with tissue we’ve created a portfolio of products thatadvance healthcare across the spectrumof medicine. Such products can becategorized into the following productlines, Biosurgery, Sutures & Dermabond.

Ethicon Products est le chef de filemondial des produits et des technologiesde suture. Ses marques sont parmi lesplus reconnues et respectées dans ledomaine hospitalier. Cette division estforte d’une longue tradition d’innovation,notamment en matière de solutions desuture, d’adhésifs topiques et de méchagechirurgical, sans compter qu’elle proposeune gamme complète de produitsd’hémostase chirurgicale.

ETHICON ENDO-SURGERYBooth / Kiosque : 20

Contact: Maria AltomareE: [email protected]

At Ethicon Endo-Surgery, we want totransform patient care through innovation.We believe that advances in surgery andsurgical education, in particular, minimallyinvasive techniques, offer value andimportant advantages for all stakeholders.Our partnerships have proveninstrumental in the design anddevelopment of new surgical productsthat benefit patients, surgeons, andhospitals.

To find out more about how we aretransforming patient care, visitwww.ethiconendosurgery.com

Chez Ethicon Endo-Surgery, nous voulonstransformer les soins aux patients aumoyen de l'innovation. Nous croyons queles percées en matière de chirurgie et deformation chirurgicale, particulièrementen ce qui a trait aux techniques peueffractives, offrent de la valeur et desavantages importants à tous lesintervenants. Nos partenariats ont joué un


48 CUA 2012 BANFF

rôle clé dans la conception et l'élaborationde nouveaux produits chirurgicaux quisont avantageux pour les patients, leschirurgiens et les hôpitaux.

Pour en savoir plus sur la façon dont nous transformons les soins aux patients, visitez le sitewww.ethiconendosurgery.com

EUROPEAN ASSOCIATION OF UROLOGY (EAU)

Booth / Kiosque : 65Contact: Angela TerbergMr. E.N. van Kleffensstraat 56842 CV Arnhem, The NetherlandsT: +31 26 3890 680F: +31 26 3890 674E: [email protected]

The European Association of Urology (EAU) represents more than 16,000urology professionals across Europe andworldwide. Its mission is to raise the levelof urological care in Europe. The EAUAnnual Congress is one of the largesturological congresses in the world. Check our website for more information:www.uroweb.org.

FERRING PHARMACEUTICALSBooth / Kiosque : 41

Contact: Stephen Zisis200 Yorkland Blvd., Suite 800North York, ON, M2J 5C1T: 416-490-0121F: 416-493-1692E: [email protected]

Ferring’s FirmagonTM is a first class GnRHantagonist for prostate cancer patients.Learn why Firmagon’s direct mechanismof action with no initial surge providesfaster, more profound and sustained

testosterone control for better cancermanagement.

FirmagonMD de Ferring est le premierantagoniste de la GnRH de sa classe pourles patients atteints de cancer de laprostate. Apprenez pourquoi lemécanisme d’action direct de Firmagonsans élévation initiale du niveau detestostérone permet d’offrir un contrôleplus complet et soutenu pour un meilleurtraitement du cancer.

FIBERTECH CANADA E.R. INC.Booth / Kiosque : 26

Contact: Paul Laborie6513A Mississauga Road N.Mississauga, ON, L5N1A6E: [email protected]

Fibertech Canada E.R. Inc. is now theexclusive Canadian distributor for EDAPExtracorporeal Lithotriptors with ExclusiveIntuitive Localization System technology.In addition, Fibertech provides a widerange of endoscopic services and offersthe Endoboy Surgical Assist Arm.

Fibertech Canada Inc. ER est maintenantle distributeur canadien exclusif pourEDAP Lithotripteurs extracorporelles avecla technologie exclusive de localisationsystème intuitif. En outre, Fibertech offreune vaste gamme de servicesendoscopiques et offre le bras ENDOBOYPneumatique, la troisième main duchirurgien.


CUA 2012 BANFF 49

GLAXOSMITHKLINEBooths / Kiosques : 40/51/52

Contact: Patricia Gauthier7333 Mississauga RoadMississauga, ON, L5N 6L4T: 905-819-3015E: [email protected]

GlaxoSmithKline (GSK) is a leadingresearch-based pharmaceutical companywith a challenging and inspiring mission:to improve the quality of human life byenabling people to do more, feel better,and live longer. This mission gives GSK thepurpose to develop innovative medicines,vaccines and healthcare solutions thathelp millions of people. GSK is consistently recognized as one ofthe 50 best employers in Canada and is atop 20 investor in Canadian research anddevelopment, contributing more than$100 million in 2011 alone. With a proudtradition of charitable and communitysupport, GSK is designated a CaringCompany by Imagine Canada. Discovermore at www.gsk.ca.

GSK has a strong presence in biologicals,pharmaceuticals and vaccines, with aproduct portfolio that extends across avariety of therapeutic areas and diseasesincluding urology.

GlaxoSmithKline (GSK) est un géantpharmaceutique voué à la recherche dontla mission ambitieuse et édifiante estd’améliorer la qualité de la vie en aidantles gens à être plus actifs, à se sentirmieux et à vivre plus longtemps. De cettemission découle l’objectif de GSK qui estde concevoir des médicaments, desvaccins et des solutions de soins de santé

novateurs qui aident des millions depersonnes. GSK est constammentreconnue comme l’un des 50 employeursde choix au Canada et figure parmi les 20entreprises qui investissent le plus enrecherche et développement au Canada,ayant consacré plus de 100 millions dedollars à ce secteur en 2011 seulement.De plus, grâce à sa fière tradition dephilanthropie et de soutiencommunautaire, GSK a été désignéeSociété généreuse par le programmeImagine Canada.

GSK joue un rôle prépondérant dans lessecteurs des agents biologiques, desspécialités pharmaceutiques et desvaccins; sa gamme de produits vise unlarge éventail de champs thérapeutiqueset de maladies, y compris urologie.www.gsk.ca

JAC-CELL MEDIC INC.Booth / Kiosque : 35

Contact: Mark Meltzer 5764 Pare Street Mont-Royal, QC, H4P 2M2T: 514-731-4567, x 222F: 514-731-0002E: [email protected]

Jac-cell Medic is a leading distributor ofinstruments and accessories for cosmeticsurgery. We provide value and savings onthe highest quality of disposable andreusable products. Breast retractors,microsurgery instruments, precisiondissection needles, cautery pens, salinetransfer kits, aspiration and infiltrationtubing and the lowest prices on silicondrains and reservoirs, including the new“ouchless” 2 in 1 round drains.


50 CUA 2012 BANFF

Specialists in Fat Grafting equipment with our Autoclavable fat transfersystems, 60cc & 10cc Manual Centrifuge,Fat harvesting Canula and reinjection needles, transfer adaptors…

JANSSEN INC.Booth / Kiosque : 18

Contact: Luis Fernandes19 Green Belt DriveToronto, ON, T3C 1L9T: 416-382-5000F: 416-449-2658E: [email protected]

As a member of the JanssenPharmaceutical Companies of Johnson & Johnson, Janssen Inc. is dedicated toaddressing the most important unmetmedical needs in pain management,psychiatry, oncology, immunology,psoriasis, virology, anemia, attentiondeficit hyperactivity disorder, dementia,gastroenterology and women’s health.Driven by our commitment to thepassionate pursuit of science for thebenefit of patients, we work together to bring innovative ideas, products andservices to patients around the world.

À titre de membre du groupe desentreprises pharmaceutiques Johnson & Johnson, Janssen Inc. s’emploie àrépondre aux besoins non satisfaits lesplus importants dans le domaine de ladouleur, la psychiatrie, l’oncologie,l’immunologie, le psoriasis, la virologie,l’anémie, le trouble déficitaire del’attention avec hyperactivité, la démence,la gastroentérologie et la santé de lafemme. Poussés par notre passion demettre la science au service des patients,

nous collaborons à de nouvelles solutions,produits et services pour le bien despatients dans le monde entier.

KARL STORZ ENDOSCOPYCANADA LTD.

Booths / Kiosques : 46/47Contact: Florian Stegen7171 Millcreek DriveMississauga, ON, L5N 3R3T: 905-816-4500F: 905-816-4599E: [email protected]

Karl Storz Endoscopy Canada is a leaderin Endoscopic equipment and instrumentsthat emphasize visionary design,craftsmanship and clinical effectivenessand facilitate demanding Urologyprocedures.

Karl Storz Endoscopy Canada est unmeneur dans la production d’équipementet d’instruments endoscopiques. Leconcept visionnaire de nos artisans metl'accent sur l'efficacité clinique de tousnos produits avec emphase de facilitervos procédures d’urologie.

KIDNEY CANCER CANADATable in Foyer

Contact: Joan Basiuk27 Bayberry CrescentToronto, ON, M2K 1T9T: 416-223-8001E: [email protected]

Kidney Cancer Canada (KCC) is acharitable patient-led support organizationestablished to improve the quality of lifefor patients living with kidney cancer. KCCadvocates for access to new treatments,provides support and information to


CUA 2012 BANFF 51

patients, funds much-needed kidneycancer research, and works to increaseawareness of kidney cancer.

L’Association canadienne du cancer du rein (ACCR) est un organisme debienfaisance créé et dirigé par despatients avec mission d’améliorer laqualité de vie de ceux-ci et de leursproches. L’ACCR milite pour l’accès auxnouveaux traitements, informe et soutientles patients, finance la recherche ettravaille à faire connaître cette forme rare de cancer.

LABORIE MEDICALBooth / Kiosque : 33

Contact: Christine Frewen6415 Northwest Drive, Unit 10 Mississauga, ON, L4V 1X1T: 1-888-522-6743, x 4232F: 450-671-7182E: [email protected]

LABORIE, the worldwide industry leader inUrodynamics, is pleased to provide youwith the most advanced solutions in PelvicFloor Dysfunction Management. LABORIEis committed to bringing you the mostinnovative products: from private officesto world class research institutions, oursolutions are designed to expand withyour practice.

LABORIE, leader mondial de l’urodynamie,vous offre les solutions les plusperformantes dans la gestion desdysfunctions du plancher pelvien.LABORIE s’engage a vous apporter lesproduits les plus innovants: pour votreconsultation privée ou votre centre de

recherche, nos solutions sont conçuespour évoluer avec votre pratique.

ELI LILLY CANADABooths / Kiosques : 59/60

Contact: Monita Chan3650 Danforth Ave.Toronto, ON, M1N 2E8T: 416-693-3790F: 416-699-7234E: [email protected]

Lilly is a leading, innovation-drivenPharmaceutical Corporation committed todeveloping a growing portfolio of best-in-class/first-in-class pharmaceuticalproducts that help people live longer,healthier and more active lives. We arecommitted to providing answers thatmatter through medicines andinformation, for some of the world's most urgent medical needs.

Lilly est une société pharmaceutique depointe axée sur l’innovation qui s’appliqueà développer un portefeuille toujourscroissant de produits pharmaceutiques,parmi les meilleurs et les premiers de leurclasse, afin de permettre aux patients devivre plus longtemps, en meilleure santéet de mener une vie plus active. Lilly estfermement résolue à apporter desréponses qui comptent, sous forme demédicaments et d'informations, à certainsdes impératifs médicaux les plus urgentsdans le monde.


52 CUA 2012 BANFF

MDBRIEFCASE INC.Table in Foyer

Contact: Janet Kimura20 Eglinton Avenue West, Suite 1300Toronto, ON, M4R 1K8 T: 416-488-5500, x 221F: 416-288-0566E: [email protected]

mdBriefCase Inc. has been the leadingprovider of online continuing education for Canadian health care professionalssince 2002. mdBriefCase creates morethan 100 online learning programsannually in collaboration with leadingexperts, professional societies andacademic institutions for its 85,000+health care professional membership.Programs are offered throughwww.mdBriefCase.com,www.AdvancingIn.com,andwww.rxBriefCase.com.

mdBriefCase Inc. est le principalprestataire de formation médicalecontinue en ligne pour les professionnelsde la santé au Canada depuis 2002.mdBriefCase crée chaque année plus de100 programmes d’apprentissage en ligneen collaboration avec des spécialistes depremier plan, des associationsprofessionnelles et des établissementsd’enseignement à l’intention de sesmembres : plus de 85 000 professionnelsde la santé. Les programmes sont offertspar www.mdBriefCase.com,www.AdvancingIn.com, etwww.rxBriefCase.com.

MEDIWATCH USA INC.Booth / Kiosque : 36

Contact: Nick Darker1501 Northpoint Parkway, Suite 103West Palm Beach, FL 33407, United StatesT: 561-471-2611F: 866-871-8262E: [email protected]

The Mediwatch range of urology & pelvicfloor diagnosis products includes:

Intuitive Sensic urodynamics systems,Encompass anorectal manometry &pudendal stimulation, Portascan+ PVRscanners, Uroval bulbocavernosus reflextesting, Venus pelvic floor rehabilitationand Urodyn+ & Portaflow uroflowmeters.

Ask for more information on any productand a demonstration at our stand.

Mediwatch possède une gamme deproduits servant au diagnostique desproblèmes urinaires et du plancherpelvien : Le système Sensic pourl’urodynamie, Encompass pour lamanométrie rectal et la stimulation du nerf pudendal, Portascan+ PVR, Uroval pour vérifier le réflexebulbocaverneux,Vénus pour laréhabilitation du plancher pelvien etUrodyn+ & Portaflow pour lesdébimétries.

Pour toute autre information oudémonstration, s’il vous plait visiter notre kiosque.


CUA 2012 BANFF 53

MEDTRONIC OF CANADA LTD.Booth / Kiosque : 12

Contact: Kitty Zanata99 Hereford Street Brampton, ON, L6Y 0R3T: 905-460-3642F: 905-460-3999E: [email protected]

Medtronic is the world’s leading medicaltechnology company offering InterStimtherapy for the management of chronicintractable fecal and urinary incontinence.We offer a simple functional evaluationtest to select patients and a minimallyinvasive implant procedure for the system.Clinical evidence for long term success iswell established. Come to our booth to seehow easy it is to do the peripheral nerveevaluation.

Medtronic est l’entreprise chef mondialeen technologie médicale, offrant lathérapie InterStim pour le traitement del'incontinence fécale et urinaire réfractairechronique. Nous vous offrons un testsimple pour l'évaluation fonctionnellesimple pour aider à sélectionner lespatients et une procédure d'implantminimalement invasive. Les évidencesclinicaux de réussite à long terme sontbien établie pour l'incontinence fécale.Venir nous visiter notre table pour voircomment il est facile de faire l'évaluationdes nerfs périphériques.

MINOGUE MEDICAL INC.Booth / Kiosque : 39

Contact: Danny Minogue 180 Peel Street, Suite #300 Montreal, QC, H3C 2G7 T: 1-800-665-6466F: 514-287-0853E: [email protected]

Minogue Medical Inc. is the exclusiveCanadian distributor of the IntuitiveSurgical da Vinci® Si HD™ SurgicalSystem. The da Vinci® Prostatectomy(dVP) is the fastest growing treatment forprostate cancer today. Other proceduresinclude the da Vinci® Nephrectomy/PartialNephrectomy, Radical Cystectomy, andPyeloplasty. We are also the exclusiveCanadian distributor for Neotract whohave developed the innovative Urolift®

System for treating lower urinary tractsymptoms due to benign prostatichyperplasia (BPH).

Minogue Medical Inc. est le distributeurcanadien exclusif du système chirurgicalda Vinci® Si HD™. La prostatectomie daVinci® (dVP) est le traitement en évolutionle plus rapide pour le cancer de laprostate aujourd’hui. Les autresprocédures incluent la néphrectomie/néphrectomie partielle, cystectomieradicale, et pyeloplastie. Egalement ledistributeur canadien exclusif pourNeotract qui a mis au point le SystèmeUrolift®, une technologie pour letraitement des symptômes du tractusurinaire causé par une hyperplasiebénigne de la prostate.


54 CUA 2012 BANFF

NOVARTIS ONCOLOGYBooth / Kiosque : 29

Contact: Paule Racine385 Bouchard Blvd.Dorval, QC, H9S 1A9T: 514-631-6775, x 3207F: 514-631-1867E: [email protected]

Novartis Oncology is dedicated toanswering unmet medical needs. Ourpriority is to discover, develop and makebroadly available novel therapies that mayimprove and extend the lives of patients.

Novartis Oncologie se consacre àsatisfaire les besoins médicaux noncomblés. Notre priorité est de découvrir,de mettre au point, et d’offrir à tous destraitements novateurs pouvant amélioreret prolonger la vie des patients.

OLYMPUS CANADA INC.Booths / Kiosques : 8/9

Contact: Roxanne DeAbreu-Breen25 Leek Crescent Richmond Hill, ON, L4B 4B3T: 289-269-0204F: 905-886-7469E: [email protected]

Olympus Canada offers urologists thevision to see and the power to treat withleading edge visualization and best inclass surgical tissue management. Ourleading edge technologies enableurologists to perform a wide range ofprocedures with pinpoint precision andmaximum safety. For more information on our products, please contact OlympusCanada: 1-800-387-0437www.olympuscanada.com

Olympus Canada offre aux urologues lavision et le pouvoir de traiter avec unevisualisation de pointe et une gestion destissus chirurgicaux reconnue commemeilleure dans sa catégorie. Nostechnologies permettent aux urologuesd'effectuer une variété de procédures avechaute précision et sécurité maximale. Pourde plus amples informations sur nos produits,veuillez contacter Olympus Canada : 1-800-387-0437www.olympuscanada.com

PALADIN LABS INC.Booths / Kiosques : 4/5

Contact: Philippe Leblond100 Alexis Nihon Blvd., Suite 600St-Laurent, QC, H4M 2P2T: 514-340-1112 x 5445F: 514-344-4675E: [email protected]

Paladin Labs is a Canadian specialtypharmaceutical company focused onbringing innovative therapies to Canada.Key products include Trelstar (LHRHa),Testim (testosterone gel), and Urocit-K(potassium citrate) in urology. Visit ourbooth to find out more about our products!www.paladinlabs.com

Paladin est une compagniepharmaceutique canadienne avec missiond’apporter des produits pharmaceutiquesspécialisés au Canada. Les produitsprincipaux comprennent Trelstar (LHRHa),Testim (gel de testostérone) et Urocit-K(citrate de potassium) en urologie. Visitez notre kiosque pour en savoir plus sur nosproduits! www.paladinlabs.com


CUA 2012 BANFF 55

PENDOPHARMBooth / Kiosque : 7

Contact:6111 Royalmount Ave., Suite 100Montreal, QC, H4P 2T4 T: 514-340-9800F: 514-733-9684

A Strong Focus on Specialty Medicines

PENDOPHARM is a rapidly growing andindependent business that focuses oncommercializing a portfolio of specialtyprescription products and an establishedline of OTC/BTC products.

Strategically committed to growth,PENDOPHARM is actively engaged inlicensing, developing and marketing late-stage prescription products as well as consumer brands.

Axée sur les produits pharmaceutiquesspécialisés

PENDOPHARM est une entreprisepharmaceutique indépendante ayant uneforte croissance et dont les activités decommercialisation se concentrent sur un portefeuille de produits d’ordonnancespécialisés ainsi qu’une gammeimportante et établie de produits offertsen vente libre et derrière le comptoir de la pharmacie.

Engagée par sa stratégie commerciale à prendre de l’expansion, PENDOPHARMtravaille activement pour acquérir deslicences, établir des partenariats ainsi

que réaliser les derniers stages dedéveloppement de médicamentsd’ordonnance spécialisés et de produitsdestinés aux consommateurs, afin de lescommercialiser.

PFIZER CANADA INC.Booths / Kiosques : 48/50

Contact: Karen Southin17300 TransCanada HighwayKirkland, QC, H9J 2M5T: 514-426-7549E: [email protected]

Pfizer Canada Inc. is the Canadianoperation of Pfizer Inc, the world's leadingbiopharmaceutical company. Pfizerdiscovers, develops, manufactures andmarkets prescription medicines forhumans and animals. At Pfizer, we'reworking together for a healthier world. For more information, visit www.pfizer.ca

Pfizer Canada inc. est la filiale canadiennede Pfizer Inc., première entreprisepharmaceutique à l'échelle mondiale.Pfizer découvre, met au point, fabrique et commercialise des médicamentsd’ordonnance pour les humains et lesanimaux. Chez Pfizer, nous bâtissonsensemble un monde en meilleure santé.Pour en savoir plus, visitez le sitewww.pfizer.ca


56 CUA 2012 BANFF

PROSTATE CANCER CANADATable in Foyer

Contact: Katherine patterson 2 Lombard Street, 3rd FloorToronto, ON, M5C 1M1T: 416-441-2131E: [email protected]

Prostate Cancer Canada is the onlynational foundation dedicated to theelimination of the disease throughresearch, education support andawareness.

Our goals are twofold – to fund researchthat will uncover better diagnostic andtreatment options and to providecomprehensive support services for thoseliving with prostate cancer.

Cancer de la Prostate Canada est la seulefoundation nationale vouée à l’éliminationde la maladie par la recherche, soutien àl’éducation et la sensibilisation.

Nos objectfs sont de deux ordres – pourfinancer la recherche qui va découvrir desmeilleures façons de diagnostiquer et lesoptions de traitement et de fournir desservices de soutien complets pour lespersonnes vivant avec le cancer de laprostate.

RED LEAF MEDICAL INC.Booth / Kiosque : 21

Contact: Charles Ko4055 Sladeview Crescent, Unit 12 Mississauga, ON, L5L 5Y1 T: 905-569-7771F: 905-569-7778E: [email protected]

Red Leaf Medical Inc. is a provider

of premier medical products to help patients get the most out of life every day. The Company is rapidly growing and specializes in the acquisition,development and commercialization ofinnovative medical devices in the field of urology.

Red Leaf Medical Inc. est un fournisseurde produits médicaux de premier planpour aider les patients à mieux profiter de la vie chaque jour. La société, dont la croissance est rapide, se spécialisedans l'acquisition, le développement et la commercialisation d'instrumentsmédicaux novateurs dans le domaine de l'urologie.

ROYAL COLLEGE OF PHYSICIANSAND SURGEONS OF CANADA

Table in FoyerContact: Sandra Canniff774 Echo DriveOttawa, ON, K1S 5N8 T: 613-730-6243F: 613-730-2410E: [email protected]

The Royal College sets the higheststandards for specialty medical educationin Canada. At the same time, we supportlifelong learning for specialist physiciansand promote sound health policy.

Le Collège royal établit les normes lesplus élevées qui soient en formationmédicale spécialisée au Canada.Parallèlement, nous soutenonsl'apprentissage continu des médecinsspécialistes et faisons la promotion depolitiques de santé réfléchies.


CUA 2012 BANFF 57

SANOFI AVENTIS CANADA INC.Booth / Kiosque : 43

Contact:2150 St. Elzear Blvd. WestLaval, QC, H7L 4A8T: 514-331-92201-800-363-6364 (general enquiries);1-800-265-7927 (customer service)

As a leading healthcare partner weprovide, and are developing, innovativemedicines for treatments in severaltherapeutic areas: cardiovascular disease,thrombosis, oncology, metabolicdisorders, the central nervous system, andinternal medicine. We also play a role byinvesting in activities that improve healthand quality of life in our communities.

Partenaire de premier plan du secteur dela santé, nous fournissons et mettons aupoint des médicaments innovants dansdes domaines thérapeutiques variés : lacardiologie, la thrombose, le systèmenerveux central, l’oncologie, les maladiesmétaboliques et la médecine interne.Nous investissons aussi dans des activitésqui améliorent la santé et la qualité de viedans les collectivités où nous sommesimplantés.

SCIENCE AND MEDICINE CANADATable in Foyer

Contact: Gary Browne120 East Beaver Creek Road, Suite 315Richmond Hill, ON, L4B 4V1T: 905-762-0772, x 304F: 905-762-0776E: [email protected]

Science & Medicine Canada (SMC) is aToronto-based continuing healtheducation (CHE) agency with over 20

years of experience in urology/uro-oncology and demonstrated excellence inmedical education. The CanadianUrological Association has recentlypartnered with SMC to develop andprovide urology-related CHE to healthcareproviders across Canada.

Science & Medicine Canada (SMC) est uneagence basée à Toronto offrant de laformation médicale continue (FMC).Possédant plus de 20 annéesd’expérience, elle a fait preuved’excellence en formation médicale dansles domaines de l’urologie et del’uro‑oncologie. L’Association desurologues du Canada (AUC) s'estrécemment associée à SMC pour mettresur pied et fournir des activités de FMC enlien avec l'urologie aux fournisseurs desoins de santé partout au Canada.

SEEMORE IMAGING CANADABooth / Kiosque : 66

Contact: Jane Timmis4099 Burkehill RoadWest Vancouver, BC, V7V 3L9T: 604-922-0874F: 604-922-0875E: [email protected]

SeeMore USB ultrasound probes areaffordable & application-specific -abdominal, endocavity, vascular access,MSK, and regional nerve block. Thesystem is compatible with most laptop,netbook & tablet computers runningWindows; all software is included and canbe downloaded to any number ofcomputers – the ultimate in portability.www.seemore.ca


58 CUA 2012 BANFF

SIEMENSBooth / Kiosque : 13

Contact: Richard Newman6865 Century Ave., Suite 3001Mississauga, ON, L5N 2E2T: 416-786-1949F: 905-593-4602E: [email protected]

For 100 years the innovative ideas fromSiemens have helped make Canada abetter place. From the Atlantic to Pacificoceans, more than 4,400 employees inCanada work together to provide answersthat last in the fields of industry, energyand healthcare, as well as deliverinfrastructure solutions for cities. Since it was federally chartered in Augustof 1912, Siemens has stood for technicalachievements, innovation, quality andreliability. Sales for Siemens in Canada infiscal 2011 (ended September 30), were$3.0 billion CAD. The company has 61offices and 13 manufacturing/assemblyfacilities across Canada. Furtherinformation is available atwww.siemens.ca.

Depuis 100 ans, les idées novatrices deSiemens contribuent à la qualité de vie auCanada. De l’Atlantique au Pacifique, plusde 4 400 employés travaillent ensembleau Canada pour apporter des réponsesdans les domaines de l’industrie, del’énergie et de la santé, tout en proposantdes solutions pour les infrastructuresurbaines. Depuis qu’elle a obtenu sacharte fédérale en août 1912, Siemens estsynonyme de réalisations techniques,d’innovation, de qualité et de fiabilité. Lesventes de Siemens Canada pour l’exercicefinancier 2011 (qui a pris fin le 30

septembre) s’élevaient à 3 milliards dedollars canadiens. La compagnie exploite61 bureaux et 13 usines au Canada. Pouren savoir davantage, consultez le sitewww.siemens.ca.

SOCIÉTÉ INTERNATIONALED'UROLOGIE (SIU)

Booth / Kiosque : 64Contact: 1155 University, Suite 1155Montreal, QC, H3B 3A7T: 514-875-5665F: 514-875-0205E: [email protected]

The SIU is an international professionalorganization serving urologists and actingas a platform for sustainable urologicaleducation and collaborative humanitarianactivities to improve urological careworldwide.

Visit our booth for details on SIU 2012 inFukuoka, Japan, September 30-October 4,and our 2013 Congress in Vancouver,October 20-24!

La SIU est une organisation internationaleprofessionnelle au service des urologues,une tribune servant à l’education continueet au développement de projetshumanitaires pour l’amélioration et leperfectionnement des soins urologiques à travers le monde.

Visitez notre stand pour obtenir plus dedétails sur les prochains congrès de laSIU, à Fukuoka au Japon, du 30Septembre au 4 octobre 2012 et àVancouver, du 20 au 24 octobre 2013!


CUA 2012 BANFF 59

THUNDER BAY REGIONALHEALTH SCIENCES CENTRE

Booth / Kiosque : 67Contact: Linda Molenda980 Oliver RoadThunder Bay, ON, P7B 6V4 T: 807-684-6028F: 807-684-5893E: [email protected]

Thunder Bay Regional Health SciencesCentre (TBRHSC) is recruiting a full timeUrologist. TBRHSC is a state-of-the-artAcademic Health Sciences Centre, with375 acute care beds, providing regionalservices to a population base of 250,000people. We are the Regional Trauma and Cancer Referral Centre(s) forNorthwestern Ontario, and are affiliatedwith the Northern Ontario School ofMedicine (NOSM) and the Thunder BayRegional Research Institute (TBRRI).

TRITON PHARMA INC.Booth / Kiosque : 37

Contact: Robert Ohayon1001, de Maisonneuve Blvd. West, Room #940Montreal, QC, H3A 3C8 T: 514-288-0333, x 22F: 514-288-5397E: [email protected]

Privately held - President: Sybil Dahan

Operational as of January 2005

Markets several products with particularfocus on women’s health

- Vaniqa: unwanted facial hair- Enablex: overactive bladder- Oesclim Patch: estrogen TD therapy- Bellergal Spacetabs: non-hormonal

treatment of menopause- Estragyn Vaginal Cream: atrophic

vaginitis

Dermatology:

- Topiderm HC 2% cream: dermatoses- Dermaflex-20 cream: urea cream- Dermaflex HC 1% cream & lotion:

urea & hydrocortisone 1%

Q-Urol: Natural Health Product: chronicpelvic pain syndrome (CPPS)

Cysta-Q: Natural Health: painful bladdersyndrome/interstitial cystitis

Website: www.tritonpharma.ca


60 CUA 2012 BANFF

ULTRAMED INC.Booth / Kiosque : 61

Contact: 50 Steeles Avenue East, Suite 15Milton, ON, L9T 4W9T: 905-878-4400F: 905-878-5044E: [email protected]

Ultramed Inc. is pleased to exhibit thefinest quality equipment for members.

R. Wolf Endoscopy, Downs Surgical handheld instruments, PNN (Wallsten) BalloonAblation, Uroplasty Urinary Incontinenceand Wallach Diagnostic and TherapeuticGynaecology equipment are just some ofthe superior products we have availablefor no charge trial and evaluation.

Ultramed Inc. est heureuse de présenterson matériel de la plus grande qualité àvos membres.

Les instruments de gynécologiediagnostique et thérapeutique R. WolfEndoscopy, Downs Surgical hand heldinstruments, PNN (Wallsten) BalloonAblation, Uroplasty Urinary Incontinence etWallach ne sont que quelques-uns desproduits supérieurs que nous offrons dansle cadre d’un programme gratuit d’essaiet d’évaluation.

UROLOGY NURSES OF CANADATable in Foyer

Contact: Francis StewartEast Wing - 3rd Floor, Women's CollegeHospitalToronto, ON, M5S 1B6T: 416-323-6400, x 4437F: 416-323-6237E: [email protected]

The Urology Nurses of Canada is aNational Not-for-Profit Organization whosemandate is to enhance the specialty ofUrologic nursing in Canada by promotingeducation research and clinical practice.The activities of the UNC are designed toenrich members' professional growth anddevelopment. We thank the CUA for theirongoing support.

VANTAGE ENDOSCOPYBooth / Kiosque : 14

Contact: Kevin Noseworthy151 Amber St., Unit 14Markham, ON, L3R 3B3T: 866-677-4121F: 866-677-4122E: [email protected]

Vantage Endoscopy based in Markhamwith national Canadian representation ispleased to service the urology and Uro-gynecological markets as the exclusivesupplier of Life-Tech urodynamics andNeomedic slings. With outstandingproducts, Canadian service and supportand very competitive pricing, please stopby our booth and come see what we haveto offer.


CUA 2012 BANFF 61

WARNEX MEDICAL LABORATORIES

Booth / Kiosque : 56Contact: Catherine Sartoros3885 Industriel Blvd.Laval, QC, H7L 4S3T: 450-663-6724, x 277F: 450-663-4428E: [email protected]

Warnex Medical Laboratories offers aPCA3 testing service, a new gene-basedtool to help detect prostate cancer from aurine sample. PCA3 can be used to helpidentify new prostate cancers, patientswho should have a repeat biopsy, orcandidates for active surveillancefollowing a prostate cancer diagnosis.

Warnex laboratoires médicaux offre unservice d’analyse PCA3, un nouvel outilbasé sur la génétique aidant à détecter le cancer de la prostate à partir d’unéchantillon d’urine. L’analyse PCA3 peutêtre utilisé pour aider à détecter unnouveau cancer de la prostate, identifierles patients chez qui une autre biopsieserait nécessaire et identifier lescandidats nécessitant une surveillanceactive suite à un diagnostic de cancer de la prostate.

WATSON PHARMA COMPANYBooths / Kiosques : 57/58

Contact: Peter Dale2295 Bristol Circle, Unit 104Oakville, ON, L6H 6P8T: 905-855-4428F: 905-855-4433E: [email protected]

Watson Pharma Company is the newlyformed Canadian subsidiary of WatsonPharmaceuticals, Inc. (NYSE: WPI), aleading integrated global pharmaceuticalcompany. Watson Pharma Company is engaged in the marketing, sale anddistribution of branded pharmaceuticalproducts and biologics within theCanadian market. We are focused ondelivering innovative products thataddress key therapeutic categories in Urology and Women's Health.

Watson Pharma Company est la nouvelle filiale canadienne de WatsonPharmaceuticals, Inc. (NYSE : WPI), uneimportante société pharmaceutiqueinternationale intégrée. Watson PharmaCompany s’occupe du marketing, de lavente et de la distribution de produits etbiologiques’ pharmaceutiques de marquesur le marché canadien. Nous nousconcentrons à offrir des produitsinnovateurs dans les domainesthérapeutiques de l’urologie et de la santé des femmes. Abbott


CUA 2012 BANFF 63

Richard S. Foster, MDIndiana University School of MedicineDepartment of UrologyIndianapolis, IN

Keith Jarvi, MDProfessor of Surgery, Division of Urology, Department of Surgery at theUniversity of Toronto, Chief of Urology;Director of the Murray Koffler UrologicWellness Centre at the Mount Sinai HospitalToronto, ON

Gerald Jordan, MDUrology Professor, Eastern Virginia Medical SchoolChairman Devine Center for Genitourinary Reconstructive Surgery, Sentara Norfolk General HospitalNorfolk, VA

Kevin T. McVary, MD, FACSAttending UrologistProfessor of Urology, Feinberg SchoolNorthwestern Memorial HospitalChicago, IL

Manoj Monga, MD, FACS Director, Stevan B. Streem Center for Endourology & Stone DiseaseGlickman Urological & Kidney InstituteThe Cleveland Clinic FoundationShaker Heights, OH

Mark A. Moyad, MD, MPHJenkins/Pokempner Director of Preventive & Complementary Medicine at the University of MichiganMedical Center (Department of Urology)Ann Arbour, MI

Victor Nitti, MD Professor and Vice Chairman Department of Urology New York University Langone MedicalCenterNew York, NY

Hiep Nguyen, MD UrologyChildren's Hospital Boston, HarvardMedical SchoolBoston, MA

Richard M. Satava, MD, FACSProfessor of SurgeryDepartment of SurgeryUniversity of Washington Medical CenterSeattle, WA

Mark Schoenberg, MD Director of Urologic OncologyThe James Buchanan Brady Urological InstituteThe Johns Hopkins Medical InstitutionsBaltimore, MD

Pramod C. Sogani, MDAttending SurgeonProfessor of UrologyMemorial Sloan-Kettering Cancer CenterNew York, NY

INVITED FACULTY / CONFÉRENCIERS INVITÉS

64 CUA 2012 BANFF

WINNER IN A CLINICAL TOPIC

The prize for the winning essay in a Clinical topic is awarded to Dr. Philippe DenisViolette of Division of Urology, McGill University Health Centre, Montreal, QC, for his essay Solitary Solid Renal Mass: Can We Predict Malignancy?(abstract POD-03.05).

No essays were submitted in the Basic Science category.

GAGNANT DE LA CATÉGORIE SUJET CLINIQUE

Le prix du meilleur travail portant sur un sujet en recherche clinique a été décerné au Dr. Philippe Denis Violette de la Division of Urology, McGill University Health Centre, Montréal, QC, pour son travail intitulé Solitary Solid Renal Mass: Can We Predict Malignancy? (résumé POD-03.05).

Aucun travail n’a été soumis dans la catégorie recherche fondamentale.

CUA PRIZE ESSAY / TRAVAIL PRIMÉ DE L’AUC

CUA 2012 BANFF 65

FRIDAY / VENDREDIJUNE 22 JUIN

0900-1200 CUA Finance CommitteeComité des finances de l’AUCRoom / Salle : Angus

1000-1700 7th Annual Canadian Association of Genito-urinary Medical Oncology(CAGMO) Meeting | Part 17ième Assemblée annuelle de l’Association canadienned’oncologie médicale génito-urinaire I Part 1Room / Salle : New Brunswick

1200-1700 CUA Executive CommitteeComité exécutif de l’AUCRoom / Salle : Alberta

1700-1800 Medical Advisory Boardof Kidney Cancer CanadaLe Conseil médical consultatifde l'Association canadienne du cancer du reinRoom / Salle : Angus

SATURDAY / SAMEDIJUNE 23 JUIN

0730-1330 7th Annual Canadian Association of Genito-urinary Medical Oncology(CAGMO) Meeting | Part 27ième Assemblée annuelle de l’Association canadienned’oncologie médicale génito-urinaire I Part 2Room / Salle : New Brunswick

0800-1200 Canadian Academy of Urological Surgeons (CAUS)Académie canadienne deschirurgiens oncologues (CAUS)Room / Salle : Baron Shaughnessy

0800-1230 CUA Patient InformationCommittee (PIC)Comité info-patients de l’AUC (PIC)Room / Salle : Empress

0830-1300 CUA SocioeconomicCommitteeComité socioéconomique de l’AUCRoom / Salle : Victoria

1200-1430 CUOG Executive Committee MeetingComité exécutif du CUOGRoom / Salle : Angus

1200-1700 CUA Executive CommitteeComité exécutif de l’AUCRoom: Alberta

CUA AND AFFILIATED MEETINGS / CUA ET ÉVÈNEMENTS AFFILIÉS

66 CUA 2012 BANFF

1200-1700 Specialty Committee,Royal College of Physicians and Surgeons of CanadaComité des Spécialités, Collège royal des médecinset chirurgiens du CanadaRoom / Salle : Coleman

1230-1400 CKCIS MeetingRéunion CKCISRoom / Salle : Ivor Petrak

1300-1700 Residency Affairs Committee (RAC)Comité des affaires des résidents (RAC)Room / Salle : McKenzie

1400-1600 Canadian EndourologyGroupGroupe canadien d’endo-urologieRoom / Salle : Beatty

1430-1700 CUOG Annual GeneralMeetingAssemblée générale annuelle du CUOGRoom / Salle : Baron Shaughnessy

SUNDAY / DIMANCHEJUNE 24 JUIN

0700-0830 Canadian Urological Research Consortium(CURC)Réunion du CURCRoom / Salle : Beatty

0800-1100 CUAJ - Peer-ReviewedWorkshopAtelier JAUC: Évaluation par les pairsRoom / Salle : Coleman

0830-1000 CUA NominatingCommitteeComité des candidatures de l’AUCRoom / Salle : Angus

0840-0940 Clinical EpidemiologyGroup Réunion du Grouped’épidémiologie cliniqueRoom / Salle : Ivor Petrak

1000-1100 CUASF Scientific CouncilConseil scientifique de la FBAUCRoom / Salle : Empress

1015-1115 Continuing ProfessionalDevelopment MeetingConseil scientifique de l'AUC - Programmede bourse AstellasRoom / Salle : Strathcona


CUA 2012 BANFF 67

1100-1200 CUA Astellas Grant Program Scientific CouncilComité de développementprofessionnel continu (CDP)Room / Salle : Empress

1300-1500 CUASF AdministrativeCouncilComité administratif de la FBAUCRoom / Salle : Empress

1330-1730 Pediatric Urologists ofCanada (PUC) MeetingRéunion de la PUCRoom / Salle : Ivor Petrak

MONDAY / LUNDIJUNE 25 JUIN

0700-0900 CUA Annual GeneralMeetingAssemblée générale annuelle de l’AUCRoom / Salle : Baron Shaughnessy/Beatty

0900-1130 Canadian Male SexualHealth Council (CMSHC)Conseil canadien sur lasanté sexuelle de l’homme(CMSHC)Room / Salle : Strathcona

1200-1300 SIU Canadian SectionSection Canadienne de la SIURoom / Salle : Beatty

1600-1730 Bladder Cancer CanadaMedical Advisory Boardand Medical ResearchBoard MeetingCancer de la vessie CanadaRoom / Salle : Frontenac

1600-1800 Urology Nurses of CanadaInfirmières en urologie duCanadaRoom / Salle : Baron Shaughnessy

1700-1800 International VolunteerUrology - CancircBénévoles en urologie internationaleRoom / Salle : Beatty

TUESDAY / MARDIJUNE 26 JUIN

0630-0800 Council of CanadianUniversity Urology Chairs (CCUUC)CCUUCRoom / Salle : Palliser

0800-1000 CUAJ Editorial BoardMeetingComité de redaction du Journal de l’AUCRoom / Salle : AngusThis event isan Accredited Group Learning Ac-tivity (Section 1) as defined by theMaintenance of Certification Pro-gram of the Royal College ofPhysicians and Surgeons ofCanada and is co-developed andapproved by the Canadian Urologi-cal Association


68 CUA 2012 BANFF

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and is co-developed and approved by the Canadian Urological Association

AGENDAHOW TO DEVELOP A STRONG ACADEMIC PROGRAM IN CANADARoom: Baron Shaughnessy Date: Saturday June 23rd, 2012

8:00 to 8:30 Breakfast

8:30 to 8:40 Welcome and Opening Remarks

8:40 to 9:10 Dr. Larry Goldenberg - Department of Urology vs. Division. Does It Matter?

9:10 to 9:20 Discussion

9:20 to 9:50 Dr. Sender Herschorn- Developing a Culture of Research and Academics

9:50 to 10:00 Discussions

10:00 to 10:20 Health Break

10:20 to 10:50 Dr. John Denstedt- Academic Urology: A Chairman of Surgery's Perspective

10:50 to 11:00 Discussion

11:00 to 11:30 Panel Discussion (Financial and Funding Strategies)Dr. Armen Aprikian (Moderator).

11:30 to 12:00 Business Meeting

CANADIAN ACADEMY OF UROLOGICAL SURGEONS (CAUS) BANFF 2012

0900-1200 CUA Finance Committee / Comité des finances de l’AUC

Room – Salle: Angus

1000-1700 7th Annual Canadian Association of Genitourinary Medical Oncology (CAGMO) Meeting | Part 17e Réunion annuelle de l’Association canadienne d’oncologie médicale génito-urinaire

Room – Salle: New Brunswick

1200-1700 CUA Executive Committee / Comité exécutif de l’AUC

Room – Salle: Alberta

1700-1800 The Medical Advisory Board of Kidney Cancer CanadaLe Conseil médical consultatif de l’Association canadienne du cancer du rein


FRIDAY / VENDREDI JUNE 22 JUIN

CUA 2012 BANFF 69

0730-1330 7th Annual Canadian Association of Genitourinary Medical Oncology(CAGMO) Meeting | Part 27ième Assemblée Annuelle de l’Association canadienne d’oncologiemédicale génito-urinaire

Room – Salle: New Brunswick

0800-1200 Canadian Academy of Urological Surgeons (CAUS)Académie canadienne des chirurgiens oncologues (CAUS)

Room – Salle: Baron Shaughnessy

0800-1230 CUA Patient Information Committee (PIC)Comité info-patients de l’AUC (PIC)

Room – Salle: Empress

0800-1300 CUA Socioeconomic Committee / Comité socioéconomique de l’AUC

Room – Salle: Victoria

1200-1430 CUOG Executive Committee Meeting / Comité exécutif du CUOG


1200-1700 CUA Executive Committee / Comité exécutif de l’AUC

Room – Salle: Alberta

SATURDAY / SAMEDI JUNE 23 JUIN

70 CUA 2012 BANFF

1200-1700 RCPSC – Specialty Committee Meeting in UrologyComité des Spécialités, Collège Royal des médecins et chirurgiens du Canada

Room – Salle: Coleman

1230-1400 CKCIS Meeting / Réunion CKCIS

Room – Salle: Ivor Petrak

1300-1700 Residency Affairs Committee (RAC)Comité des affaires des residents (RAC)

Room – Salle: McKenzie

1400-1600 Canadian Endourology Group / Groupe canadien d’endo-urologie

Room – Salle: Beatty

1430-1700 CUOG Annual General MeetingAssemblée générale annuelle du CUOG


SATURDAY / SAMEDI JUNE 23 JUIN

CUA 2012 BANFF 71

0700-0830 Canadian Urological Research Consortium (CURC) MeetingRéunion du CURC


0800-1100 CUAJ Peer-Reviewed WorkshopAtelier JAUC: Évaluation par les pairs

Room – Salle: Coleman

0800-0810 Welcome / Mot de Bienvenue

Room – Salle: Van Horne AMichael Chetner, CUA President | Président de l’AUCJay Lee & Trevor SchulerScientific Committee Co-chairs | Co-président du comité scientifique

0810-0840 SOA1State-of-the-Art Lecture 1 / Conférence d'honneur 1

Room – Salle: Van Horne A

Update in Endourology: SWL and PCNLMise à jour en endo-urologie : LECOC et NLPC

Objectives / Objectifs1 Review current literature to refine patient selection for SWL

2 Identify modifications in SWL treatment protocols designedto maximize efficacy and decrease morbidity

3 Discuss role for ureteral stenting and medical expulsive therapy

4 Identify techniques to optimize preoperative planning andintraoperative implementation of percutaneous renal access

5 Describe new innovations in technique and technology for PCNLdesigned to optimize results

1 Passer en revue les articles récents afin d'améliorer la sélection des patients pour une LECOC

2 Préciser les modifications à apporter aux protocoles thérapeutiques par LECOCen vue de maximiser l’efficacité et de réduire la morbidité

3 Discuter du rôle des endoprothèses urétérales et du traitement par desmédicaments favorisant l'expulsion

Introduction:Trevor Schuler, Edmonton, AB

Speaker/Conférencier:Manoj Monga, Shaker Heights, OH

SUNDAY / DIMANCHE JUNE 24 JUIN

CUA 2012 BANFF 73

74 CUA 2012 BANFF

4 Identifier les techniques permettant d’optimiser la planification préopératoire et l’instauration peropératoire d’un accès rénal percutané

5 Décrire les récentes innovations techniques et technologiques concernant la NLPC en vue de l’optimisation des résultats

0830-1000 CUA Nominating Committee / Comité des candidatures de l’AUC


0840-0940 Clinical Epidemiology Group Réunion du Groupe d’épidémiologie clinique


0840-0940 POD-01Podium Session 1: Stones and ImagingSéance Podium 1: Lithiases et imagerie

Room – Salle: Van Horne AModerators/Modérateurs: Ben Chew, Vancouver, BC Manoj Monga, Shaker Heights, OH

0840-0850 POD-01.01 Surgical Management of Kidney Stone Disease: a Population-based Time Series Analysis

Ordon, Michael1; Saskin, Refik2; Mamdani, Muhammad3; Urbach, David2; Honey, R. John D'A.1; Pace, Kenneth11St. Michael's Hospital, Toronto, ON, Canada; 2Institute for Clinical and Evaluative Sciences,Toronto, ON, Canada; 3Applied Health Research Centre, St. Michael's Hospital, Toronto, ON, Canada

0850-0900 POD-01.02 Ultra-low Dose CT Comparable to Standard CT in Patients with Suspected Renal Colic

Archambault, Jason1; Sivalingam, Sri2; Hrymak, Carmen1; Kirkpatrick, Iain11University of Manitoba, Winnipeg, MB, Canada; 2University of Wisconsin, Madison, WI, United States


0900-0910 POD-01.03 Therapeutic Benefits of Solifenacin (Vesicare) in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms(LUTS) Post Ureteroscopy for Stone Management

Zadra, Joseph1; Hoare, Dylan2; Hartsburg, Cory1; Ray, Andrew1; Iocca, Angelo11Barrie Urology Associates, Barrie, ON, Canada; 2Queen's University, Kingston, ON, Canada

0910-0920 POD-01.04 Impact of Radiological Technologists on the Outcome of Shock Wave Lithotripsy

Elkoushy, Mohamed; Morehouse, Douglas; Anidjar, Maurice; Elhilali, Mostafa; Andonian, SeroMcGill University Health Center, Montreal, QC, Canada

0920-0930 POD-01.05 Cost-effectiveness of Shock Wave Frequencies of 60 versus 120 Shocks per Minute for Upper Ureteral Stones: Economic Analysis of a Randomized, Double-blind Trial

Klinghoffer, Zachary1; Tu, Hin Yu Vincent1; Pace, Kenneth21McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada

0930-0940 POD-01.06 The Influence of Body Mass Index on Outcomes FollowingPercutaneous Nephrolithotomy: a Global Perspective

Fuller, Andrew1; Razvi, Hassan1; Denstedt, John D.1; Nott, Linda1; de la Rosette, Jean21Division of Urology, Department of Surgery, The University of Western Ontario, London, ON,Canada; 2Department of Urology, AMC University Hospital, Amsterdam, Netherlands

0940-1010 Break in Exhibit Hall / Pause dans le hall d’exposition

Room – Salle: Van Horne BC and/et Foyer

1000-1100 CUASF Scientific Council / Conseil scientifique de la FBAUC



CUA 2012 BANFF 75

76 CUA 2012 BANFF

1010-1100 EF1Educational Forum 1 / Forum éducatif 1


Complications of Stone ManagementComplications de la prise en charge des calculs rénaux

Objectives / Objectifs

1 To review the complications and management of operative surgical proceduresfor kidney stones including extracorporeal shockwave lithotripsy, ureteroscopyand percutaneous nephrolithotomy

2 To review complications of residual stone fragments and their natural history

3 To review complications of medical management of kidney stone diseaseincluding medication interactions and side effects

1 Examiner les complications et la gestion des interventions chirurgicales visantl’extraction des calculs rénaux, dont la lithotripsie extracorporelle par ondes dechoc, l’urétéroscopie et la néphrolithotomie percutanée

2 Examiner les complications liées aux fragments résiduels de calculs et leurévolution naturelle

3 Examiner les complications de la prise en charge par médicaments des calculsrénaux, y compris les interactions médicamenteuses et les effets secondaires

1015-1115 Continuing Professional Development MeetingRéunion du comité de développement professionnel continu (CDP)

Room – Salle: Strathcona

Moderator/Modérateur:Ben Chew, Vancouver, BC

Faculty/Faculté: Trevor Schuler, Edmonton, ABJohn Dushinski, Calgary, AB


1100-1130 SOA2State-of-the-Art Lecture 2 (CAUS Lecture) / Conférence d'honneur 2 (Conférence de la CAUS)


Uretheral Reconstruction: What Does the Evidence Support?Reconstruction urétrale : Vers quoi pointent les données?

Objectives / Objectifs1 The attendees will after this lecture have an understanding of the current

terminology and anatomy of the urethra, as they relate to Urethralreconstruction

2 The attendees will after this lecture have an understanding of the thinkingmechanisms related to selection of urethral management or curative techniques

3 The attendees will after this lecture have been exposed to select techniques ofurethral reconstruction as they relate to the general urologists practice

4 The attendees will have been apprised concerning the methodology of analysisregarding the literature supported recommendations presented

1 Après cette présentation, les participants auront une bonne compréhension del’anatomie de l’urètre et de la terminologie connexe, en particulier en lien avecla reconstruction urétrale

2 Après cette présentation, les participants auront une bonne compréhension desmécanismes de réflexion en lien avec la sélection des techniques de prise encharge ou de traitement des troubles urétraux

3 Après cette présentation, les participants auront pris connaissance detechniques particulières de reconstruction urétrale pouvant être utilisées dansla pratique générale de l’urologie

4 Les participants auront été informés au sujet de la méthodologie analytiqueutilisée avec les recommandations appuyées par la documentation

1100-1200 CUA Astellas Grant Program Scientific CouncilConseil Scientifique de l’AUC - Programme de bourse Astellas


1130-1230 Opening Brunch in the Exhibit HallBrunch de bienvenue dans le hall d'exposition


Introduction: Keith Rourke, Edmonton, AB

Speaker/Conférencier: GeraldJordan, Norfolk, VA


CUA 2012 BANFF 77

78 CUA 2012 BANFF



Current Management of Genitourinary TraumaPrise en charge actuelle des traumatismes de l’appareil génito-urinaire

Objectives / Objectifs1 Outline the acute management options for a posterior urethral disruption

2 Gain an appreciation for the treatment of pelvic fracture urethral distractiondefects (PFUDD)

3 Discuss the diagnosis and treatment of common genital injuries

1 Faire ressortir les options de prise en charge aiguë d’une rupture de l’urètrepostérieur

2 Comprendre le traitement des lésions urétrales après fracture pelvienne

3 Discuter du diagnostic et du traitement des lésions génitales courantes

1300-1500 CUASF Administrative Council / Comité administratif de la FBAUC


1320-1330 AUA Presidential Address / Allocution du Président de l'AUA

Room – Salle: Van Horne AIntroduction: Michael Chetner, Calgary, ABSpeaker/Conférencier: Dr. Pramod Sogani, New York, NY

1330-1730 Pediatric Urologists of Canada (PUC) Meeting / Réunion de la PUC


1330-1430 POD-02Podium Session 2: Oncology Séance Podium 2: Oncologie


Moderator/Modérateur:Keith Rourke, Edmonton, AB

Faculty/Faculté:Ron Kodama, Toronto, ONGerald Jordan, Virgina, VAKeith Rourke, Edmonton, AB

Moderators/Modérateurs:John Izawa, London, ONYves Fradet, Quebec, QC


1330-1340 POD-02.01 MDV3100, an Androgen Receptor Signaling Inhibitor (ARSI), ImprovesOverall Survival in Prostate Cancer Patients Post-docetaxel: Results from the Phase 3 Affirm Study

Saad, Fred1; Scher, Howard2; Fizazi, Karim3; Mulders, Peter4; Taplin, Mary Ellen5; Sternberg,Cora6; Miller, Kurt7; de Wit, Ron8; Hirmand, Mohammad9; Selby, Bryan9; De Bono, Johann101Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada; 2Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 3University of ParisSud, Villejuif, France; 4Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands;5Dana-Farber Cancer Institute, Boston, MA, United States; 6San Camillo-Forlanini Hospital,Rome, Italy; 7Charité Universitätsmedizin, Berlin, Germany; 8Erasmus University MedicalCenter, Rotterdam, Netherlands; 9Medivation Inc., San Francisco, CA, United States; 10The Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom

1340-1350 POD-02.02 Neoadjuvant Gemcitabine/Cisplatin Chemotherapy for Muscle InvasiveUrothelial Carcinoma of the Bladder: a Single Institution Experience

El-Gehani, Faraj1; Venner, Peter2; Ghosh, Sunita2; North, Scott21Department of Medical Oncology, Edmonton, AB, Canada; 2Cross Cancer Institute, Edmonton, AB, Canada

1350-1400 POD-02.03 Regional Differences in Practice Patterns and Outcomes after Radical Cystectomy

Bachir, Bassel G.1; Yafi, Faysal A.1; Aprikian, Armen1; Chin, Joseph L.2; Izawa, Jonathan2;Fradet, Yves3; Lacombe, Louis3; Drachenberg, Darrel4; Estey, Eric5; Farey, Adrian5; Rendon,Ricardo6; Bell, David6; Lattouf, Jean-Baptiste7; Cagiannos, Ilias8; Kassouf, Wassim1

1McGill University Health Center, Montreal, QC, Canada; 2University of Western Ontario,London, ON, Canada; 3Laval University, Quebec, QC, Canada; 4University of Manitoba,Winnipeg, MB, Canada; 5University of Alberta, Edmonton, AB, Canada; 6Dalhousie University,Halifax, NS, Canada; 7University of Montreal, Montreal, QC, Canada; 8University of Ottawa,Ottawa, ON, Canada

1400-1410 POD-02.04 The Association between Statin Medication Use and Progression after Surgery for Localized Renal Cell Carcinoma

Hamilton, Robert; Morilla, Daniel; Cabrera, Fernando; Bernstein, Melanie; Reuter, Victor; Russo, PaulMemorial Sloan-Kettering Cancer Center, New York, NY, United States


CUA 2012 BANFF 79

80 CUA 2012 BANFF

1410-1420 POD-02.05 Does Surgeon and Hospital Volume Impact Outcomes of Surgery for Renal Cell Carcinoma with Inferior Vena Caval Involvement? Results of a Canadian Population-based Study

Toren, Paul1; Abouassaly, Robert2; Yap, Stanley1; Timilshina, Narhari1; Kulkarni, Girish1; Finelli, Antonio11University of Toronto, Toronto, ON, Canada; 2Case Western University, Cleveland, OH, United States

1420-1430 POD-02.06 The Association between Renal Tumor Scoring System and Partial Nephrectomy Complications

Darren Desantis, Darren1; Lavallée, Luke T.1; Breau, Rodney H.1; Kamal, Fadi1; Watterson, James1; Blew, Brian1; Mallick, Ranjeeta2; Fergusson, Dean2; Morash, Chris1; Cagiannos, Ilias11University of Ottawa / The Ottawa Hospital, Ottawa, ON, Canada; 2The Ottawa HospitalResearch Institute, Ottawa, ON, Canada

1430-1500 Break in Exhibit Hall and Laparascopic Skills CompetitionPause dans le hall d'exposition et concours d’adresse en laparoscopie




Testis CancerCancer du testicule

Objectives / Objectifs1 Discuss controversies in the management of low stage testis cancer

2 Discuss different approaches to the post chemotherapy mass in high stagetestis cancer

3 Identify long term side effects of testis cancer chemotherapy

1 Discuter des controverses entourant la prise en charge du cancer du testiculeaux premiers stades

Introduction:Niels Jacobsen, Edmonton, AB

Speaker/Conférencier:Richard Foster, Indianapolis, IN


2 Discuter différentes approches thérapeutiques en cas de massepostchimiothérapie dans les cancers du testicule aux stades avancés

3 Identifier les effets secondaires à long terme de la chimiothérapie utiliséecontre le cancer du testicule



High Risk Superficial Bladder CancerCancer vésical superficiel à risque élevé

Objectives / Objectifs1 Define high risk non-muscle invasive urothelial carcinoma of the bladder

(high risk NMIBC) and describe its natural history

2 Describe intravesical options for management of high risk NMIBC

3 Describe salvage options for high risk NMIBC

1 Définir le carcinome urothélial de la vessie à risque élevé sans envahissementmusculaire et décrire son évolution naturelle

2 Décrire les options thérapeutiques intravésicales dans ce type de carcinome

3 Décrire les options de sauvetage possibles avec ce type de carcinome

Moderator/Modérateur: Bobby Shayegan, Hamilton, ON

Faculty/Facultés:Wassim Kassouf, Montreal, QCJonathan Izawa, London, ONBobby Shayegan, Hamilton, ON


CUA 2012 BANFF 81

82 CUA 2012 BANFF



Quality Assurance in Bladder CancerAssurance de la qualité dans le cancer de la vessie

Objectives / Objectifs1 Understand the morbidity of cystectomy

2 Understand strategies for minimizing morbidity related to cystectomy

3 Understand the alternatives to cystectomy

1 Comprendre la morbidité associée à la cystectomie

2 Comprendre les stratégies permettant de réduire au minimum la morbidité liéeà la cystectomie

3 Comprendre les options de rechange à la cystectomie

1900-2230 CUA Fun Night / Grande soirée de l'AUCThe Fairmont Banff Springs Hotel

Rooms – Salles: Riverview Lounge, Alberta & New Brunswick

Introduction:Eric Hyndman, Calgary, AB

Speaker/Conférencier:Mark Schoenberg, Baltimore, MD


0700-0900 CUA Annual General Meeting / Assemblée générale annuelle de l’AUC

Rooms – Salles: Baron Shaughnessy/Beatty

0900-1130 Canadian Male Sexual Health Council (CMSHC)Conseil Canadian sur la santé sexuelle de l’homme (CMSHC)

Room – Salle: Strathcona

0910-0920 CP1Clinical Pearls That Could Change Your PracticeDes perles cliniques qui pourraient changer votre pratique

Room – Salle: Van Horne ASpeaker/Conférencier:Niels Jacobsen, Edmonton, AB

0920-0950 SOA5State-of-the-Art Lecture 5 / Conférence d’honneur 5


Men’s Health-Diet and Supplementation from A to Z: What Works and What is Worthless?Santé des hommes – Alimentation et suppléments de A à Z : Ce qui fonctionne et ce qui ne vaut pas le coup

Objectives / Objectifs1 To discuss rules and regulations regarding diet and supplements for men’s health

2 To discuss clinical studies hat support recommending specific dietary changesand supplements to your patients

3 To discuss clinical studies that do NOT support recommending some specificdietary changes and supplements to your patients

1 Discuter des règles concernant l’alimentation et les suppléments dans la santédes hommes

2 Discuter des études cliniques appuyant la recommandation de modificationsparticulières à l’alimentation et l’emploi de suppléments précis pour vos patients

3 Discuter des études cliniques qui n’appuient PAS la recommandation demodifications particulières à l’alimentation et l’emploi de suppléments précispour vos patients

Introduction:Martin Duffy, Calgary, AB

Speaker/Conférencier: Mark Moyad,Ann Arbour, MI

MONDAY / LUNDI JUNE 25 JUIN

CUA 2012 BANFF 83

84 CUA 2012 BANFF



1020-1120 POD-03Podium Session 3: General TopicsSéance Podium 3: Sujets générales

Room – Salle: Van Horne AModerators/Modérateurs:Andrew McNeilly, Vancouver, BC Hiep Ngyen, Boston, MA

1020-1030 POD-03.01 Laparoscopic Ureteric Clipping: a Simple Alternative in the Treatmentof Ectopic Ureters Associated with a Non-functioning Upper Moiety

Romao, Rodrigo L.P.; Figueroa, Victor H.; Pippi Salle, Joao L.; Koyle, Martin; Bagli, Darius; Lorenzo, Armando J.The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

1030-1040 POD-03.02The Association between Continence, Shunt, and Quality of Life in Spina Bifida

Olesen, Jamie; Kiddoo, Darcie; Metcalfe, PeterUniversity of Alberta, Edmonton, AB, Canada

1040-1050 POD-03.03Does Antibiotic Prophylaxis Prevent Urinary Tract Infections in Infantswith Antenatally Detected Hydronephrosis? A Systematic Review andMeta-analysis

Braga, Luis1; Lorenzo, Armando2; Pemberton, Julia1; DeMaria, Jorge1; Kim, Soojin1; Milijovic, Hana11McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada

1050-1100 POD-03.04 Role of a Novel Internet Mediated Feedback Instrument in a New Ageof Simulation Training: a Randomized Control Study

Weber, Bryce1; Bagli, Darius2; Carnahan, Heather3; Gualdron, David Rojas4; Cheung, Jeffrey4;Dubrowski, Adam3

1Alberta Children’s Hospital, Calgary, AB, Canada; 2Hospital for Sick Children, Toronto, ON,Canada; 3Wilson Centre, Toronto, ON, Canada; 4Sick Kids Learning Institute, Toronto, ON,Canada


1100-1110 POD-03.05 Solitary Solid Renal Mass: Can We Predict Malignancy?

Philippe Violette1, Samuel Abourbih1, Konrad M. Szymanski1, Simon Tanguay1, ArmenAprikian1, Keith Matthews1, Fadi Brimo2, and Wassim Kassouf11Division of Urology, McGill University Health Centre, Montreal, QC, Canada; 2Division ofPathology, McGill University Health Centre, Montreal, QC, Canada

1110-1120 POD-03.06 A Prospective Randomized Trial of Povidone-iodine ProphylacticCleansing of the Rectum prior to Transrectal Ultrasound-guidedProstate Biopsy

Abughosh, Zeid1; Margolick, Joseph1; Goldenberg, Larry1; Afshar, Kourosh1; Taylor, Stephen1;Gleave, Martin1; Bowie, William2; Roscoe, Diane1; Machan, Lindsay1; Black, Peter11Vancouver Prostate Centre, Vancouver, BC, Canada; 2University of British Columbia,Vancouver, BC, Canada



BPH & ED / HBP et DE

Objectives / Objectifs1 Know the relationships between ED and LUTS

2 Know how treatment of LUTS may impact sexual function

3 Know the impact of ED meds on LUTS

4 Understand the metabolic risks on the development of LUTS/BPH

5 Gain an awareness of how to prevent the development of LUTS through lifestylemanagement

1 Connaître le lien entre la DE et les TUBA

2 Savoir comment le traitement des TUBA peut influer sur la fonction sexuelle

3 Connaître l’effet des médicaments contre la DE sur les TUBA

4 Comprendre les risques métaboliques sur l’apparition de TUBA ou d’une HBP

5 Découvrir comment prévenir l’apparition de TUBA par les modifications au stylede vie

Introduction:Jay Lee, Calgary, AB

Speaker/Conférencier: Kevin McVary, Chicago, IL


CUA 2012 BANFF 85

86 CUA 2012 BANFF

1150-1300 Lunch in Exhibit Hall / Déjeuner dans le hall d’exposition


1200-1300 SIU Canadian Section / Section Canadienne de la SIU




Medial vs Early Surgical Intervention for Benign Prostatic Hyperplasia: Treatment Decisions are Driven by Risks, Benefits and CostsIntervention médicamenteuse ou chirurgicale précoce dans l’hyperplasie bénigne de la prostate : Les décisions quant au traitement sont fondées sur les risques, les avantages et les coûts

Objectives / Objectifs1 To understand how potential risks (side effects/complications) of medical

and surgical intervention for benign prostatic enlargement drives patientdecision-making

2 To learn that long term financial implications of medical and surgicalmanagement for benign prostatic enlargement does not play a role in currentdecision-making

3 To determine whether a new strategy of therapeutic decision-making for benignprostatic hyperplasia should be the future

1 Comprendre comment les risques potentiels (effets secondaires/complications)des interventions médicamenteuses et chirurgicales utilisées pour traiterl’hyperplasie bénigne de la prostate (HBP) influent sur le processus décisionneldes patients

2 Voir que les répercussions financières à long terme de la prise en chargemédicamenteuse et chirurgicale de l’HBP ne jouent aucun rôle dans le processusdécisionnel actuel

3 Déterminer si une nouvelle stratégie décisionnelle quant au traitement de l’HBP est requise pour l’avenir

Moderator/Modérateur:Ryan Paterson, Vancouver, BC

Faculty/Facultés: Curtis Nickel, Kingston, ON(Pro-medical Therapy / Pour le traitement médicamenteux)

Paul Whelan, Hamilton, ON(Pro-surgical Therapy / Pour le traitement chirurgical)


1350-1420 CUASF Lecture / Allocution de la FBAUC


Male Infertility: The Canary in the Coal MineMale Infertility Is a Marker for Men’s Health: Past, Present and FutureInfertilité masculine : le canari dans la mine de charbonL’infertilité comme marqueur de la santé chez les hommes : passé, présent et futur

Objectives / Objectifs1 To understand what medical issues are associated with male infertility

(Metabolomic syndrome etc.)

2 To understand the future health problems for men with infertility (higher risk ofcancer etc.)

3 To understand which tests are needed to identify men with these other healthproblems

1 Comprendre les enjeux médicaux associés à l’infertilité masculine (syndromemétabolique, etc.)

2 Comprendre les problèmes de santé futurs des hommes infertiles (risque accrude cancer, etc.)

3 Comprendre quels examens sont requis pour cerner les hommes présentant cesautres problèmes de santé



The Use of Synthetic Mesh in Vaginal Surgery: Past, Present and FutureUtilisation de filet synthétique en chirurgie vaginale: passé, présent et avenir

Introduction:Ethan Grober, Toronto, ON

Speaker/Conférencier:Keith Jarvi, Toronto, ON

Introduction:Kevin Carlson, Calgary, AB

Speaker/Conférencier:Victor Nitti, New York, NY


CUA 2012 BANFF 87

88 CUA 2012 BANFF

Objectives / Objectifs1 To understand the development of mesh for vaginal prolapse and incontinence

surgery

2 To know the common complications of vaginal mesh and why they happen

3 To understand the current state of governmental and society positions on the useof transvaginal mesh and how this may affect practice

1 Comprendre l’utilisation de filet en chirurgie pour le prolapsus vaginal etl’incontinence.

2 Connaître les complications courantes de l’utilisation de filet vaginal et lesraisons de ces complications

3 Comprendre les positions actuelles au niveau du gouvernement et de la sociétéconcernant l’utilisation du filet transvaginal et son impact sur la pratique





Office Evaluation and Management of LUTs: Focus on OABÉvaluation et prise en charge des TUBA en cabinet : Point de mire sur la vessie hyperactive

Objectives / Objectifs1 Develop a strategy for the evaluation and management of a patient

with OAB failing an initial trial of anticholinergic therapy

2 Formulate a rational and effective plan for the evaluation and treatment of men with OAB symptoms

3 Formulate a rational and effective plan for the evaluation and treatment of elderly patients with OAB symptoms

1 Élaborer une stratégie pour l’évaluation et la prise en charge de cas de vessiehyperactive après échec d’un traitement initial par anticholinergique

2 Formuler un plan rationnel efficace pour l’évaluation et le traitement des hommes affichant des symptômes de vessie hyperactive

3 Formuler un plan rationnel efficace pour l’évaluation et le traitement despersonnes âgées affichant des symptômes de vessie hyperactive

Moderator/Modérateur:Kevin Carlson, Calgary, AB

Faculty/Faculté:Greg G. Bailly, Halifax, NSVictor Nitti, New York, NYKevin Carlson, Calgary, AB


1600-1730 Bladder Cancer Canada Medical Advisory Board and Medical Research Board MeetingCancer de la vessie Canada et Réunion du Conseil de recherchemédicale

Room – Salle: Frontenac

1600-1800 Urology Nurses of Canada / Infirmières en urologie Canada


1610 - 1640 SOA8State-of-the-Art Lecture 8 / Conférence d’honneur 8


The Genetic of Vesicoureteral Reflux: Not as Straightforward as We ThinkLa génétique du reflux vésico-urétéral : pas aussi simple qu’on le croit

Objectives / Objectifs1 To understand the genetic basis for vesicoureteral reflux

2 To understand the principles of SNPs genome wide analysis

3 To correlate clinical findings of VUR with its genetic basis

1 Comprendre le fondement génétique du reflux vésico-urétéral

2 Comprendre les principes de l’analyse des SNP à l’échelle génomique

3 Établir des corrélations entre les résultats cliniques liés au reflux vésico-urétéral et le fondement génétique

1645-1745 POD-04Podium Session 4: Lower Urinary TractSéance Podium 4: Troubles du bas appareil urinaire

Room / Salles: Van Horne AModerators/Modérateurs:Sender Herschorn, Toronto, ONCurtis Nickel, Kingston, ON

Introduction:Dawn McLellan, Halifax, NS

Speaker/Conférencier:Hiep Nguyen, Boston, MA


CUA 2012 BANFF 89

90 CUA 2012 BANFF

1645-1655 POD-04.01 Mirabegron Improves Patient-reported Outcomes in Patients withOveractive Bladder Syndrome: Results from a North-American Study

Nitti, Victor1; Herschorn, Sender2; Auerbach, Stephen3; Martin, Nancy4; Blauwet, Mary Beth41NYU School of Medicine, New York, NY, United States; 2University of Toronto, Toronto, ON,Canada; 3Hoag Memorial Presbyterian Hospital, Newport Beach, CA, United States; 4Astellas,Deerfield, IL, United States

1655-1705 POD-04.02 Greenlight HPS-120W vs XPS-180W Laser Vaporization of the Prostate for Benign Prostatic Hyperplasia: a ProspectiveComparative Outcomes Analysis

Zorn, Kevin; Liberman, Dan; Hueber, Pierre-Alain; Ben-Zvi, Tal; Péloquin, FrançoisUniversity of Montreal Hospital Center (CHUM), Montreal, QC, Canada

1705-1715 POD-04.03Changes in Erectile Function after Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia

Abdulla, Alym; Zareba, Piotr; Bowen, Jim; Hopkins, Rob; Tarride, Jean-Eric; Whelan, PaulMcMaster University, Hamilton, ON, Canada

1715-1725 POD-04.04 A Prospective Analysis of Consultation for Difficult Urinary Catheter Insertion at Tertiary Care Centers in Northern Alberta

Rourke, Keith; Van Zyl, Stephan; Bacsu, Chasta-DawneUniversity of Alberta, Edmonton, AB, Canada

1725-1735 POD-04.05 A Novel Urethral Catheter Design for Safer Placement and Outcomes

Garcia, Maurice1; Wu, Alex1; Bullock, Thomas1; Aaronson, David21University of California San Francisco, San Francisco, CA, United States; 2The KaiserPermanente Medical Group, Oakland, CA, United States

1735-1745 POD-04.06 Urethroplasty for Pelvic Fracture Urethral Distraction Defects (PFUDD):Factors Influencing Surgical Outcome and Erectile Dysfunction

Kinnaird, Adam; Zorn, Jeff; Rourke, KeithUniversity of Alberta, Edmonton, AB, Canada


1700-1800 International Volunteer Urology - CancircBénévoles en urologie internationale - Cancirc


1900-2300 President’s Reception and Banquet (Cocktails at 18:30) Réception et banquet présidentiel de l’AUC (Réception à 18h30)

Room – Salle: Alberta & New Brunswick


CUA 2012 BANFF 91

CUA 2012 BANFF 93

0630-0800 Council of Canadian University Urology Chairs (CCUUC) / CCUUC

Room – Salle: Palliser

0700-0710 CP2Clinical Pearls That Could Change Your PracticeDes perles cliniques qui pourrait changer votre pratique

Room – Salles: Van Horne ASpeaker/Conférencier:Anil Kapoor, Hamilton, ON



Managing the Negative Prostate BiopsyPrise en charge de la biopsie prostatique negative

Objectives / Objectifs1 To review the management options for a patient with negative prostate biopsy

2 To appreciate the use of MRI in prostate biopsy decision-making

3 To review the evidence for and against the use of 5-ARI in this setting.

4 To determine the selection criteria for repeating a prostate biopsy

5 To better understand the interpretation of PIN and ASAP in prostate biopsy reports

1 Examiner les options de prise en charge dans le cas d’un patient ayant desrésultats négatifs lors d’une biopsie prostatique

2 Comprendre l’usage de l’IRM dans le processus décisionnel en lien avec unebiopsie prostatique

3 Examiner les données pour et contre l’usage des I5AR dans ce contexte

4 Établir les critères de sélection pour la répétition d’une biopsie prostatique

5 Mieux comprendre l’interprétation de la néoplasie intraépithéliale prostatique(PIN) et de la petite prolifération acineuse atypique (ASAP) dans les rapports debiopsie prostatique

Moderator/Modérateur:Armen Aprikian, Montreal, QC

Faculty/Faculté:Neil Fleshner, Toronto, ONRobert Siemens, Kingston, ON,Bryan Donnelly, Calgary, AB

TUESDAY / MARDI JUNE 26 JUIN

94 CUA 2012 BANFF

0800-0900 POD-05Podium Session 5: Prostate CancerSéance Podium 5: Cancer de la prostate

Room – Salle: Van Horne AModerators/Modérateurs:Eric Estey, Edmonton, ABArmen Aprikian, Montreal, QC

0800-0810 POD-05.01 Effect of Denosumab on Prolonging Bone-metastasis Free Survival in Men with Non-metastatic Castrate-resistant Prostate CancerPresenting with Aggressive Prostate-specific Antigen Kinetics

Saad, Fred1; Oudard, Stephane2; Smith, Matthew3; Shore, Neal4; Miller, Kurt5; Tombal,Bertrand6; Sieber, Paul7; Fizazi, Karim8; Van Veldhuizen, Peter9; Damiao, Ronald10; Marx,Gavin11; Morote, Juan12; Feng, Amy13; Dansey, Roger13; Goessl, Carsten131Hôpital Notre-Dame du CHUM, Montréal, QC, Canada; 2Georges Pompidou Hospital, Paris,France; 3Massachusettes General Hospital Cancer Center, Boston, MA, United States;4Carolina Urological Research Center, Myrtle Beach, SC, United States; 5Charité Berlin, Berlin,Germany; 6Université Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles,Belgium; 7Urological Associates of Lancaster, Lancaster, PA, United States; 8Institut GustaveRoussy, University of Paris Sud, Paris, France; 9Kansas City VA Medical Center, Kansas City,MO, United States; 10Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil; 11SydneyHaematology and Oncology Clinic, Wahroonga NSW, Australia; 12Hospital Vall d’Hebron,Barcelona, Spain; 13Amgen Inc, Thousand Oaks, CA, United States

0810-0820 POD-05.02Need for Intervention and Survival in a Cohort of Patients on ActiveSurveillance (AS) for Low-risk Prostate Cancer

Preston, Mark1; Paly, Jonathan1; Carrasquillo, Robert2; Coen, John1; Zietman, Anthony1; Smith,Matthew R.1; Wu, Chin-Lee1; McDougal, W. Scott1; Feldman, Adam S.11Massachusetts General Hospital, Boston, MA, United States; 2Harvard Medical School,Boston, MA, United States

0820-0830 POD-05.03 A Population-based Analysis of Pathological Outcomes FollowingRadical Prostatectomy in Academic vs. Non-academic Institutions

Nayak, Jasmir; Mau, Elke; Drachenberg, Darrel; Suderman, Derek; Guilbert, Kimi; Mak,Giselle; Lambert, Pascal; Quon, HarveyUniversity of Manitoba, Winnipeg, MB, Canada


CUA 2012 BANFF 95

0830-0840 POD-05.04 Between-surgeon Variation in Outcomes of Radical Prostatectomy forClinically Localized Prostate Cancer: Analysis of 1014 ConsecutiveMen Treated at the University of Alberta

Fairey, Adrian1; Jacobsen, Niels2; Yasui, Yataku2; Liu, Qi2; Voaklander, Don2; Estey, Eric21University of Southern California, Los Angeles, CA, United States; 2University of Alberta,Edmonton, AB, Canada

0840-0850 POD-05.05 Population-based Study of Long-term Rates of Surgery for UrinaryIncontinence following Radical Prostatectomy for Prostate Cancer

Nam, Robert; Herschorn, Sender; Loblaw, Andrew; Liu, Ying; Klotz, Laurence; Carr, Lesley;Kodama, Ronald; Saskin, Refik; Law, CalvinSunnybrook Health Sciences Centre, Toronto, ON, Canada

0850-0900 POD-05.06 A Randomized Trial Comparing External Beam Radiation andCryotherapy in Localized Prostate Cancer: 10 Year Follow-up

Donnelly, Bryan1; Saliken, John2; Brasher, Penny2; Lau, Harold2; Trpkov, Kiril3; Robinson, John31Prostate Cancer Centre Calgary, Calgary, AB, Canada; 2Tom Baker, Calgary, AB, Canada;3Calgary Lab Services, Calgary, AB, Canada

0800-1000 CUAJ Editorial Board MeetingComité de rédaction du Journal de l’AUC




Controversies in Castrate-resistant Metastatic Prostate CancerControverses entourant le cancer métastatique de la prostate résistant à la castration

Objectives / Objectifs1 Review the new developments and recent clinical trial results of novel agents in

patients with castrate resistant prostate cancer (CRPC)

Moderator/Modérateur:Alan So, Vancouver, BC

Faculty/Faculté:Neil Fleshner, Toronto, ON


96 CUA 2012 BANFF

2 Define the role of the Urologist as well as multi-disciplinary approach to the management of CRPC

3 Assess state-of-the-art management of CRCP, both in terms of guidelines as well as novel agents that will be available in the near future

1 Examiner les récents développements et résultats d’essais cliniques portant surles nouveaux agents chez les patients atteints d’un cancer de la prostaterésistant à la castration (CPRC)

2 Établir le rôle de l’urologue et d’une approche multidisciplinaire dans la prise encharge du CPRC

3 Évaluer la prise en charge de pointe du CPRC, tant sur le plan des lignesdirectrices que des nouveaux agents qui seront lancés sur le marché dans un avenir rapproché

0950-1010 Break / Pause

Room – Salle: Foyer



Robotics and Innovation / Robotique et innovation

Objectives / Objectifs1 Understand the new technologies such as robotics, surgical rehearsal and other

innovations which are improving the practice of surgery and how to implementthem into daily practice

2 Discover how the new technologies in the laboratory, such as nanotechnologyand tissue engineering, will require a fundamental change in the practice of surgery

3 Be aware of the moral and ethical implications of advanced medical technologiesand their impact on individuals, behavior, society and human kind

1 Comprendre les nouvelles technologies comme la robotique, les systèmes de répétition des interventions chirurgicales et autres innovations améliorant lapratique chirurgicale et comment les mettre en œuvre dans la pratiquequotidienne

2 Découvrir comment les nouvelles technologies utilisées en laboratoire, comme lananotechnologie et l’ingénierie tissulaire, exigeront un changement fondamentaldans la pratique de la chirurgie

3 Réfléchir aux répercussions morales et éthiques des technologies médicalesavancées et leur impact sur les particuliers, les comportements, la société et

Introduction:Trevor Schuler, Edmonton, AB

Speaker/Conférencier:Richard Satava, Seattle, WA


CUA 2012 BANFF 97

l’humanité

1040-1125 Urological Jeopardy / Jeu “Les grosses têtes” de l’urologie


1125-1240 EF8Educational Forum 8 and LUNCH / Forum éducatif 8 et DÉJEUNER


Exploring New Options in the Treatment of ED/BPH?: Uts and Testosterone Replacement TherapyExplorer des nouvelles options dans le traitement de l’ED, de l’HBP et des TUBA et le traitement de remplacement de la testostérone

Objectives / Objectifs1 To critically evaluate evolving data on hypogonadal men and androgen

replacement therapy

1 To assess the existing scientific support for use of PDE5i’s in BPH/LUTS

3 To understand the role of PDE5’s in the use of LUTS and ED in the comorbidpatient

1 Évaluer, avec un sens critique, les données en évolution sur les hommes atteintsd’hypogonadisme et le traitement de remplacement androgénique

2 Évaluer les données scientifiques existantes appuyant le recours aux inhibiteursde la PDE5 dans le traitement de l’HBP ou des TUBA

3 Comprendre le rôle des inhibiteurs de la PDE5 dans le traitement des TUBA et dela DE chez le patient atteint de comorbidités

1240-1440 MP-01Moderated Poster Session 1: Prostate CancerSéance de posters modérés 1: Cancer de la prostate

Room – Salle: Baron ShaughnessyModerators/Modérateurs: Bryan Donnelly, Calgary, AB

Moderator/Modérateur:Gerald Brock, London, ON

Faculty/Faculté:François Bénard, Montréal, QC,Curtis Nickel, Kingston, ON, Gerald Brock, London, ON


98 CUA 2012 BANFF

MP-01.01The Impact of a Sensitivity Adapted Antimicrobial ProphylacticStrategy on Prostate Biopsy Sepsis

Rowe, Neal; Breau, Rodney H.; Cagiannos, Ilias; Zvonar, Rosemary; Fergusson, Dean;Lavallee, Luke T.; Mallick, Ranjeeta; Morash, Christopher G.University of Ottawa, Ottawa, ON, Canada

MP-01.02 Serum Adipokine Levels Improve Prostate Cancer PredictionCompared to Clinical Data Only

Margel, David1; Trottier, Greg1; Yap, Stanley1; Connor, Mike2; Elharram, Malik1; Bhindi, Bimal1;Kulkarni, Girish1; Finelli, Antonio1; Zlotta, Alexandre1; Fleshner, Neil11Division of Urology, Department of Surgical Oncology, University Health Network, Universityof Toronto, Toronto, ON, Canada; 2University of York, Toronto, ON, Canada

MP-01.03 PCA3 Test as an Adjunct in Diagnosis of Prostate Cancer

Yutkin, Vladimir1; Al-Zahrani, Ali1; Williams, Andrew1; Hidas, Guy2; Martinez, Carlos1; Izawa,Jonathan1; Pode, Dov2; Chin, Joseph11University of Western Ontario, Uro-Oncology Fellowship Program, London, ON, Canada;2Hadassah and Hebrew University Medical Center, Jerusalem, Israel

MP-01.04 Percentage of Gleason 4 on Repeat Biopsy: How Much Matters?

Punnen, Sanoj; Glass, Allison; Cowan, Janet; Carroll, PeterUniversity of California, San Francisco, CA, United States

MP-01.05 Diagnostic Accuracy of Seminal Vesicle Biopsy in Evaluating SeminalVesicle Invasion: Comparison with MRI

Suntharasivam, Thiru; Hameed, Ammar; Doble, AndrewUrology Department, Addenbrookes University Hospital, Cambridge, United Kingdom

MP-01.06 Ultra-extended Prostate Biopsy Improves Detection of PathologicProgression in Patients on Active Surveillance for Prostate Cancer

Wong, Lih-Ming1; Trottier, Greg1; Fleshner, Neil1; Lawrentchuk, Nathan1; Kulkarni, Girish1;Zlotta, Alexander2; Trachtenberg, John1; Toi, Ants3; Timilshina, Narhari4; Finelli, Antonio11Department of Urology, Princess Margaret Hospital, Toronto, ON, Canada; 2Department ofUrology, Mount Sinai Hospital, Toronto, ON, Canada; 3Department of Radiology, PrincessMargaret Hospital, Toronto, ON, Canada; 4Division of General Internal Medicine & ClinicalEpidemiology, University Health Network, Toronto, ON, Canada


CUA 2012 BANFF 99

MP-01.07Is There a Role for Routine Anterior Zone Sampling during TransrectalUltrasound Guided Saturation Prostate Biopsy

Cole, Eric1; Shayegan, Bobby1; Matsumoto, Edward1; Greenspan, Michael1; Daya, Dean2;Patlas, Michael3; Pinthus, Jehonathan11McMaster Institute of Urology, Hamilton, ON, Canada; 2McMaster Department of Pathology,Hamilton, ON, Canada; 3McMaster University Department of Radiology, Hamilton, ON, Canada

MP-01.08 International Multi-centre Study Examining Selection Criteria forActive Surveillance in Men Undergoing Radical Prostatectomy

Wong, Lih-Ming1; Neal, David2; Johnston, Richard2; Shah, Nimesh2; Warren, Anne2; Hovens, Chris3; Goldenberg, Larry4; Gleave, Martin4; Costello, Anthony3; Corcoran, Niall31Princess Margaret Hospital, Toronto, ON, Canada; 2Addenbrookes Hospital, Cambridge,United Kingdom; 3The Australian Prostate Cancer Centre at Epworth and Departments ofUrology and Surgery, Royal Melbourne Hospital, Melbourne, Australia; 4The VancouverProstate Centre, Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada

MP-01.09Gleason Upgrading and Increased Cancer Volume on Repeat ProstateBiopsy in Patients on Active Surveillance (AS)

Preston, Mark A.1; Carrasquillo, Robert2; Paly, Jonathan J.1; Coen, John J.1; Zietman, AnthonyI.1; Smith, Matthew R.1; Wu, Chin-Lee1; McDougal, W. Scott1; Feldman, Adam S.11Massachusetts General Hospital, Boston, MA, United States; 2Harvard Medical School,Boston, MA, United States

MP-01.10Multi-institutional Validation of the CAPRA-S Score to PredictOutcomes after Radical Prostatectomy

Punnen, Sanoj1; Freedland, Stephen2; Presti, Joseph3; Aronson, William4; Terris, Martha5;Kane, Christopher6; Amling, Christopher7; Carroll, Peter1; Cooperberg, Matthew1

1University of California, San Francisco, CA, United States; 2Duke University, Durham, NC,United States; 3Stanford University, Palo Alto, CA, United States; 4University of California, LosAngeles, CA, United States; 5Medical School of Georgia, Augusta, GA, United States;6University of California, San Diego, CA, United States; 7Oregon Health Sciences University,Portland, OR, United States

MP-01.11 High Intensity Focused Ultrasound for Localized Prostate Cancer:Impact of Nadir PSA on Cancer Control

Shayegan, Bobby1; Dason, Shawn1; Pinthus, Jehonathan1; Farrokhyar, Forough2; Orovan,William1

1Division of Urology, McMaster University, Hamilton, ON, Canada; 2Department of Surgery,McMaster University, Hamilton, ON, Canada


100 CUA 2012 BANFF

MP-01.12Radical Prostatectomy in Patients with High Risk Prostate Cancer:Predicting Oncological Outcomes in a Single Series

Autran Gomez, Ana Maria; Chin, Joseph; Izawa, JonathanLondon Health Sciences Centre, University of Western Ontario, London, ON, Canada

MP-01.13Prospective, Randomized Use of the VLOC Vesicourethral Anastamosisduring Robot-assisted Radical Prostatectomy: Long-term Follow-up

Zorn, Kevin1; Trinh, Quoc-Dien2; Liberman, Dan2; Elhakim, Assaad21University of Montréal (CHUM), Montréal, QC, Canada; 2University of Montreal Hospital Center(CHUM), Montreal, QC, Canada

MP-01.14Comparison of Open and Robotic-assisted Prostatectomy: The University of British Columbia Experience

Gagnon, Louis-Olivier; Lynch, Kenny; Hurtado, Antonio; Goldenberg, Larry; Gleave, MartinDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

MP-01.15 How Does Robot-assisted Laparoscopic Radical ProstatectomyCompare to Open Surgery in Men with High Risk Prostate Cancer?

Punnen, Sanoj; Cowan, Janet; Carroll, PeterUniversity of California, San Francisco, CA, United States

MP-01.16 Positive Surgical Margins at Radical Prostatectomy: Population-based Averages within PSA and Gleason Strata

Izard, Jason1; Salazar, Marco2; Chatterjee, Suman3; Lin, Daniel1; Wright, Jonathan11Department of Urology, University of Washington, Seattle, WA, United States; 2SoundUrological Associates, Edmonds, WA, United States; 3William Osler Health Centre, Brampton,ON, Canada

MP-01.17 Prostate Cancer Less than Two Cells from the Surgical MarginPredicts Biochemical Recurrence

Izard, Jason1; True, Lawrence2; May, Philip1; Ellis, William1; Lange, Paul1; Lin, Daniel1; Wright, Jonathan11Department of Urology, University of Washington, Seattle, WA, United States; 2Department of Pathology, University of Washington, Seattle, WA, United States


CUA 2012 BANFF 101

MP-01.18 Striated Muscle in Radical Prostatectomy Specimens: Is It Predictive of Post-prostatectomy Urinary Incontinence?

Skeldon, Sean; Gani, Johan; Evans, Andrew; Van der Kwast, Theo; Radomski, SidneyUniversity of Toronto, Toronto, ON, Canada

MP-01.19Radiotherapy after Radical Prostatectomy: TreatmentRecommendations Differ between Urologists and RadiationOncologists

Lavallée, Luke T.1; Fergusson, Dean2; Grenon, Renee3; Morgan, Scott4; Momoli, Franco2;Morash, Christopher1; Cagiannos, Ilias1; Breau, Rodney H.11Division of Urology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; 2OttawaHospital Research Institute, University of Ottawa, Ottawa, ON, Canada; 3Children’s Hospital ofEastern Ontario, Ottawa, ON, Canada; 4Division of Radiation Oncology, The Ottawa Hospital,University of Ottawa, Ottawa, ON, Canada

MP-01.20 Osteoporosis Management Program Decreases the Incidence of HipFracture in Prostate Cancer Patients on Androgen Deprivation Therapy

Chien, Gary1; Zhumkhawala, Ali1; Gleason, Joseph1; Cheetham, Craig1; Niu, Fang1; Dell,Richard2; Jacobsen, Steven31Kaiser Permanente, Los Angeles, CA, United States; 2Kaiser Permanente, Downey, CA, UnitedStates; 3Kaiser Permanente, Pasadena, CA, United States

MP-01.21Testosterone Suppression: Impact of Testosterone Level on DiseaseProgression in Advanced Prostate Cancer

Dason, Shawn; Tong, Justin; Allard, Christopher; Shayegan, BobbyDivision of Urology, McMaster University, Hamilton, ON, Canada

MP-01.22Inadequate Testosterone Suppression in Prostate Cancer PatientsFailing on GnRH Agonists: Preliminary Data from the Delay Study

Casey, Richard1; Morales, Alvaro2; Siemens, Robert31The Male Health Centre, Oakville, ON, Canada; 2Queen’s University, Kingston, ON, Canada;3Queen’s University, Oakville, ON, Canada Richard Casey1 and Alvaro Morales2


102 CUA 2012 BANFF

1240-1440 MP-02Moderated Poster Session 2: Endourology/StonesSéance de posters modérés 2: Endo-urologie/Lithiases

Room – Salle: BeattyModerators/Modérateurs:Ryan Paterson, Vancouver, BC Darren Beiko, Kingston, ON

MP-02.01 Holmium Laser Enucleation of the Prostate for Glands Larger than 200 Grams

Bhojani, Naeem; Mandeville, Jessica A.; Boris, Ronald S.; Lingeman, James E.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States

MP-02.02 Impact of 5-alpha Reductase Inhibitors on Enucleation andMorcellation Efficiency during Holmium Laser Enucleation of the Prostate

Bhojani, Naeem; Mandeville, Jessica A.; Boris, Ronald S.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States

MP-02.03 Early Outcomes of Office-based Laser Vaporization of the Prostatewith the High Power Diode Laser

Davis, Jeffrey; Patel, Roshan; Culkin, Daniel; Sindhwani, PuneetUniversity of Oklahoma, Health Sciences Center, Oklahoma City, OK, United States

MP-02.04 Novel Ultra-low Dose Non-contrast CT (NCCT) for Urolithiasis:Prospective Comparison of Diagnostic Accuracy with ConcurrentStandard Dose Imaging

Sivalingam, Sri; Pickhardt, Perry; Ruma, Julie; Nakada, Stephen Y.University of Wisconsin, WI, United States

MP-02.05 Does a Routine Baseline Plain Radiograph Influence the Need forSubsequent Imaging Studies in Patients with Ureteral Calculi?

Foell, Kirsten1; Ordon, Michael2; Ghiculete, Daniela2; Honey, R. John D’A.2; Pace, Kenneth T.21St. Michael’s Hospital, Toronto, ON, Canada; 2St. Michael’s Hospital, University of Toronto,Toronto, ON, Canada


CUA 2012 BANFF 103

MP-02.06 Urolithiasis Prevention Beginning in the Emergency Room: Support forEarly Intervention During the Acute Event

Sivalingam, Sri; Penniston, Kris; Nakada, Stephen Y.University of Wisconsin, Madison, WI, United States

MP-02.07 Characterization of Patients with Heterozygous Cystinuria

Elkoushy, Mohamed; Andonian, Sero

MP-02.08 Office-based Ureteral Stent Placement Is Feasible and Effective forAcute, Obstructing Ureteral Calculi

Sivalingam, Sri; Tamm-Daniels, Inge; Nakada, Stephen Y.University of Wisconsin, Madison WI, United States

MP-02.09 Variations among Urology Trainees in Their Use of Fluoroscopy duringUreteroscopy

Elkoushy, Mohamed; Andonian, SeroMcGill University Health Center, Montreal, QC, Canada

MP-02.10 Prediction of Calcium Oxalate Monohydrate Stone Composition duringUreteroscopy

Hamidizadeh, Reza; Teichman, Joel M. H.Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada

MP-02.11 Backstop Eliminates Retropulsion and Withstands Ho:YAG Energy

Melnyk, Megan1; Sea, Jason1; Teichman, Joel1; Qiu, Jinze3; Wang, Bingqing3; Milner, Thomas2;Chew, Ben1; Robinson, Michael11University of British Columbia, Vancouver, BC, Canada; 2University of Texas, Austin, TX, UnitedStates

MP-02.12 The Safety of Percutaneous Nephrolithotomy (PNL) in an ElderPopulation: Outcomes and Complications of Septuagenarians,Octogenarians and Nonagenarians

De, Shubha1; Thalivasan, Simone2; Pareek, Gyan2; Haleblian, George21Dalhousie University, Department of Urology, Halifax, NS, Canada; 2Brown University,Department of Urology, Providence, RI, United States


104 CUA 2012 BANFF

MP-02.13 Withdrawn

MP-02.14 Retrograde Access for Percutaneous Nephrolithotomy: Is This The Way to Go?

Sivalingam, Sri1; Al-Essawi, Turki2; Hosking, Denis21University of Wisconsin, Madison, WI, United States; 2University of Manitoba, Winnipeg, MB,Canada

MP-02.15 Without Stone Culture Infectious Kidney Organisms Are Misidentifiedin almost 1/4 of Patients Undergoing Percutaneous Nephrolithotomy

Bhojani, Naeem1; Williams, James C.2; Mandeville, Jessica A.1; Lingeman, James E.11Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States; 2IndianaSchool of Medicine, Department of Anatomy, Indianapolis, IN, United States

MP-02.16 Interim Analysis of a Multi-centre Randomized Controlled TrialComparing Three Different Modalities of Newer Lithotrites forIntracorporeal Lithotripsy

Arsovska, Olga1; Miller, Nicole2; Krambeck, Amy3; Humphreys, Mitchell3, Matlaga, Brian4;Nakada, Stephen5; Nadler, Robert6; Lingeman, James7; Razvi, Hassan8; Paterson, Ryan1;Chew, Ben11University of British Columbia, Vancouver, BC, Canada; 2Vanderbilt University Medical Center,Nashville, TN, United States; 3Mayo Clinic College of Medicine, Phoenix, AZ, United States;4Johns Hopkins -Baltimore, MD, United States; 5University of Wisconsin, Madison, WI, UnitedStates; 6Northwestern University, Chicago, IL, United States; 7Methodist Urology, Indianapolis,IN, United States; 8University of Western Ontario, London, ON, Canada

MP-02.17 Combined Percutaneous Nephrolithotomy/Parathyroidectomy underOne Anesthetic in Patients with Primary Hyperparathyroidism andStones

Bhojani, Naeem1; Mandeville, Jessica A.1; Graffis, Richard2; Lingeman, James E.21Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States; 2Indiana School of Medicine, Department of General Surgery, Indianapolis, IN, United States

MP-02.18 Shock Wave Lithotripsy Referral Patterns Changes Over a Decade at aSingle Centre



CUA 2012 BANFF 105

MP-02.20 How Accurate Are Urologists at Estimating Lesion SizeEndoscopically?

Massaro, Peter1; Abdolell, Mohamed2; Norman, Richard11Department of Urology, Dalhousie University, Halifax, NS, Canada; 2Department of DiagnosticRadiology, Dalhousie University, Halifax, NS, Canada

1240-1440 MP-03Moderated Poster Session 3: RenalSéance de posters modérés 3: Rénal

Room – Salle: Van Horne BModerators/Modérateurs:Anil Kapoor, Hamilton, ONJun Kawakami, Calgary, AB

MP-03.01Does the Method of Bladder Cuff Excision Affect Disease Recurrenceafter Nephrouretectomy for Upper Tract Urothelial Carcinoma? A Single-centre Comparison of Three Bladder Cuff Excision Methods

Allard, Christopher; Alamri, Abdulaziz; Matsumoto, Edward; Dason, Shawn; Kapoor, AnilMcMaster Institute of Urology, Hamilton, ON, Canada

MP-03.02Regional Differences in Practice Patterns and Associated Outcomesfor Upper Tract Urothelial Carcinoma in Canada: Outcomes from the Canadian Upper Tract Collaboration

Wassim, Kassouf1; Rendon, Ricardo2; Bell, David2; Izawa, Jonathan3; Chin, Joseph3; Kapoor,Anil4; Matsumoto, Edward4; Lattouf, Jean-Baptiste5; Saad, Fred5; Lacombe, Louis6; Fradet,Yves6; Fairey, Adrian7; Jacobson, Niels7; Drachenberg, Darryl8; Cagiannos, Ilias9; So, Alan10;Black, Peter10; Metcalfe, Michael101McGill University, Montréal, QC, Canada; 2Dalhousie University, Halifax, NS, Canada;3University of Western Ontario, London, ON, Canada; 4McMaster University, Hamilton, ON,Canada; 5University of Montreal, Montreal, QC, Canada; 6Laval University, Quebec, QC,Canada; 7University of Alberta, Edmonton, AB, Canada; 8University of Manitoba, Winnipeg, MB, Canada; 9University of Ottawa, Ottawa, ON, Canada; 10University of British Columbia,Vancouver, BC, Canada


106 CUA 2012 BANFF

MP-03.03Impact of Body Mass Index (BMI) on Outcomes of Patients with Upper and Lower Urinary Tract Cancers Treated by Radical Surgery:Results from a Canadian Multicenter Collaboration

Bachir, Bassel G.1; Aprikian, Armen G.1; Izawa, Jonathan I.2; Chin, Joseph L.2; Fradet, Yves3;Fairey, Adrien4; Estey, Eric4; Jacobsen, Niels4; Rendon, Ricardo5; Cagiannos, Ilias6; Lacombe,Louis3; Tanguay, Simon1; Lattouf, Jean-Baptiste7; Kapoor, Anil8; Matsumoto, Edward8; Saad,Fred7; Bell, David5; Black, Peter C.9; So, Alan I.9; Drachenberg, Darrel10; Kassouf, Wassim1

1McGill University Health Center, Montreal, QC, Canada; 2University of Western Ontario,London, ON, Canada; 3Laval University, Quebec, QC, Canada; 4University of Alberta, Edmonton,AB, Canada; 5Dalhousie University, Halifax, NS, Canada; 6University of Ottawa, Ottawa, ON,Canada; 7University of Montreal, Montreal, QC, Canada; 8McMaster University, Hamilton, ON,Canada; 9University of British Columbia, Vancouver, BC, Canada; 10University of Manitoba,Winnipeg, MB, Canada

MP-03.04A Population-based Study of Surgeon Characteristics Associated withthe Uptake of Contemporary Techniques in Renal Surgery

Yap, Stanley1; Alibhai, Shabbir1; Margel, David1; Abouassaly, Robert2; Timilshina, Narhari1;Finelli, Antonio11University of Toronto, Toronto, ON, Canada; 2University Hospitals Case Medical Center,Cleveland, OH, United States

MP-03.05Association between Comorbidity and Survival after RadicalNephroureterectomy: Results from the Canadian Upper TractCollaboration

Fairey, Adrian1; Jacobsen, Niels2; Tanguay, Simon3; Rendon, Ricardo4; Bell, David4; Izawa,Jonathan5; Chin, Joe5; Kapoor, Anil6; Matsumoto, Edward6; Black, Peter7; So, Alan7; Lattouf,Jean-Baptiste8; Saad, Fred8; Drachenberg, Darrell9; Cagiannos, Ilias10; Lacombe, Louis11;Fradet, Yves11; Kassouf, Wassim3

1University of Southern California, Pasadena, CA, United States; 2University of Alberta,Edmonton, AB, Canada; 3McGill University, Montréal, QC, Canada; 4Dalhousie University,Halifax, NS, Canada; 5University of Western Ontario, London, ON, Canada; 6McMasterUniversity, Hamilton, ON, Canada; 7University of British Columbia, Vancouver, BC, Canada;8University of Montreal, Montreal, QC, Canada; 9University of Winnipeg, Winnipeg, MB,Canada; 10University of Ottawa, Ottawa, ON, Canada; 11Laval University, Quebec City, QC,Canada

MP-03.06Ipsilateral Adrenalectomy at the Time of Radical Nephrectomy - Does It Impact Overall Survival?

Yap, Stanley1; Alibhai, Shabbir1; Abouassaly, Robert2; Timilshina, Narhari1; Margel, David1;Finelli, Antonio11University of Toronto, Toronto, ON, Canada; 2University Hospitals Case Medical Center,Cleveland, OH, Canada


CUA 2012 BANFF 107

MP-03.07Oncolytic Virotherapy Combined with Targeted Therapy for theTreatment of Renal Cell Carcinoma

Lawson, Keith1; Shi, Zhong Qiao1; Spurrell, Jason1; Kawakami, Jun2; Morris, Don11Department of Oncology, University of Calgary, Calgary, AB, Canada; 2Division of Urology,Department of Surgery, University of Calgary, Calgary, AB, Canada

MP-03.08Clinical Role of the SWI/SNF Complex Gene PBRM1 in Clear Cell RenalCell Carcinoma

Morales, Carlos; Kurban, Ghada; Matevski, Donco; Massey, Christine; Evans, Andrew; Gallie,Brenda L.; Jewett, Michael A.S.University Health Network, Princess Margaret Hospital, Toronto, ON, Canada

MP-03.09Canadian Kidney Cancer Information System (CKCis): a ProspectivePlatform to Better Understand Outcomes of Patients with KidneyCancer

Tanguay, Simon1; Kapoor, Anil2; Wood, Lori3; Heng, Daniel4; Zhihui, Liu5; Hanley, James5; Lane, Kelly6; Chow, Raymond6; Hamilton, Wendella1; Jewett, Michael71McGill University Health Center, Montreal, QC, Canada; 2McMaster University, Hamilton, ON,Canada; 3Capital District Health Authority, Halifax, NS, Canada; 4Alberta Health Services,Calgary, AB, Canada; 5McGill University, Montréal, QC, Canada; 6University Health Network,Toronto, ON, Canada; 7University Health Center, Toronto, ON, Canada

MP-03.10Validation of a Partial Nephrectomy Bench Model Developed via aNovel Material Engineering Process

Alamri, Abdulaziz; Abdulla, Alym; Madjeruh, John; Matsumoto, EdwardMcMaster University, Hamilton, ON, Canada

MP-03.11Laparoscopic Partial Nephrectomy for ≥ 4 cm Renal Masses Alyami, FahadDalhousie University, Halifax, NS, Canada

MP-03.12Defining Small Renal Masses “trifecta” after Laparoscopic PartialNephrectomies

Blouin, Annie-Claude1; Dujardin, Thierry2; Audet, Jean-François2; Caumartin, Yves2; Lacombe,Louis2; Imbeault, Annie2; Fradet, Vincent2; Fradet, Yves2; Pouliot, Frédéric21Université Laval, Quebec, QC, Canada; 2Centre hospitalier universitaire de Québec, Quebec,QC, Canada


108 CUA 2012 BANFF

MP-03.13Fuhrman Grade Does Not Improve the Discriminant Ability in Patientswith Papillary Renal Cell Carcinoma

Ismail, Salima; Sun, Maxine; Abdo, Al’a; Djahangirian, Orchid; Hanna, Nawar; Karakiewicz, PierreCancer Prognostics and Health Outcome Unit, University of Montreal Health Center, Montreal, QC, Canada

MP-03.14Comparative Study for Carbonic Anhydrase-ix, Vascular EndothelialGrowth Factor and Platelet Derived Growth Factor Receptor-alphaImmunohitochemical Expression in Renal Cell Carcinoma

Bishr, Mohamed1; Le Page, Cecile1; Gannon, Philippe O.1; Barres, Véronique1; Albadine, Roula2;Saad, Fred2; Lattouf, Jean-Baptiste21Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and Institutdu cancer de Montréal, Montréal, QC, Canada; 2Centre hospitalier de l’Université de Montréal(CHUM), Montréal, QC, Canada

MP-03.15Percutaneous Renal Cryoablation: Results from a Prospective Study

Metcalfe, Charles1; Welsh, Mike2; Donnelly, Bryan31University of British Columbia, Vancouver, BC, Canada; 2University of Calgary, Department ofRadiology, Calgary, AB, Canada; 3University of Calgary, Division of Urology, Calgary, AB,Canada

MP-03.16Contrast-enhanced Ultrasound for Follow-up after RadiofrequencyAblation of Small Renal Masses

Kapoor, Anil1; Allard, Christopher1; Matsumoto, Edward1; Coret, Andu21McMaster University, Institute of Urology, Hamilton, ON, Canada; 2McMaster University,Department of Radiology, Hamilton, ON, Canada

MP-03.17Prophylactic vs. Selective Ureteral Stenting in Preventing UretericComplications Post Renal Transplant: a Retrospective Review

Ordon, Michael; Ghiculete, Daniela; Stewart, Robert; Pace, Kenneth; Honey, R. John D’A.St. Michael’s Hospital, Toronto, ON, Canada


CUA 2012 BANFF 109

MP-03.18Supplemental Hydrogen Sulphide Reduces Graft Inflammation and Modulates Inflammatory and Anti-apoptotic Gene Expression in Renal Grafts Transplanted Following Prolonged Cold Storage

Lobb, Ian1; Liu, Weihua2; Garcia, Bertha2; Lan, Zhu3; Sener, Alp41Microbiology and Immunology, University of Western Ontario, Matthew Mailing Centre,London, ON, Canada; 2Pathology, University of Western Ontario, London, ON, Canada;3Surgery, University of Western Ontario, Matthew Mailing Centre, London, ON, Canada;4Surgery and Microbiology and Immunology, University of Western Ontario, Matthew MailingCentre, London, ON, Canada

MP-03.19Does Donor Side Affect Outcomes? A Comparison of Right versus LeftAllografts in Deceased Donor Renal Transplantation

Ordon, Michael; Ghiculete, Daniela; Stewart, Robert; Pace, Kenneth; Honey, R. John D’A.St. Michael’s Hospital, Toronto, ON, Canada

MP-03.20 Detrimental Effects of Prolonged Warm Renal Ischemia ReperfusionInjury Are Abrogated by Supplemental Hydrogen Sulphide: an AnalysisUsing Real-time Intravital Microscopy

Zhu, Justin1; Kalbfleisch, Melanie1; Bihari, Relka1; Lobb, Ian1; Davison, Michael1; Mok, Amy1;Lawendy, Abdel1; Sener, Alp21University of Western Ontario, London, ON, Canada; 2Matthew Mailing Center forTranslational Transplant Studies, London, ON, Canada

MP-03.21En Bloc Adult Organ Transplantation

Tran, Kim-Chi1; Taqi, Ali1; Warren, Jeff2; Caumartin, Yves3; Nguan, Christopher4; McAlister,Vivian1; Luke, Patrick11University of Western Ontario, London, ON, Canada; 2University of Ottawa, Ottawa, ON,Canada; 3University of Laval, QC, Canada; 4University of British Columbia, Vancouver, BC,Canada

MP-03.22Maximal Kidney Length Predicts Need for Native Nephrectomy in Patients with Autosomal Dominant Polycystic Kidney DiseaseUndergoing Renal Transplantation

Cristea, Octav1; Yanko, Daniel2; Langford, Sarah2; House, Andrew2; Stitt, Larry1; Sener, Alp2; Luke, Patrick21Schulich School of Medicine & Dentistry, London, ON, Canada; 2London Health SciencesCentre, London, ON, Canada


110 CUA 2012 BANFF

MP-03.23Risk Stratification and Management Strategy for UndetectedThrombophilia in Pediatric Renal Transplant Recipients

Davis, Jeffrey; Sindhwani, Puneet; Turman, MartinUniversity of Oklahoma, Health Sciences Center, Oklahoma City, OK, United States

1240-1440 MP-04Moderated Poster Session 4: Voiding DysfunctionSéance de posters modérés 4: Troubles mictionnels

Room – Salle: Van Horne CModerators/Modérateurs:Ron Gerridzen, Ottawa, ONRichard Baverstock, Calgary, AB

MP-04.01The Role of Dutasteride in Preventing BPH Clinical Progression inAsymptomatic Men with an Enlarged Prostate

Toren, Paul; Margel, David; Kulkarni, Girish; Finelli, Antonio; Zlotta, Alexandre; Fleshner, NeilUniversity of Toronto, Toronto, ON, Canada

MP-04.02Comparison of Ultrasound and Fluoroscopic Imaging for UrodynamicAssessment of Non-neurogenic Voiding Dysfunction in Males

Bacsu, Chasta-Dawne1; Tse, Vincent2; Chan, Lewis21Concord Repatriation General Hospital, Saskatoon, SK, Canada; 2Concord RepatriationGeneral Hospital, Sydney, Australia

MP-04.03Does Independently-interpreted Retrograde Urethrography AccuratelyDiagnose and Stage Anterior Urethral Stricture Disease?

Bach, Phil; Rourke, KeithUniversity of Alberta, Edmonton, AB, Canada

MP-04.04Do Cuff Size/Reservoir Size Impact Erosion, Revision, Infection andOutcome Rates in Patients Who Underwent AUS Placement for StressUrinary Incontinence after Primary Treatment for Prostate Cancer

Popovic, Mihailo; Lucas, Steven; Haddad, Joseph; Singla, AjayWayne State University, School of Medicine, Urology, Detroit, MI, United States


CUA 2012 BANFF 111

MP-04.05The Sphincter Sum: a Practical and Effective Tool for EvaluatingPatients with Post-prostatectomy Incontinence

Gustafson, PaulUniversity of British Colombia Urology, Vancouver, BC, Canada

MP-04.06Revision Urethroplasty for Recurrent Urethral Stricture: a ComparativeAnalysis of Efficacy and Outcomes

Levine, Max A.; Kinnaird, Adam S.; Rourke, Keith F.Division of Urology, University of Alberta, Edmonton, AB, Canada

MP-04.07Primary Realignment versus Suprapubic Cystostomy for theManagement of Posterior Urethral Distraction Defects: a SystematicReview and Meta-analysis

Barrett, Keith; Braga, Luis H.; Davies, Timothy O.McMaster University, Division of Urology, Hamilton, ON, Canada

MP-04.08The Mesh Wallstent (UroLume) in the Treatment of Detrusor ExternalSphincter Dyssynergia in Men with Spinal Cord Injury

Binsaleh, Saleh1; Laplante, Michael21King Saud University, Faculty of Medicine, Riyadh, Saudi Arabia; 2McGill University, Montréal,QC, Canada

MP-04.09Surgical Treatment of Male Incontinence Using the Argus Male Sling:Our First 5-Case Experience

Baverstock, Richard1; Carlson, Kevin1; Amaral, Nicole1; Herschorn, Sender21vesia [Alberta Bladder Centre], Division of Urology, University of Calgary, Calgary, AB,Canada; 2Division of Urology, University of Toronto, Toronto, ON, Canada

MP-04.10A Potential Gold Standard for Reconstruction of Long Segment BulbarUrethral Strictures - Intermediate Outcomes of the Dorsal OnlayAugmented Anastomosis with Buccal Mucosa Graft

Hoy, Nathan; Kinnaird, Adam; Rourke, KeithUniversity of Alberta, Division of Urology, Edmonton, AB, Canada


112 CUA 2012 BANFF

MP-04.11Effect of Baseline Characteristics of Subjects with Overactive Bladderon Changes in Daytime and Nighttime Urgency Urinary IncontinenceEpisodes Following Antimuscarinic Treatment

Herschorn, Sender1; Wang, Joseph2; Ntanios, Fady21University of Toronto, Toronto, ON, Canada; 2Pfizer Inc., New York, NY, United States

MP-04.12The Selective B3-Adrenoreceptor Agonist Mirabegron Is Effective and Well Tolerated in Patients with Overactive Bladder Syndrome

Herschorn, Sender1; Nitti, Victor2; Auerbach, Stephen3; Lee, Misun4; Martin, Nancy41University of Toronto, Toronto, ON, Canada; 2New York University School of Medicine, NewYork, NY, United States; 3Hoag Memorial Presbyterian Hospital, Newport Beach, CA, UnitedStates; 4Astellas, Deerfield, IL, United States

MP-04.13Open-label, Ascending Dose Cohort Study of LiRIS (lidocaine-releasingintravesical system) in Women with Moderate to Severe InterstitialCystitis

Steele, Stephen S.1; Nickel, J. Curtis1; Steinhoff, Gary2; Egerdie, Blair3; Gajewski, Jerzy4; Bailly, Greg4; Himes, Julie51Queen’s University, Kingston, ON, Canada; 2University of British Columbia, Victoria, BC,Canada; 3The University of Western Ontario, Kitchener, ON, Canada; 4Dalhousie University,Halifax, NS, Canada; 5Taris Biomedical, Lexington, MA, United States

MP-04.14Noninvasive Diagnosis of Painful Bladder Syndrome / InterstitialCystitis Using Near Infrared Spectroscopy

Shadgan, Babak; Stothers, Lynn; Macnab, AndrewUniversity of British Columbia, Vancouver, BC, Canada

MP-04.15Monitoring of Lower Urinary Tract Function in Patients with SpinalCord Injury Using Near Infrared Spectroscopy

Shadgan, Babak; Stothers, Lynn; Macnab, Andrew; Nigro, MarkUniversity of British Columbia, Vancouver, BC, Canada


CUA 2012 BANFF 113

MP-04.16The Signal Transduction of Skin Electrode Can Launch on the Bladderof Diabetic Rabbits and Ameliorate Its Hypomotility

Wang, Xinmin1; Zhang, Qingmei1; Xu, Ping1; Cao, Lin1; Xue, Meng1; Wang, Wei21Department of Endocrinology, The Second Clinical Medical College of Jinan University(Shenzhen Peoples Hospital), Shenzhen, China;2H. Medical and Health Physics, McMaster University, Hamilton, ON, Canada

MP-04.17Cost-effectiveness of Sacral Neuromodulation in RefractoryOveractive Bladder: a Canadian Perspective

Gajewski, Jerzy1; Corcos, Jacques2; Dwyer, Neil T3; Gray, Gary4; Hassouna, Magdy5; Magali,Robert6; Tu, Le-Mai7; Sadri, Hamid81Dalhousie University, Halifax, NS, Canada; 2Jewish General Hospital, Montreal, QC, Canada;3Moncton Hospital, Moncton, NB, Canada; 4Royal Alexandra Hospital, Edmonton, AB, Canada;5Toronto Western Hospital, Toronto, ON, Canada; 6Foothills Hospital, Calgary, AB, Canada;7Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, Canada; 8Medtronic ofCanada, Brampton, ON, Canada

MP-04.18Sacral Neuromodulation Failures

Chang, Michelle; Gajewski, JerzyDepartment of Urology, Dalhousie University, Halifax, NS, Canada

MP-04.19A Cost-effectiveness Analysis of Tension-free Vaginal Tape vs. Burch Colposuspension for Female Stress Incontinence

Elterman, Dean; Chughtai, Bilal; Laudano, Melissa; Li, Philip; Tyagi, Renuka; Kavaler,Elizabeth; Te, Alexis; Kaplan, Steven; Lee, RichardWeill Medical College of Cornell University, New York, NY, United States

MP-04.20Urinary Tract Mesh Erosion Following Female Pelvic Surgery

Cox, Ashley; Herschorn, Sender; Carr, LesleySunnybrook Health Science Centre, Toronto, ON, Canada

MP-04.21Long-term Outcomes of Pessary Use in Women with Pelvic Organ Prolapse

Ramsay, Sophie; Bouchard, Frederick; Tu, Le MaiUniversité de Sherbrooke, Sherbrooke, QC, Canada


114 CUA 2012 BANFF

MP-04.22Management and Outcomes of Complex versus Simple Female Urethral Diverticula

Carlson, KevinUniversity of Calgary/vesia [Alberta Bladder Centre], Calgary, AB, Canada

MP-04.23Developing a Multi-disciplinary Lower Urinary Tract Centre: the vesia [Alberta Bladder Centre] Experience

Baverstock, Richard1; Carlson, Kevin21vesia [Alberta Bladder Centre], Calgary, AB, Canada; 2vesia [Alberta Bladder Centre] Divisionof Urology, University of Calgary, Calgary, AB, Canada

1440-1450 Break / Pause

Room – Salle: Foyer

1450-1600 MP-05Moderated Poster Session 5: Pediatric UrologySéance de posters modérés 5: Urologie pédiatrique

Room – Salle:Van Horne CModerators/Modérateurs:Peter Metcalfe, Edmonton, AB Peter Anderson, Halifax, NS

MP-05.01Impact of Side of Allograft Placement and Location of ArterialAnastomosis on Delayed Renal Function after Pediatric RenalTransplantation

Figueroa, Victor H.; Lorenzo, Armando J.; Kim, Wooheon T.; Romao, Rodrigo L.P.; Pippi Salle,Joao L.; Koyle, Martin A.; Taylor, KatherineThe Hospital for Sick Children, Toronto, ON, Canada

MP-05.02Minimally Invasive Open Technique for Management of Upper PoleEctopic Ureter in Children with Duplicated Systems

Sheikh, Adeel1; Zaidi, Adil2; DeMaria, Jorge1; Luis, Braga11McMaster Institute of Urology, Hamilton, ON, Canada; 2St. George’s University, Great River,NY, United States


CUA 2012 BANFF 115

MP-05.03 Observation versus Immediate Intervention in Ureteropelvic Junction Obstruction: Does It Matter?

Stearns, Gillian1; Reeder, Jay1; Barrieras, Diego2; Houle, Anne-Marie2; Franc-Guimond, Julie2;Riddell, Jonathan11SUNY Upstate, Syracuse, NY, United States; 2CHU Sainte-Justine, Montréal, QC, Canada

MP-05.04A Prospective Study Using a New Bulking Agent for the Treatment of Pediatric Vesicoureteral Reflux: Bulkamid®

Cloutier, Jonathan1; Blais, Anne-Sophie2; Moore, Katherine2; Bolduc, Stéphane21Division of Urology CHUL, CHUQ, Quebec, QC, Canada; 2Division of Urology, CHUL-CHUQ,Université Laval, Quebec, QC, Canada

MP-05.05Does Routine Ultrasounds Change Management in the Follow-up of Patients with Vesicoureteral Reflux?

Wildgoose, Petra1; Weber, Bryce2; Lorenzo, Armando3; Bagli, Darius3; Farhat, Walid3; Harvey, Elizabeth3; Pippi Salle, Joao Luiz31McMaster Medical School, Calgary, AB, Canada; 2Alberta Children’s Hospital, Calgary, AB,Canada; 3Hospital for Sick Children, Toronto, ON, Canada

MP-05.06Methodological Quality Assessment of Randomized Controlled Trials inHypospadias Literature

Braga, Luis1; Lorenzo, Armando2; Vizcarra, Rachel1; Pemberton, Julia1; DeMaria, Jorge1;Byrne, Roisin31McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada;3University of Calgary, Calgary, AB, Canada

MP-05.07Is There a Role for Prophylactic Antibiotics after Stented HypospadiasRepair?

Kanaroglou, Niki; Alotay, Abdulhakim; Romao, Rodrigo; Koyle, Martin; Lorenzo, Armando;Bagli, Darius; Farhat, WalidSick Kids, Toronto, ON, Canada


116 CUA 2012 BANFF

MP-05.08The Effect of Androgen Stimulation on Post-operative ComplicationRates after Penoscrotal Hypospadias Repair: a Systematic Review and Meta-analysis

Cole, Eric1; Wright, Ian1; Lorenzo, Armando2; Pemberton, Julia1; Vizcarra, Rachel1; Farrokhyar, Forough1; Braga, Luis11McMaster University, Hamilton, ON, Canada; 2University of Toronto, Toronto, ON, Canada

MP-05.09Clitoroplasty and Vaginoplasty in Adolescents and Adults with Disorders of Sex Development (DSD): Lessons Learned

Pippi Salle, Joao L.1; Romao, Rodrigo L.P.1; Allen, Lisa1; DeMaria, Jorge2; Braga, Luis H.P.2; Jednak, Roman3; Dave, Sumit4; Lorenzo, Armando J.1; Farhat, Walid1; Koyle, Martin1; Bagli, Darius11The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 2McMaster University, Hamilton, ON, Canada; 3McGill University, Montréal, QC, Canada;4University of Western Ontario, London, ON, Canada

MP-05.10Correlation of Ultrasound (US) with Laparoscopy (LAP) in KuwaitiPatients (pts) with Unilateral Non-palpable Testicles (NPT): Impact of Weight (WT) and Contralateral Testicular Size

Elsawy, Mohamed1; El-Hout, Yaser2; Gupta, Vipul1; Farhat, Walid2; Alsaid, Abdulnasser11Ibn Sina Hospital, Sulaibikhat, Kuwait; 2Sick Kids Hospital, Toronto, ON, Canada

MP-05.11Attempt at Fertility Preservation in Two Children with ParatesticularRhadomyosarcoma

Spelliscy, Courtney; Kiddoo, DarcieUniversity of Alberta, Edmonton, AB, Canada

MP-05.12 Urodynamic Improvements after Medical Treatment of Partial BladderOutlet Obstruction in an Animal Model

Maciejewski, Conrad1; Tredget, Edward2; Metcalfe, Peter11University of Alberta, Division of Urology, Edmonton, AB, Canada; 2University of Alberta,Division of Plastic Surgery, Edmonton, AB, Canada


CUA 2012 BANFF 117

MP-05.13Outcomes Following Fecal Continence Procedures in Patients with Neurogenic Bowel Dysfunction

Kiddoo, Darcie; Metcalfe, Peter; Hoy, NathanUniversity of Alberta, Edmonton, AB, Canada

MP-05.14Onabotulinumtoxin A Endoscopic Detrusor Injection for the Treatmentof Neurogenic Bladder in Children: Effect of Dose Adjustment, MultipleInjections and Avoidance of Reconstructive Procedures

Figueroa, Victor H.; Romao, Rodrigo L.P.; Pippi-Salle, Joao L.; Kanaroglou, Niki; Koyle, MartinA.; Bagli, Darius J.; Lorenzo, Armando J.The Hospital for Sick Children, Toronto, ON, Canada

1450-1600 MP-06Moderated Poster Session 6: ED, Peyronie’s Disease, InfertilitySéance de posters modérés 6: ED, maladie de La Peyronie etinfertilité

Room – Salle: BeattyModerators/Modérateurs: Serge Carrier, Montreal, QCPeter Pommerville, Victoria, BC

MP-06.01Antinuclear Antibody Titres Are Not Significantly Altered in Peyronie’sDisease

Shamloul, Rany1; Bella, Anthony J.1; Zappagigna, Christopher21University of Ottawa, Civic Hospital, Ottawa, ON, Canada; 2University of Ottawa, Ottawa, ON,Canada

MP-06.02A Novel Rat Model for Peyronie’s Disease That DemonstratesDurability and Functional Detriments

Garcia, Francisco1; De Young, Ling2; Chung, Eric3; Brock, Michael2; Brock, Gerald41Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON,Canada; 2Lawson Health Research Institute, London, ON, Canada; 3Department of Urology,Princess Alexandria Hospital, Brisbane, Australia; 4St. Joseph’s Health Care, Division ofUrology, London, ON, Canada


118 CUA 2012 BANFF

MP-06.03Efficacy and Histologic Changes of Repeated Saline or IntralesionalVerapamil Injections and Traction Therapy in an Animal Model ofPeyronie’s Disease

Garcia, Francisco1; Chung, Eric2; De Young, Ling3; Wang, Peter1; Brock, Michael3; Brock,Gerald41Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON,Canada; 2Department of Urology, Princess Alexandria Hospital, Brisbane, Australia; 3LawsonHealth Research Institute, London, ON, Canada; 4St. Joseph’s Health Care, Division of Urology,London, ON, Canada

MP-06.04Do Patients Know Their Nerve-sparing Status Following RadicalProstatectomy?

Skeldon, Sean; Gani, Johan; Radomski, SidneyUniversity of Toronto, Toronto, ON, Canada

MP-06.05 Erectile Function Recovery Following Nerve Sural Grafting in OpenRadical Prostatectomy

Autran Gomez, Ana Maria; Izawa, Jonathan; Chin, JosephLondon Health Sciences Centre, University of Western Ontario, London, ON, Canada

MP-06.06Resident Training Laboratory, Held in Conjunction with Conference,Meaningfully Impacts Resident Technical Skills and Perceptions forPenile Implant Surgery

Zappavigna, Christopher1; Christine, Brian2; Bella, Anthony J.11University of Ottawa, Division of Urology, Ottawa, ON, Canada; 2Urology Centers of Alabama, Birmingham, AL, United States

MP-06.07Robotic Assisted versus Pure Microsurgical Vasectomy Reversal:Prospective Control Trial

Gudeloglu, Ahmet1; Brahmbahtt, Jamin2; Priola, Karen1; Parekattil, Sijo11University of Florida and Winter Haven Hospital, Winter Haven, FL, United States; 2University of Tennessee, Memphis, TN, United States

MP-06.08 Cost-effectiveness of Varicocelectomy and Percutaneous Embolizationin the Management of Varicocele-associated Infertility

Klinghoffer, Zachary; Kovac, Jason; Fischer, Marc AnthonyMcMaster University, Hamilton, ON, Canada


CUA 2012 BANFF 119

MP-06.09Use of Clomiphene Citrate for Male Idiopathic Infertility: InterimAnalysis of a Prospective Study Langille, Gavin1; Spencer, Leia2; Jarvi, Keith2; Grober, Ethan2; Lo, Kirk C.21Dalhousie University, Halifax, NS, Canada; 2University of Toronto, Toronto, ON, Canada

1450-1600 MP-07Moderated Poster Session 7: BladderSéance de posters modérés 7: Vessie

Room – Salle: ColemanModerators/Modérateurs:Fred Saad, Montreal, QCJoseph Chin, London, ON

MP-07.01Safety of Intravesical Mycobacterial Cell Wall-DNA Complex GivenImmediately Postsurgery in Patients with Non-muscle-invasiveBladder Cancer

Morales, Alvaro1; Jablonski, David2; Lihou, Christine3; Lang, Zig3; Champagne, Monique4;Cohen, Zvi41Queen’s University, Kingston, ON, Canada; 2Winter Park Urology Associates, Orlando, FL,United States; 3Endo Pharmaceuticals Inc, Chadds Ford, PA, United States; 4Bioniche LifeSciences Inc, Pointe-Claire, QC, Canada

MP-07.02 The Impact of Concomitant Carcinoma in Situ on Upstaging FollowingRadical Cystectomy for Bladder Cancer

Yafi, Faysal1; Aprikian, Armen1; Chin, Joseph2; Fradet, Yves3; Izawa, Jonathan2; Estey, Eric4;Fairey, Adrian4; Rendon, Ricardo5; Cagiannos, Ilias6; Lacombe, Louis3; Lattouf, Jean-Baptiste7;Bell, David5; Drachenberg, Darrel8; Kassouf, Wassim1

1McGill University, Montréal, QC, Canada; 2University of Western Ontario, London, ON, Canada;3Laval University, Quebec, QC, Canada; 4University of Alberta, Edmonton, AB, Canada;5Dalhousie University, Halifax, NS, Canada; 6University of Ottawa, Ottawa, ON, Canada;7University of Montreal, Montreal, QC, Canada; 8University of Manitoba, Winnipeg, MB, Canada

MP-07.03Young Age Predicts Favorable Disease Characteristics and Outcomesamong Patients with Urothelial Carcinoma of the Bladder

Izard, Jason1; Wright, Jonathan1; Black, Peter2; Porter, Michael11Department of Urology, University of Washington, Seattle, WA, United States; 2Department of Urologic Sciences, University of British Colombia, Vancouver, BC, Canada


120 CUA 2012 BANFF

MP-07.04Evaluation of the Survival Benefit of Multidisciplinary Care in HighRisk Bladder Cancer

Sandhu, Gurdarshan1; Nepple, Kenneth1; Schoenberg, Mark2; Strope, Seth11Washington University School of Medicine, St. Louis, MO, United States; 2The JamesBuchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD,United States

MP-07.05Increased Expenditures on Follow-up Care after Definitive Surgery for Bladder Cancer

Sandhu, Gurdarshan; Nepple, Kenneth; Grubb 3rd Robert; Yang, Liu; Strope, SethWashington University School of Medicine, St. Louis, MO, United States

MP-07.06Utilization of Peri-operative Chemotherapy for Bladder Cancer: a Population-based Study

Siemens, D. Robert1; Rhee, Jonathan1; Tannock, Ian2; Peng, Yingwei1; Li, Gavin1; Mackillop,William1; Booth, Chris11Queen’s University, Kingston, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Canada

MP-07.07Utilization and Predictors of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Veteran’s HealthAdministration

Sandhu, Gurdarshan1; Luo, Suhong2; Zeringue, Angelique2; Carson, Kenneth2; Nepple, Kenneth1; Strope, Seth1; Hudson, M’Liss2; Grubb 3rd, Robert21Washington University School of Medicine, St. Louis, MO, United States; 2VA St. LouisHealthcare System, Department of Veterans Affairs, St. Louis, MO, United States

MP-07.08 Laparoscopic Radical Cystectomy - Is There Evidence of LearningCurve? Experience of 60 Consecutive Cases Performed in a HighVolume Tertiary Cancer Centre

Khan, Faisal1; Abroaf, Ahmed2; Jackson, M1; Durkan, G C1; Heer, R1; Soomro, NA1; Johnson, MI11NHS, Newcastle, United Kingdom; 2NHS Freeman Hospital, Newcastle, United Kingdom


CUA 2012 BANFF 121

MP-07.09Hypoxia Is Independently Associated with Poor Outcome in UrothelialBladder Cancer Patients Treated with Radical Cystectomy

Bostrom, Peter J1; Thoms, John1; van Rhijn, Bas WG1; Ahmed, Omer1; Evans, Andrew1; Mirtti, Tuomas2; Sykes, Jenna1; Milosevic, Michael1; Zlotta, Alexandre R3; Bristow, Robert G1

1University Health Network, Toronto, ON, Canada; 2Helsinki University Hospital, Helsinki,Finland; 3Mount Sinai Hospital, University Health Network, Toronto, ON, Canada

MP-07.10Heat Shock Protein 70 (HSP70) as a Recurrence Marker for PT1Bladder Cancer

Stakhovskyi, Oleksandr1; Margel, David1; van der Kwast, Theodorus H.1; van Rhijn, Bas W.G.1;Bostrom, Peter J.1; Bristow, Robert G.1; Fleshner, Neil E.1; Jewett, Michael A.S.1; Bapat, Bharati2; Zlotta, Alexandre R.31University Health Network, Toronto, ON, Canada; 2Mount Sinai Hospital, Samuel LunenfeldResearch Institute, Toronto, ON, Canada; 3Mount Sinai Hospital, University Health Network,Toronto, ON, Canada

MP-07.11 How Should Locoregionally Recurrent or Advanced PrimaryMalignancies of the Bladder or Ureter Be Managed? Potential Role of Multimodality Therapy Incorporating Surgery and IntraoperativeRadiotherapy

Choo, Richard; Hallemeier, Christopher; Haddock, MichaelMayo Clinic, Rochester, MN, United States

MP-07.12 Tumor Stage on Re-staging Transurethral Resection PredictsRecurrence and Progression Free Survival of High Risk SuperficialBladder Cancer

Bishr, Mohamed1; Lattouf, Jean-Baptiste2; Latour, Mathiew2; Saad, Fred21Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM) and Institutdu cancer de Montréal, Montréal, QC, Canada; 2Centre hospitalier de l’université de Montréal(CHUM), Montréal, QC, Canada

1450-1600 MP-08Moderated Poster Session 8: MiscellaneousSéance de posters modérés 8: Sujets divers

Room – Salle: Van Horne BModerators/Modérateurs:Trevor Schuler, Edmonton, ABRobert Siemens, Kingston, ON


122 CUA 2012 BANFF

MP-08.01Preliminary Results of the Resident Manpower Survey by the CUASocioeconomic Committee: Are We Training too Many Urologists?

Drachenberg, Darrel; Kaler, KamaljotUniversity of Manitoba, Winnipeg, MB, Canada

MP-08.02Incorporating Patient Simulation into In-training Exams to AssessCanMEDS Competencies in Urology Residents

Nguyen, Laura; Roberts, Matthew; Watterson, JamesUniversity of Ottawa/The Ottawa Hospital, Ottawa, ON, Canada

MP-08.03The Newly Graduated Canadian Urologist: Underemployed and Overtrained?

Welk, Blayne1; Kodama, Ron2; MacNeily, Andrew3

1University of Western Ontario, London, ON, Canada; 2University of Toronto, Toronto, ON,Canada; 3University of British Columbia, Vancouver, BC, Canada

MP-08.04 Trends in Matching to Urology Residency in Canada: Are We Becoming Non-competitive?

Melnyk, Megan; Mickelson, Jennifer J; MacNeily, Andrew EDepartment of Urological Sciences, University of British Columbia, Vancouver, BC, Canada

MP-08.05Video Laparoscopic Trainers vs. Less Expensive Simple LaparoscopicTrainers

Nguyen, Tim1; Braga, Luis2; Matsumoto, Edward21Queen’s University, Kingston, ON, Canada; 2McMaster University, Hamilton, ON, Canada

MP-08.06Do Hunner’s Ulcers Represent Bladder Ischemia?

Melnyk, Megan; Teichman, JoelUniversity of British Columbia, Department of Urological Sciences, Vancouver, BC, Canada

MP-08.07Trials and Tribulations of a Canadian Interstitial Cystitis ResearchClinic

Nickel, J Curtis; Irvine-Bird, Karen; Robb, SylviaQueen’s University, Kingston, ON, Canada


CUA 2012 BANFF 123

MP-08.08Cannabis (Marijuana) Use in Men with Chronic Prostatitis / ChronicPelvic Pain Syndrome

Nickel, J Curtis1; Tripp, Dean1; Katz, Laura1; Ginting, Jessica1; Ware, Mark2; Santor, Darcy31Queen’s University, Kingston, ON, Canada; 2Montreal General Hospital, Montreal, QC, Canada;3University of Ottawa, Ottawa, ON, Canada

MP-08.09The Clinical Spectrum of Anterior Urethral Stricture: Detailed Analysisof a Large Single Institution Cohort

Rourke, Keith; Hickle, JonathanUniversity of Alberta, Edmonton, AB, Canada

MP-08.10Impact of Radiotherapy on Surgical Repair and Outcomes in Patientswith Rectourethral Fistula

Elliott, Daniel; Poskus, Tomas; Umbreit, Eric; Larson, David; Beddy, David; Dozois, EricMayo Clinic, Rochester, MN, United States

MP-08.11Comprehension and Preferences for Graphical Representations of Quality of Life after Prostate Cancer Treatment

Izard, Jason1; Hartzler, Andrea2; Gore, John21Department of Urology, University of Washington, Seattle, WA, United States; 2Department of Medical Education, University of Washington, Seattle, WA, United States

MP-08.12Population-based Assessment of Enterocystoplasty Complicationsamong Adult Patients

Welk, Blayne1; Herschorn, Sender2; Law, Calvin2; Nam, Robert21University of Western Ontario, London, ON, Canada; 2University of Toronto, Toronto, ON,Canada

1450-1600 MP-09Moderated Poster Session 9: Basic ScienceSéance de posters modérés 9: Science fondamentale

Room – Salle: Baron ShaughnessyModerators/Modérateurs:Alan So, Vancouver, BCPeter Black, Vancouver, BC


124 CUA 2012 BANFF

MP-09.01Knockdown of Integrin-linked Kinase Reduces Invasive and Metastatic Potential of Renal Cell Carcinoma by Impeding Epithelial to Mesenchymal Transition

Han, Kyungseok; Raven, Peter; Awrey, Shannon; Li, Estelle; Ladan, Fazli; Gleave, Martin; So, AlanVancouver Prostate Centre, Vancouver, BC, Canada

MP-09.02Enhanced Tumor Oxygenation Following Short-term Sunitinib Therapyin a Renal Cell Carcinoma Model: an Unexpected Finding

Chapman, David; Wuest, Melinda; Mercer, John; Wiebe, Leonard; Moore, RonaldUniversity of Alberta, Edmonton, AB, Canada

MP-09.03Evasive Resistance to VEGF-targeted Anti-angiogenic Therapy Is Acquired by Activation Angiogenesis Pathways Independent of VEGF in Renal Cell Carcinoma

Han, Kyungseok; Raven, Peter; Gust, Kilian; Awrey, Shannon; Li, Estelle; Ladan, Fazli; Gleave, Martin; So, AlanVancouver Prostate Centre, Vancouver, BC, Canada

MP-09.04Quantitative Proteomic Analysis of Exosome-enriched ExtracellularMicrovesicles Obtained Following an in vitro Model of Urinary TractObstruction

Orton, Dennis1; Doucette, Alan1; Maksym, Geoffrey1; MacLellan, Dawn21Dalhousie University, Halifax, NS, Canada; 2Dalhousie University, IWK Health Centre, Halifax,NS, Canada

MP-09.05Rat Bone Marrow Derived Mesenchymal Stem Cell Therapy in a Parkinsonian Animal Model of Detrusor Overactivity

Campeau, Lysanne1; Soler, Roberto2; Pareta, Rajesh1; Sivanandane, Sittadjody1; Opara,Emmanuel1; Andersson, Karl Erik11Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, UnitedStates; 2Division of Urology, Federal University of Sao Paulo, Sao Paulo, Brazil


CUA 2012 BANFF 125

MP-09.06Intrathecal Cannabinoid Agonist Effects in Cystometric Evaluation of Normal Rats

Campeau, Lysanne1; Füllhase, Claudius2; Russo, Andrea3; Hedlund, Petter3; Andersson, Karl Erik11Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, UnitedStates; 2Department of Urology, University Hospital Großhadern, LMU, Munich, Germany;3Urological Research Institute, San Raffaele University, Milan, Italy

MP-09.07Rational Targeting of Fibroblast Growth Factor Receptor (FGFR)-3 in Bladder Cancer

Gust, Kilian1; McConkey, David2; Hegarty, Paul2; Awery, Shannon1; Bondaruk, Jolanta1;Czerniak, Bogdan2; Dinney, Colin2; Black, Peter11Vancouver Prostate Centre, Vancouver, BC, Canada; 2MD Anderson Cancer Center, Houston, TX, United States

MP-09.08Circulating Interlukin-6 and Nerve Growth Factor Are Associated withPeriprostatic Fat Length and Cancer Detection among Non-obese MenPresenting for Prostate Biopsies

Margel, David1; Trottier, Greg1; Yap, Stanley1; Connor, Mike2; Elharram, Malik1; Bhindi, Bimal1;Fleshner, Neil11Division of Urology, Department of Surgical Oncology, University Health Network, Universityof Toronto, Toronto, ON, Canada; 2University of York, Toronto, ON, Canada

MP-09.09Heat Shock Protein 70 (HSP70) and FGFR3 in Non-muscle-invasiveBladder Cancer Treated with BCG: Gene and Protein ExpressionAnalysis in Two Validation Cohorts

van Rhijn, Bas W.G.1; Stakhovskyi, Oleksandr1; Margel, David1; van der Kwast, Theodorus H.1;Bostrom, Peter J.1; Bristow, Robert G.1; Milosevic, Michael1; Bapat, Bharati2; Kim, Wun-Jae3;Zlotta, Alexandre R.41University Health Network, Toronto, ON, Canada; 2Mount Sinai Hospital, Samuel LunenfeldResearch Institute, Toronto, ON, Canada; 3Chungbuk National University College of Medicine,Chungbuk, Republic of Korea; 4Mount Sinai Hospital, University Health Network, Toronto, ON,Canada


126 CUA 2012 BANFF

MP-09.10NF-κappa B p65 as Prognostic Tool in Prostate Cancer: an Immunohistochemical Study from Biopsy Samples

Labouba, Ingrid1; Gannon, Philippe O.1; Forest, Valérie1; Le Page, Cécile1; Storoz, Cristina1;Benaissa, Mustapha1; Pierrard, Aurore1; Lessard, Laurent1; Mes-Masson, Anne-Marie2; Saad, Fred31Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM), Montréal,QC, Canada; 2CRCHUM / Institut du cancer de Montréal, Department of Medicine, Universitéde Montréal, Montréal, QC, Canada; 3Division of Urology, CHUM, Université de Montréal,CRCHUM, Montréal, QC, Canada

MP-09.11A New Molecular Imaging System Based on Both Transcriptional andGenomic Amplification to Detect Prostate Cancer Cells in vivo

Pouliot, Frederic1; Sato, Makoto2; Huyn, Steve2; Karanikolas, Breanne2; Wu, Lily21Department of Surgery, Urology Division, Laval University, Quebec, QC, Canada; 2IMED andUCLA, Los Angeles, CA, United States

1600-1615 Closing Ceremonies, Awards, CUASF Astellas WinnersCérémonies de clôture, prix, gagnants Astellas FBAUC

Room – salle: Van Horne A


UP-001 Orthotopic Continent Urinary Diversion vs. Ileal Conduit: Comparisonof Intraoperative and In-hospital Complications, Blood Transfusion,Length of Stay, and In-hospital Mortality

Djahangirian, Orchidee; Schmitges, Jan; Tian, Zhe; Karakiewicz, Pierre; Ismail, SalimaCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada

UP-002 Techniques and Agents Used to Conserve Blood During RadicalCystectomy: a Survey of the Society of Urologic Oncology

Punjani, Nahid1; Lavallée, Luke T.2; Momoli, Franco3; Cagiannos, Ilias2; Morash, Chris2; Fergusson, Dean3; Breau, Rodney H.21University of Ottawa, Ottawa, ON, Canada; 2University of Ottawa, Division of Urology, Ottawa,ON, Canada; 3Ottawa Hospital Research Institute, Ottawa, ON, Canada

UP-003 Should CT Urogram Be the First Radiological Investigation to EvaluateVisible Haematuria?

Akhter, Waseem; Sheikh, Mazher; Kilburn, Karen; Peedikayil, Abraham; Palit, VictorUniversity Hospital of North Tees and Hartlepool NHS Trust, Hartlepool, United Kingdom

UP-004 Laparoscopic Robot-assisted Radical Cysto-prostatectomy

Bladou, FranckMcGill University, Jewish General Hospital, Montreal, QC, Canada

UP-005 Survival Impact of Postoperative Expenditures by High VolumeSurgeons Following Definitive Surgery for Bladder Cancer

Sandhu, Gurdarshan; Nepple, Kenneth; Yang, Liu; Grubb 3rd, Robert; Strope, SethWashington University School of Medicine, St. Louis, MO, United States

UP-006 Is There a Role for the mTOR Pathway in Non-muscle Invasive Bladder Cancer?

Blais, Jean-Philippe; Hovington, Hélène; Brisson, Hervé; Lacombe, Louis; Caumartin, YvesCentre Hospitalier Universitaire de Québec, Quebec, QC, Canada

UP-007 Meta-analysis of the Efficacy and Safety of Darifenacin and OtherAnticholinergics for Managing Overactive Bladder

Elhilali, Mostafa1; Piwko, Charles2; Vincente, Colin2; Sabapathy, Suthacar2; Tu, Le Mai3;Valiquette, Luc4; Finarson, Thomas R.5; Ahmad, Asma61Mcgill University, Royal Victoria Hospital, Montreal, QC, Canada; 2Pivina Consulting, Montreal,QC, Canada; 3FRCSC University of Sherbrooke, QC, Canada; 4FRCSC Université de Montréal,Montreal, QC, Canada; 5University of Toronto, Toronto, ON, Canada; 6Pivina Consulting,Mississauga, ON, Canada

CUA 2012 BANFF 127

UNMODERATED POSTER SESSIONS / SÉANCE DE POSTERS NON-MODÉRÉS

128 CUA 2012 BANFF

UP-008 Pre-operative Sarcopenia Associated with Renal Function Outcomesin Patients Treated for Renal Masses by Extirpative Surgery

Hennessey, Katherine K.; Michael, Amanda; Elias, Rami; Kapoor, Anil; Shayegan, Bobby;Matsumoto, Edward D.; Mourtzakis, Marina; Di Sebastiano, Katie; Duivenvoorden, Helga;Pinthus, Jehonathan H.McMaster University, Hamilton, ON, Canada

UP-009 Renal Tumor Ablation for pT1 Lesions: Patterns of Recurrence andFollow-up Recommendations

Rutkowski, John; Muruve, NicCleveland Clinic Florida, Weston, FL, United States

UP-010 Cystatin C for Early Detection of Acute Kidney Injury afterLaparoscopic Partial Nephrectomy

Al Esawi, Anwar; Nadeau, Geneviève; Caumartin, Yves; Bergeron, Alain; Guimezap, Jackson;Fradet, Vincent; Caron, André; Dujardin, Thierry; Fradet, Yves; Lacombe, LouisCHUQ-Laval University, Quebec, QC, Canada

UP-011 Ex-vivo Partial Nephrectomy with Autotransplant to Treat ComplexRenal Tumors: Case Report and Review of the Literature

Nayak, Jasmir; Archambault, Jason; Koulack, Joshua; McGregor, ThomasUniversity of Manitoba, Winnipeg, MB, Canada

UP-012 LKB1 Drives Adiponectin Receptor 1 Expression in Clear Cell RenalCell Carcinoma: from Tumor Development to Disease Characteristics

Zareba, Piotr; Duivenvoorden, Wilhelmina; Beatty, Laura; Lhotak, Sarka; Lu, Jian-Ping; Austin, Richard; Daya, Dean; Pinthus, JehonathanMcMaster University, Hamilton, ON, Canada

UP-013 Kidney Cancer Survivorship Survey: Gap Between Urologist andSurvivor Perceptions

Basiuk, Joan1; Jewett, Michael2; Maskens, Deborah3; Canil, Christina41Kidney Cancer Canada, Toronto, ON, Canada; 2Princess Margaret Hospital / University ofToronto, Toronto, ON, Canada; 3Kidney Cancer Canada, Guelph, ON, Canada; 4The OttawaHospital Cancer Centre / University of Ottawa, Ottawa, ON, Canada

UP-014 Comparison of Renal Function Outcomes Between LaparoscopicPartial Nephrectomy with Early Unclamping versus LaparoscopicPartial Nephrectomy with Zero Ischemia

Tse, Richard1; Karreman, Erwin2; Maslany, Jogan1; Knaus, Russel1; Tse, Edward11University of Saskatchewan, Regina, SK, Canada2University of Saskatchewan, Regina Qu’Appelle Health Region, Regina, Saskatchewan


UP-015 Reduction of Renal Parenchymal Volume and Renal Function inPatients after Partial Nephrectomy for Renal Cell Carcinoma (RCC)

Ajzenberg, Henry1; Legere, Laura1; Satkunasivam, Raj2; Finelli, Antonio1; Kachura, John3;O’Malley, Martin3; Tuchscherer, Paul4; Quinn, Paul4; Choi, Jung4; Jewett, Michael11Princess Margaret Hospital, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada;3Toronto General Hospital, Toronto, ON, Canada; 4Toronto Western Hospital, Toronto, ON,Canada

UP-016 Results of a Survey on the Management of Upper Tract Urothelial Cancer

Zappavigna, Christopher; Rowe, Neal; Morash, Christopher G.; Breau, Rodney; Cagiannos, IliasUniversity of Ottawa, Division of Urology, Ottawa, ON, Canada

UP-017 Management of Collecting Duct Carcinoma: a Systematic Review,Management Approach, and Case Series

Dason, Shawn1; Sheridan-Jonah, Anna1; Allard, Christopher1; Kajal, Babita2; Aziz, Tariq2; Gill,Jaskirat3; Jamshaid, Hira3; Kapoor, Anil11Division of Urology, McMaster University, Hamilton, ON, Canada, 3Department of Pathologyand Molecular Medicine, McMaster University, Hamilton, ON, Canada; 4McMaster University,Hamilton, ON, Canada

UP-018 Withdrawn

UP-019 Improving Outcomes Through the Development of Quality Indicators(QI) in Renal Cell Cancer (RCC)

Finelli, Anthony1; Bjarnason, Georg2; Black, Peter3; Cagiannos, Ilias4; Heng, Daniel5; Kapoor,Anil6; Kollmannsberger, Christian7; Mohammadzadeh, Forough8; Moore, Ronald9; Soulieres,Denis10; Tanguay, Simon11; Venner, Peter12; Jewett, Michael1; Rendon, Ricardo13; Wood, Lori131Princess Margaret Hospital (UHN), Toronto, ON, Canada; 2Sunnybrook Odette Cancer Center,Toronto, ON, Canada; 3Department of Urological Sciences, UBC, Vancouver, BC, Canada;4University of Ottawa, Ottawa, ON, Canada; 5Tom Baker Cancer Center, University of Calgary,Calgary, AB, Canada; 6Juravinski Cancer Center, Hamilton, ON, Canada; 7BCCA VancouverCancer Center, University of British Colombia, Vancouver, BC, Canada; 8UHN, Toronto, ON,Canada; 9Department of Urology, University of Alberta, Edmonton, AB, Canada; 10Departmentof Medicine, Université de Montréal, Montreal, QC, Canada; 11McGill University Health Center,McGill University, Montreal, QC, Canada; 12Cross Cancer Institute, University of Alberta,Edmonton, AB, Canada; 13QEII HSC, Dalhousie University, Halifax, NS, Canada

UP-020 Rising Incidence of Upper Tract TCC (UTTCC) in Kettering, UnitedKingdom

Khan, Faisal1; Payne, David2; Al-Sudani, Mohammed2; Khan, Zeb2; England, Roland21Freeman Hospital, Newcastle, United Kingdom; 2NHS, Kettering, United Kingdom

CUA 2012 BANFF 129


130 CUA 2012 BANFF

UP-021 The Fer Kinase, a Nuclear Effector of Growth-promoting FactorsFavoring Castration-resistant Prostate Cancer

Rocha, Joice1; Zouanat, Fatima1; Benidir, Tarik1; Zoubeidi, Amina2; Hamel, Lucie1; Scarlata, Eleonora1; Aprikian, Armen1; Chevalier, Simone11Urologic Oncology Research Group, McGill University, Montreal, QC, Canada; 2The VancouverProstate Cancer, University of British Columbia, Vancouver, BC, Canada

UP-022 Single Photon Emission Computed Tomography/CT Imaging ofMetastases Using Prostate Specific Membrane Antigen Antibody

Chevalier, Simone1; Derbekyan, Vilma1; Scarlata, Eleonora1; Moffett, Serge2; Hamel, Lucie1;Zouanat, Fatima1; Aprikian, Armen1; Anidjar, Maurice11McGill University Health Centre Research Institute, Montreal, QC, Canada; 2ProScan,Montreal, QC, Canada

UP-023 PSA Bounce Following Prostate Brachytherapy for Clinically LocalizedProstate Adenocarcinoma: a Single Institution Study with Minimum 3Years Follow-up

Nayak, Jasmir; Ong, Aldrich; Bews, Jeff; Chowdhury, Amit; Drachenberg, DarrelUniversity of Manitoba, Winnipeg, MB, Canada

UP-024 Is Perineural Invasion in Prostate Biopsies Associated with AdversePathological Outcomes? Old Paradigm Revisited

Margel, David1; Elharram, Malik1; Finelli, Antonio1; Zlotta, Alexandre1; Trachtenberg, John1;Evans, Andrew2

1Division of Urology, Department of Surgical Oncology, University Health Network, Universityof Toronto, Toronto, ON, Canada; 2Department of Pathology, University Health Network,University of Toronto, Toronto, ON, Canada

UP-025 The Association between Male Pattern Baldness and Second to ForthFinger Ratio with Prostate Cancer: a Prospective Cohort Study

Margel, David; Venkateswaran, Seetha; Darwish, Abbas; Chadwick, Karen; Fleshner, NeilDivision of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, ON, Canada

UP-026 Coexisting Prostate Cancer Found at the Time of Holmium LaserEnucleation of the Prostate for Benign Prostatic Hyperplasia:Predicting Its Presence and Grade in Analyzed Tissue

Bhojani, Naeem; Boris, Ronald S.; Mandeville, Jessica A.; Lingeman, James E.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States


UP-027 Prostate Cancer Screening: Attitudes and Practices of FamilyPhysicians in Ontario

Allard, Christopher1; Lusis, Janis2; Dason, Shawn1; Kapoor, Anil11McMaster Institute of Urology, Hamilton, ON, Canada; 2Brampton Hospital, Brampton, ON,Canada

UP-028 Transrectal Ultrasound with Vibroelastography for the Detection ofProstate Cancer

Gagnon, Louis-Olivier1; Mahdavi, Sara2; Moradi, Mehdi2; Baghani, Ali2; Jones, Edward3;Salcudean, Septimiu2; Goldenberg, Larry11Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada;2Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, Canada;3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,BC, Canada

UP-029 Human Prostate Cancer Magnetic Resonance Elastography andCorrelation with Histology

Gagnon, Louis-Olivier1; Sahebjavaher, Ramin2; Garteiser, Philippe3; Sinkus, Ralph3; Baghani,Ali2; Moradi, Mehdi2; Jones, Edward4; Nguan, Chris1; Goldenberg, Larry1; Salcudean, Septimiu21Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada;2Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, Canada;3Hôpital Beaujon, Centre de Recherche Biomédicale Bichat Beaujon (CRB3), Paris, France;4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,BC, Canada

UP-030 Changes in Positive Surgical Margins over Time Reflect a RiskMigration in Patients Undergoing Radical Prostatecomy at a TertiaryCare Center

Longpre, Michelle; Gleave, Martin; Harriman, David; Hurtado-Coll, AntonioUniversity of British Columbia, Vancouver, BC, Canada

UP-031 Holmium Laser Ablation of the Prostate Gland (HoLAP) Followed byBrachytherapy (BT) for Treatment of Patients with Clinically LocalizedProstate Carcinoma (PC) and Obstructive Urinary Symptoms (LUTS)

Kumar, SurendraOakwood Annapolis Hospital, Wayne, MI, United States

UP-032 Identification of Thrombotic Risk for Men with Advanced ProstateCancer: a Pilot Study Evaluating Hemostatic Status UsingThromboelastography

Siemens, D. Robert; Toukh, Mazen; Othman, Maha; Black, Angela; Graham, CharlesQueen’s University, Kingston, ON, Canada

CUA 2012 BANFF 131


132 CUA 2012 BANFF

UP-033 Predictors of Failing Active Surveillance on the 2nd Prostatic Biopsy

Wong, Lih-Ming1; Trottier, Greg1; Fleshner, Neil1; Lawrentchuk, Nathan1; Kulkarni, Girish1;Zlotta, Alexandre2; Trachtenberg, John1; Toi, Ants3; Finelli, Antonio11Division of Uro-oncology, Princess Margaret Hospital, Toronto, ON, Canada; 2Division ofUrology, Mount Sinai Hospital, Toronto, ON, Canada; 3Department of Radiology, PrincessMargaret Hospital, Toronto, ON, Canada

UP-034 Prostate Cancer Detection after Multiple Negative Biopsies

Metcalfe, Charles; Metcalfe, Michael; Goldenberg, Larry; Gleave, Martin; Black, Peter; So, AlanUniversity of British Columbia, Vancouver, BC, Canada

UP-035 Intermediate Clinical Outcomes of Robot-assisted LaparoscopicProstatectomy (RALP)

Wong, Carson1; Gu, Xiao2; Spaliviero, Massimiliano21SouthWest Urology, Inc., Middleburg Heights, OH, United States; 2University of OklahomaHealth Sciences Center, Oklahoma, OK, United States

UP-036 Factors Influencing Choice of Robotic-assisted vs. Open RadicalProstatectomy for Prostate Cancer Treatment

Chien, Gary; Chang, Allen; Thomas, Anil; Derboghossians, Armen; Slezak, JeffreyKaiser Permanente, Los Angeles, CA, United States

UP-037 What Is the Prevalence and Impact of Depression, Anxiety, andDistress in Patients with Newly Diagnosed Localized Prostate Cancer?

Punnen, Sanoj; Cowan, Janet; Whitson, Jared; Carroll, Peter; Cooperberg, MatthewUniversity of California, San Francisco, CA, United States

UP-038 Autologous Retropubic Urethral Sling: a Novel, Quick, IntraoperativeTechnique for Improving Continence after Robot-assistedLaparoscopic Prostatectomy

Punnen, Sanoj; Cowan, Janet; Whitson, Jared; Carroll, PeterUniversity of California, San Francisco, CA, United States

UP-039 Predictors of Gleason 8 Cancer among Men with Gleason 7 and 8Cancer on Prostate Biopsy Cores

Heimrath, Olivier P.; Belanger, Eric C.; Kos, Zuzana; Cagiannos, Ilias; Morash, Christopher G.; Lavallée, Luke T.; Preston, Mark; Breau, Rodney H.University of Ottawa, Ottawa, ON, Canada


UP-040 Comparison of Serum Testosterone Levels in Prostate Cancer PatientsReceiving LHRH Agonist Therapy with or without the Removal of theProstate

Venkateswaran, Seetha1; Margel, David1; Yap, Stanley1; Hersey, Karen1; Locke, Jennifer1; Yip, Paul2; Fleshner, Neil11Princess Margaret Hospital, Toronto, ON, Canada; 2Toronto General Hospital, Toronto, ON,Canada

UP-041 A Prospective Phase II Trial of Stereotaxic Hypofractionated Cyberknife(CK) Treatment for Locally Recurrent Prostate AdenocarcinomaFollowing External Beam Radiotherapy (EBRT)

Fortin, Israel; Bahary, Jean-Paul; Saad, Fred; Péloquin, Laurence; Lambert, Carole; Barkati, Maroie; Nguyen, Thu Van; Waters, AlexandraCHUM, Montreal, QC, Canada

UP-042 Involvement of TBK1 in Prostate Cancer Progression through IKKεCellular Localization Control

Huon, Yannick1; Péant, Benjamin1; Mes-Masson, Anne-Marie1; Saad, Fred21CRCHUM, ICM and Faculty of Medicine, Université de Montréal, Montreal, QC, Canada;2CRCHUM, ICM, Faculty of Medicine and Division of Urology, CHUM, Université de Montréal,Montreal, QC, Canada

UP-043 The Association between Aspirin and Non-steroidal Anti-inflammatoryDrug Use and the Risk of Prostate Cancer Detection upon Biopsy

Bhindi, Bimal; Margel, David; Fernandes, Kimberly; Trottier, Greg; Hersey, Karen; Finelli,Antonio; Trachtenberg, John; Toi, Ants; Evans, Andrew; van der Kwast, Theodorus; Fleshner,NeilUniversity Health Network, Toronto, ON, Canada

UP-044 Withdrawn

UP-045 Withdrawn

UP-046 Active Surveillance for Prostate Cancer in Patients with a PSA >10

Toren, Paul; Timilshina, Narhari; Kulkarni, Girish; Fleshner, Neil; Finelli, AntonioUniversity of Toronto, Toronto, ON, Canada

CUA 2012 BANFF 133


134 CUA 2012 BANFF

UP-047 Targeting the Proprotein Convertases in Prostate Cancer

Day, Robert1; D’Anjou, François1; Couture, Frédéric1; Levesque, Christine1; Kwaitkowska,Anna1; Routhier, Sophie1; Desjardins, Roxane1; Guérin, Brigitte2; Doueik, Alexandre3; Carmel,Michel3; Sabbagh, Robert31Institut de pharmacologie de Sherbrooke et Université de Sherbrooke, Sherbrooke, QC,Canada; 2Centre d’imagerie moléculaire de Sherbrooke et Université de Sherbrooke,Sherbrooke, QC, Canada; 3Centre hospitalier universitaire de Sherbrooke et Université deSherbrooke, Sherbrooke, QC, Canada

UP-048 Histopathological Features Following Prostate High Intensity FocusUltrasound Salvage Therapy for Radiation-failure

Autran Gomez, Ana Maria; Chang, Susanne; Gomez-Lemus, Jose; Lee, Linda; Izawa,Jonathan; Chin, JosephLondon Health Sciences Centre, University of Western Ontario, London, ON, Canada

UP-049 Insight into Dietary Prevention of Prostate Cancer: Effects of Fish Oiland Krill Oil on Inflammation

Moreel, Xavier; Dong, Ruijing; Julien, Pierre; Fradet, VincentLaval University, Quebec, QC, Canada

UP-050 Inconsistent Testosterone Monitoring and Antiandrogen Use inProstate Cancer Patients Receiving Androgen Deprivation Therapy

Dalla Nora, Sergio1; Shayegan, Bobby21Ferring Inc., North York, ON, Canada; 2Juravinski Cancer Centre, McMaster University,Hamilton, ON, Canada

UP-051 Single Nucleotide Polymorphisms (SNPs) Associated with LateRadiation Toxicity after Prostate Brachytherapy

Leong, Nelson1; Parliament, Matthew1; Martell, Kevin2; Ghosh, Sunita2; Pervez, Nadeem1;Pedersen, John1; Yee, Don1; Murtha, Albert1; Amanie, John1; Usmani, Nawaid11Cross Cancer Institute, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada

UP-052 Prostate Cancer Antigen 3 Density Shows Similar Predictive Value of Positive Prostate Biopsy as Prostate Cancer Antigen 3 Alone

Dovirak, Ostap1; Goode, Roland2; Marshall, Susan2; Consiglio, Joseph2; Duff, Michael2; Chevli,Kent21State University of New York at Buffalo, Department of Urology, Buffalo, NY, United States;2State University of New York at Buffalo, Buffalo, NY, United States

UP-053 Use of Patient Educational Technologies (PET) by Patients Diagnosedwith Prostate Cancer

Carlson, Kevin1; Crump, R. Trafford2; Baverstock, Richard11University of Calgary, Calgary, AB, Canada; 2University of British Columbia/Centre for HealthServices and Policy Research, Vancouver, BC, Canada


UP-054 Comparison of Pathological Outcomes of Radical Prostatectomy inAfrican Americans and Caucasians Who Are Potential Candidates forActive Surveillance

Popovic, Mihailo; Lucas, StevenWayne State University, School of Medicine, Urology, Detroit, MI, United States

UP-055 Ontario’s First 18th Choline Prostate PET Images: Histology and Multi-parametric MRI Correlation

Gibson, Eli1; Rachinsky, Irina2; Gaed, Mena3; Romagnoli, Cesare2; Lee, Ting-Yim1; Gómez, José A.4; Moussa, Madeleine4; Crukley, Cathie3; Chin, Joseph L.5; Bauman, Glenn S.6; Ward, Aaron D.71Robarts Research Institute, The University of Western Ontario, London, ON, Canada;2Department of Medical Imaging, The University of Western Ontario, London, ON, Canada;3Lawson Health Research Institute, London, ON, Canada; 4Department of Pathology, TheUniversity of Western Ontario, London, ON, Canada; 5Department of Urology, The University ofWestern Ontario, London, ON, Canada; 6Department of Oncology, The University of WesternOntario, London, ON, Canada; 7Department of Medical Biophysics, The University of WesternOntario, London, ON, Canada

UP-056 Laparoscopic Robot-assisted Extended Pelvic Lymph Node Dissectionfor High Risk Prostate Cancer

Bladou, Franck1; Luz, Murillo2; Anidjar, Maurice21McGill University, Jewish General Hospital, Montreal, QC, Canada; 2McGill University,Montreal, QC, Canada

UP-057 Comparative Morbidity between Salvage High Intensity FocusedUltrasound and Cryotherapy for Radiorecurrent Prostate Cancer

Al-Zahrani, Ali; Yutkin, Vladimir; Autran Gomez, Ana Maria; Chin, JosephDivision of Urology, Department of Surgery, London Health Sciences Centre, University ofWestern Ontario, London, ON, Canada

UP-058 A Nomogram Containing the NF-kappa B p65 Biomarker PredictsBiochemical Recurrence of Prostate Cancer Patients Following Radical Prostatectomy

Gannon, Philippe O.1; Lessard, Laurent1; Stevens, Louis-Mathieu2; Labouba, Ingrid1; Forest,Valérie1; Bégin, Louis R.3; Minner, Sarah4; Tennstedt, Pierre5; Schlomm, Thorsten5; Mes-Masson, Anne-Marie6; Saad, Fred71Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM), Montreal,QC, Canada; 2Division of Cardiac Surgery, CHUM, CRCHUM, Montreal, QC, Canada; 3Division ofAnatomic Pathology, Hopital Sacré-Coeur de Montréal, Montreal, QC, Canada; 4Institute ofPathology, University Medical Center Hamburg-Eppendorff, Hamburg, Germany; 5Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorff, Hamburg,Germany; 6CRCHUM / Institut du cancer de Montréal, Department of Medicine, Université deMontréal, Montreal, QC, Canada; 7Division of Urology, CHUM, Université de Montréal,CRCHUM, Montreal, QC, Canada

CUA 2012 BANFF 135


136 CUA 2012 BANFF

UP-059 Management of Post Radiation Therapy Complications amongProstate Cancer Patients: a Single Surgeon Experience

Flannigan, Ryan1; Baverstock, Richard21University of British Columbia, Vancouver, BC, Canada; 2vesia [Alberta Bladder Centre],Division of Urology, University of Calgary, Calgary, AB, Canada

UP-060 Salvage High Intensity Focused Ultrasound for Local Prostate CancerRecurrence after Brachytherapy

Alzahrani, Ali1; Yutkin, Vladimir2; Autran Gomez, Ana Maria2; Chin, Joseph21London Health Sciences Centre, London, ON, Canada; 2Division of Urology, Department ofSurgery, London Health Sciences Centre, University of Western Ontario, London, ON, Canada

UP-061 Holmium Laser Transurethral Incision of the Prostate (Hol-TUIP):Predictors of Long Term Outcome

Elshal, Ahmed; Elmansy, Hazem; Elhilali, MostafaMcGill University, Urology Department, Montreal, QC, Canada

UP-062 Evaluation of Autonomic Nervous System Activity by 24 Hour HolterMonitorization in Men with Benign Prostate Hyperplasia

Zorba, Orhan Ünal; Uzun, Hakki; Cicek, Yuksel; Kirbas, Serkan; Erdogan, Turan; Yazar, SelimRize University, Rize Medical Faculty, Rize, Turkey

UP-063 Randomized Double-blind Placebo Controlled Trial of IntradetrusorInjections of Botulinum Toxin for the Treatment of RefractoryOveractive Bladder Secondary to Benign Prostatic Hyperplasia

Elterman, Dean; Lee, Daniel; Sheth, Seema; Chughtai, Bilal; Lee, Richard; Kaplan, Steven; Te, AlexisWeill Medical College of Cornell University, New York, NY, United States

UP-064 Evaluation of Prostate Cancer Cells Responsiveness to an EGFRTargeting Combi-molecule

Poisson, Alexis; Delvoye, Nathalie; Le Page, Cecile; Peant, Benjamin; Mes-Masson, Anne-Marie; Saad, FredICM/CHUM, Montreal, QC, Canada

UP-065 Dynamic MRI Urethrography: Fluid Turbulence in a Urethral StrictureModel

Moles, Jonathan; Thornhill, Rebecca; Shabana, Wael; Saltel, EricThe Ottawa Hospital, Ottawa, ON, Canada


UP-066 Spicing up Radiation Treatment for Prostate Cancer

Venier, Natalie1; Colquhoun, Alexandra1; Loblaw, Andrew D.1; Fleshner, Neil2; Klotz, Laurence1;Venkateswaran, Vasundara11Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 2Princess Margaret Hospital,University Health Network, Toronto, ON, Canada

UP-067 Canadian Urology Resident Scholarly Performance

Andrews, J. Matthew; Norman, Richard W.Department of Urology, Dalhousie University, Halifax, NS, Canada

UP-068 Virtual Problem-based Learning (PBL): a Needs AssessmentExamining Traditional versus Virtual Problem-based Learning

Mickelson, Jennie1; Lim, Rachel2; Amandeep, Ghuman2; Gourlay, William2; Masterson, John2;MacNeily, Andrew2

1University of British Columbia , Department of Urologic Sciences, Vancouver, BC, Canada;2University of British Columbia, Vancouver, BC, Canada

UP-069 A National Survey of Chief Residents on the Communicator Role inUrology Residency: Are We Communicating the Message?

Roberts, Gregory; Fuoco, Michael; Beiko, Darren; Touma, Naji; Siemens, RobertQueen’s University, Urology, Kingston, ON, Canada

UP-070 Is Online Script Concordance Test a Good CPD Tool to InduceReflection on Controversial Issues in the Management of ProstateCancer?

Bénard, François1; St-Germain, France2; Lamoureux, Cristine1; Saad, Fred3; Charlin, Bernard11University of Montreal, Montreal, QC, Canada; 2Sanofi-Aventis Canada, Laval, QC, Canada;3Centre hospitalier universitaire de l’Université de Montréal (CHUM), Montreal, QC, Canada

UP-071 A Systematic Review on the Effect of Lysine Analogs on Blood Lossand Transfusion Requirements during Pelvic Surgery

Punjani, Nahid1; Kokolo, Madzouka B.2; Fergusson, Dean A.2; Cagiannos, Ilias3; Knoll, Gregory4; Momoli, Franco2; Morash, Chris3; Lavallée, Luke T.3; Tinmouth, Alan5; Breau, Rodney H.31University of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Institute, Ottawa, ON,Canada; 3University of Ottawa - Division of Urology, Ottawa, ON, Canada; 4University ofOttawa - Division of Nephrology, Ottawa, ON, Canada; 5University of Ottawa - Division ofClinical Hematology, Ottawa, ON, Canada

UP-072 Antibiotic Prophylaxis Prescribing Patterns for Trans-urethralResection of Prostate: a Need for Canadian Guidelines?

Lawson, Keith1; Vicas, Ingrid2; Hofmeister, Marianna2; Lockyer, Jocelyn2; Carlson, Kevin11Division of Urology, University of Calgary, Calgary, AB, Canada; 2Physician Learning Program,University of Calgary, Calgary, AB, Canada

CUA 2012 BANFF 137


138 CUA 2012 BANFF

UP-073 En Bloc Vascular Stapling of Renal Hilum during LaparoscopicNephrectomy

McKay, Jeffrey1; Goodman, Saul2; Neville, Christopher3; Cripps, Stephanie4; Perks, Alexandra41University of British Columbia, Chilliwack, BC, Canada; 2Fraser Health Authority, Chilliwack,BC, Canada; 3Fraser Health Authority, Abbotsford, BC, Canada; 4Fraser Health Authority,Langley, BC, Canada

UP-074 Evaluation of Autonomic Nervous System Activity by 24 Hour HolterMonitorization in Women with Idiopathic Overactive Bladder

Zorba, Orhan Ünal; Uzun, Hakki; Cicek, Yuksel; Kirbas, Serkan; Bostan, MehmetRize University, Rize Medical Faculty, Rize, Turkey

UP-075 Seasonal Variation in Urological Pelvic Pain Syndromes: Seven Yearsof Google™ Search Trends

Roberts, Gregory1; Williamson, Tyler2; Teichman, Joel3; Nickel, Curtis11Queen’s University Urology, Kingston, ON, Canada; 2Centre for Studies in Primary Care,Kingston, ON, Canada; 3Department of Urological Sciences, University of British Colombia,Vancouver, BC, Canada

UP-076 Sub-inhibitory Antibiotic Concentrations Negatively Affects Both theUropathogen Staphylococcus Saprophyticus and Host Imm uneResponses

Fahmy, Nader; Fuller, Andrew; Goneau, Lee; MacDonald, Kyle; Erdeljan, Petar; Bathini,Varunkumar; Razvi, Hassan; Cadieux, PeterThe University of Western Ontario, London, ON, Canada

UP-077 First Inflatable Penile Prosthesis Infections and a Proposed Survey forPost-implant Monitoring

Narayanan, Ramkishen; Aliotta, Jessica; Leung, Tony; Duff, Michael; Barlog, Kevin; Chevli, K. KentUniversity at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, United States

UP-078 How Many Semen Samples Are Required to Make the Diagnosis ofAzoospermia?

Khambati, Aziz1; Jarvi, Keith2; Lo, Kirk21University of Toronto Urology, Toronto, ON, Canada; 2Mount Sinai Hospital, Toronto, ON,Canada

UP-079 Fertility of Patients with a History of Bilateral Cryptorchidism Treated:a Comparative Study about 120 Patients

Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouziDepartment of Urology, Sahloul, Sousse, Tunisia


UP-080 Spectrum of Ureteropelvic Junction Obstruction (UPJO) MorphologicalCharacteristics from Infancy to Adulthood and Implications in SurgicalManagement

Romao, Rodrigo L.P.1; Foell, Kirsten2; Figueroa, Victor1; Lorenzo, Armando J.1; Farhat, Walid1;Pace, Kenneth T.2; Bagli, Darius1; Koyle, Martin1; Honey, R. John D’A.2; Pippi Salle, Joao L.11The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 2St. Michael’sHospital, University of Toronto, Toronto, ON, Canada

UP-081 The Challenge and Morbidity of Intermittent Ureteropelvic JunctionObstruction (IUPJO) in Children

Romao, Rodrigo L.P.; Figueroa, Victor H.; Pippi Salle, Joao L.; El-Naeema, Aziza; Lorenzo,Armando J.; Bagli, Darius; Farhat, Walid; Koyle, MartinThe Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

UP-082 Role of Magnetic Resonance Urography in Girls with UrinaryIncontinence: a Single Centre Experience

Figueroa, Victor H.; Chavhan, Govind; Romao, Rodrigo L.P.; Lee, Justin K.; Pippi Salle, Joao L.;Bagli, Darius J.; Koyle, Martin A.; Lorenzo, Armando J.; Farhat, Walid The Hospital for Sick Children, Toronto, ON, Canada

UP-083 Peristeen Anal Irrigation as a Substitute of Mace Procedure in ChildrenWho Are in Need of Reconstructive Bladder Surgery

Alhazmi, Hamdan; Alenezi, Husain; Salem, Mahmoud; Fouda Neel, KhalidKing Saud University, Riyadh, Saudi Arabia

UP-084 Hemorrhagic Cystitis Secondary to BK Virus: a Case Report ofManagement with Intravesical Cidofovir in the Pediatric Patient andReview of Literature

Bidnur, Samir; Wu, Christopher; Rassekh, Rod; Mickelson, Jennifer; MacNeily, AndrewUniversity of British Columbia, Vancouver, BC, Canada

UP-085 The Use of EMLA Cream During Circumcision: a Prospective Studyabout Sixty Children

Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouzDepartment of Urology, Sahloul, Sousse, Tunisia

UP-086 Glandular Amputation during Circumcision: a Review of 12 CasesResults of a New Technique for Glans Self-transplantation

Mallat, Faouzi; Hmida, Wissem; Hhidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Mosbah, Ali FaouziUrology, Sahloul, Sousse, Tunisia

CUA 2012 BANFF 139


140 CUA 2012 BANFF

UP-087 Cystic Intratesticular Lesions in Pediatric Patients: a RetrospectiveCase Series

Hoag, Nathan; Afshar, Kourosh; Youssef, David; Masterson, John; Murphy, James; MacNeily,AndrewUniversity of British Columbia, Vancouver, BC, Canada

UP-088 Retrospective Review of Diagnosis of Testicular Torsion in BoysPresenting to Pediatric Emergency Department with Acute ScrotalPain

Liang, Teresa1; Metcalfe, Peter2; Sevcik, William2; Noga, Michelle21University of British Columbia, Burnaby, BC, Canada; 2University of Alberta, Edmonton, AB, Canada

UP-089 Penoscrotal Lymphedema: Sexuality, Fertility, Functional and AestheticOutcome of the Surgical Treatment - Our Experience about 14 Cases

Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slam, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouziDepartment of Urology, Sahloul, Sousse, Tunisia

UP-090 Comparison of Apoptotic Gene Expression Profiles between Peyronie’sDisease Plaque and Control Tunica Albuginea

Zorba, Orhan Ünal1; Ozgon, Gulay2; Sirma, Sema2; Ozbek, Ugur2; Kadıoglu, Ates21Rize University, Rize Medical Faculty, Rize, Turkey; 2Istanbul University, Istanbul MedicalFaculty, Istanbul, Turkey

UP-091 Climacturia Post-prostatectomy Remains a Largely Unknown ClinicalEntity in Contemporary Urologic Training Based on Results Obtained at a Resident Training Laboratory

Zappavigna, Christopher1; Christine, Brian2; Bella, Anthony J.1University of Ottawa, Division of Urology, Ottawa, ON, Canada; 2Urology Centers of Alabama,Birmingham, AL, United States

UP-092 Post-prostatectomy Penile Rehabilitation and Erectile DysfunctionTreatment: Senior Resident Perceptions and Institutional PracticesBased on Results Obtained at a Resident Training Laboratory

Zappavigna, Christopher; Bella, Anthony J.University of Ottawa, Division of Urology, Ottawa, ON, Canada

UP-093 Leadership in Canadian Urology: What Is the Right Stuff?

Robinson, Michael; MacNeily, Andrew; McInnes, Colin; Lennox, Peter; Carr, Nicholas; Skarlicki,Daniel; Masterson, John; Arneja, JugpalUniversity of British Columbia, Vancouver, BC, Canada


UP-094 What Is the Best Local Anesthesia during Extracorporeal ShockwaveLithotripsy? Prospective Randomized Clinical Study Comparing EMLAand Lidocaine

Mallat, Faouzi; Hmida, Wissem; Hidoussi, Adnen; Slama, Adel; Jaidane, Mehdi; Ben Sorba,Nebil; Mosbah, Ali FaouziUrology, Sahloul, Sousse, Tunisia

UP-095 Trans-splenic Percutaneous Nephrolithotomy with SecondaryProcedure via the Same Tract

Bhojani, Naeem; Mandeville, Jessica A.; Boris, Ronald S.; Lingeman, James E.Indiana School of Medicine, Department of Urology, Indianapolis, IN, United States

UP-096 Uric Acid Stone Prevalence Doubles in the Severely and MorbidlyObese (BMI>35) Compared to the Overweight (BMI 25-30)

Sivalingam, Sri; Penniston, Kris; Nakada, Stephen Y.University of Wisconsin, Madison, WI, United States

UP-097 Targeted Intervention versus Conservative Intervention for thePrevention of Kidney Stone Recurrence

Arsovska, Olga; Wu, Christopher; Sutton, Roger A. L.; Paterson, Ryan F.; Chew, Ben H.University of British Columbia, Vancouver, BC, Canada

UP-098 Pulsed Fluoroscopy in Ureteroscopy and PercutaneousNephrolithotomy


UP-099 Laparoscopic Nephrectomy with Intact Specimen Extraction forMassive Polycystic Kidney Disease: Updated Technique and OutcomeAnalysis

Bansal, Rahul Kumar; Tu, Hin Yu Vincent; Kapoor, AnilMcMaster Institute of Urology, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada

UP-100 Urologists in Cyberspace: Evaluating Quality of American Urologists’Websites on the Internet

Yan, Hanmu; Margel, David; Fleshner, Neil; Wong, Lih-MingDepartment of Urology, Princess Margaret Hospital, Toronto, ON, Canada

UP-101 Robotic-assisted Microsurgery: the Initial 603 Case Experience

Gudeloglu, Ahmet; Priola, Karen; Parekattil, SijoUniversity of Florida and Winter Haven Hospital, Winter Haven, FL, United States

CUA 2012 BANFF 141


142 CUA 2012 BANFF

UP-102 Assessment of the Understanding of Androgen Deprivation Therapy(ADT) Associated Side Effects in Primary Care Physicians

Soeyonggo, Tony1; Locke, Jennifer1; Del Giudice, Lisa2; Alibhai, Shabbir3; Fleshner, Neil4;Warde, Padraig51Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Family andCommunity Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 3Departmentof Medicine, University Health Network, Toronto, ON, Canada; 4Department of Surgery(Urology), Princess Margaret Hospital, Toronto, ON, Canada; 5Department of RadiationOncology, Princess Margaret Hospital, Toronto, ON, Canada

UP-103 Senior Resident Perceptions of Industry Interaction with ProstheticUrologists Based on Results Obtained at a Resident TrainingLaboratory

Zappavigna, Christopher; Bella, Anthony J.University of Ottawa, Division of Urology, Ottawa, ON, Canada

UP-104 Factors Affecting Surgical Performance and Operating Room Safety in Urology: a Preliminary Evaluation

Lee, Jason Y.1; Gettman, Matthew2; Landman, Jaime3; McDougall, Elspeth M.3; Sundaram, Chandru P.4; Sweet, Robert5; Zorn, Kevin C.61St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 2Mayo Clinic, Rochester,MN, United States; 3University of California - Irvine, Orange, CA, United States; 4IndianaUniversity, Indianapolis, IN, United States; 5University of Minnesota, Minneapolis, MN, UnitedStates; 6University of Montreal (CHUM), Montreal, QC, Canada

UP-105 The Management of Post-transplant Lymphoceles: Changes in Practice at l’Hôtel-Dieu de Québec

Deschênes-Rompré, Marie-Pier; Diallo, Yoro; DeSerres, Sacha; Houde, Isabelle; Caumartin, YvesCentre hospitalier universitaire de Québec, Quebec, QC, Canada

UP-106 Factors Associated with an Increased Risk of Delayed Graft Functionin Donation after Cardiac Death Kidneys

Boyle, S.L.1; McGregor, Thomas B.2; Moser, Mike3; Sharpe, Mike3; Luke, Patrick31The University of Western Ontario, Department of Surgery, Division of Urology, London, ON,Canada; 2University of Manitoba, Department of Surgery, Division of Urology, Transplant andMIS, Winnipeg, MB, Canada; 3The University of Western Ontario, Department of Surgery,Division of Urology and Transplant, London, ON, Canada

UP-107 Debilitating Lower Urinary Tract Symptoms in the Post-renalTransplant Population Can Be Predicted Pre-transplantation

Dion, Marie; Cristea, Octav; Langford, Sarah; Luke, Patrick; Sener, AlpUniversity of Western Ontario, London, ON, Canada


UP-108 Thymoglobulin Differentially Increases CDR Naive T-cell ProliferationFollowing Renal Transplantation

Ullah, Shahnoor1; Telfer, Siobhan2; Mok, Amy3; Jevnikar, Anthony4; Luke, Patrick2; Sener, Alp51Schulich School of Medicine, The University of Western Ontario, London, ON, Canada;2Department of Surgery, The University of Western Ontario, London, ON, Canada; 3Departmentof Microbiology and Immunology, The University of Western Ontario, London, ON, Canada;4Department of Medicine, The University of Western Ontario, London, ON, Canada;5Department of Surgery, Department of Microbiology and Immunology, The University ofWestern Ontario, London, ON, Canada

UP-109 Retubularization of the Ileocystoplasty Pouch for Conversion into an Ileal Conduit Diversion

Massaro, Peter; Gajewski, Jerzy; Bailly, GregDepartment of Urology, Dalhousie University, Halifax, NS, Canada

UP-110 Conservative Management of High Post-void Residual Urine inAsymptomatic Men; Retrospective Analysis of Outcomes

Kalyanaraman, Balaji; Bracken, R. BruceUniversity of Cincinnati, Cincinnati, OH, United States

UP-111 No Show Rates for Follow-up after Visual Internal Urethrotomy: a Single Surgeon Experience

Patel, Premal1; Baverstock, Richard21University of Calgary, Calgary, AB, Canada; 2vesia [Alberta bladder centre], Calgary, AB,Canada

UP-112 Genitourinary Tuberculosis or Not Genitourinary Tuberculosis: Case Series and Critical Look at the Challenging Diagnosis ofGenitourinary Tuberculosis

Boyle, Shawna1; Amman, Justin2; Chin, Joseph3; Paulter, Stephen3; Denstedt, John3; Izawa,Jonathan3; Razvi, Hassan31University of Western Ontario, London, ON, Canada; 2Department of Medical Imaging, TheUniversity of Western Ontario, London, ON, Canada; 3Division of Urology, Department ofSurgery, The University of Western Ontario, London, ON, Canada

UP-113 Common Urological Presentations of the Penitentiary Populationin Kingston: a Chart Review

Lee, Taehyoung; Leveridge, Michael; Touma, NajiQueen’s University, Kingston, ON, Canada

CUA 2012 BANFF 143


144 CUA 2012 BANFF

UP-114 Targeted Robotic-assisted Microsurgical Denervation of the Spermatic Cord for Chronic Orchialgia

Gudeloglu, Ahmet; Wharton, Jessica; Priola, Karen; Parekattil, SijoUniversity of Florida and Winter Haven Hospital, Winter Haven, FL, United States

UP-115 Should Large Adrenal Myelolipomas (>6cm) Be Removed? Case Series and Review of Literature

Michael, Amanda; Elias, Rami; Kapoor, AnilMcMaster University, Hamilton, ON, Canada

UP-116 Withdrawn


CUA 2012 BANFF 145

Bailly, Greg G. EF5

Bénard, François EF8

Brock, Gerald EF8

Carlson, Kevin EF5

Chetner, Michael AUA, welcome

Donnelly, Bryan EF6

Dushinski, John EF1

Fleshner, Neil EF6, EF7

Foster, Richard SOA3

Izawa, Jonathan EF3

Jacobsen, Niels CP1

Jarvi, Keith CUASS

Jordan, Gerald EF2, SOA2

Kapoor, Anil CP2

Kassouf, Wassim EF3

Kodama, Ron EF2

McVary, Kevin SOA6

Monga, Manoj SOA1

Moyad, Mark SOA5

Nguyen, Hiep SOA8

Nickel, Curtis EF4, EF8

Nitti, Victor EF5, SOA7

Rourke, Keith EF2

Satava, Richard SOA9

Schuler, Trevor EF1

Shayegan, Bobby EF3

Schoenberg, Mark SOA4

Siemens, Robert EF6

So, Alan EF7

Sogani, Pramod C. AUA

Whelan, Paul EF4

INVITED SPEAKERS INDEX / INDEX DES CONFÉRENCIERS INVITÉS

146 CUA 2012 BANFF

AAbdulla, Alym POD-04.03

Ajzenberg, Henry UP-015

Akhter, Waseem UP-003

Al Esawi, Anwar UP-010

Alamri, Abdulaziz MP-03.10

Alhazmi, Hamdan UP-083

Allard, Christopher MP-03.01, MP-03.16, UP-027

Alyami, Fahad MP-03.11

Al-Zahrani, Ali UP-057, UP-060

Andrews, J. Matthew UP-067

Aprikian, Armen UP-022

Archambault, Jason POD-01.02

Arsovska, Olga MP-02.16, UP-097

Autran Gomez, Ana Maria MP-01.12, MP-06.05, UP-048

BBach, Phil MP-04.03

Bachir, Bassel G. POD-02.03, MP-03.03

Bacsu, Chasta-Dawne POD-04.04, MP-04.02

Barrett, Keith MP-04.07

Baverstock, Richard MP-04.09, MP-04.23

Bénard, François UP-070

Bhindi, Bimal UP-043

Bhojani, Naeem MP-02.01, MP-02.02, MP-02.15, MP-02.17, UP-026, UP-095

Bidnur, Samir UP-084

Binsaleh, Saleh MP-04.08

Bishr, Mohamed MP-03.14, MP-07.12

Black, Peter POD-03.06, MP-09.07

Bladou, Franck UP-004, UP-056

Blais, Jean-Philippe UP-006

Blouin, Annie-Claude MP-03.12

Bostrom, Peter J. MP-07.09

Boyle, Shawna UP-106, UP-112

Braga, Luis POD-03.03, MP-05.06

PRESENTER INDEX / INDEX DES PRÉSENTATEURS

CUA 2012 BANFF 147

CCampeau, Lysanne MP-09.05, MP-09.06

Carlson, Kevin MP-04.22

Chang, Michelle MP-04.18

Chapman, David MP-09.02

Chien, Gary MP-01.20, UP-036

Chin, Joseph L. UP-055

Choo, Richard MP-07.11

Cloutier, Jonathan MP-05.04

Cole, Eric MP-01.07, MP-05.08

Cox, Ashley MP-04.20

Crump, R. Trafford UP-053

DDason, Shawn MP-01.11, MP-01.21

Davis, Jeffrey MP-02.03, MP-03.23

Day, Robert UP-047

De, Shubha MP-02.12

Desantis, Darren POD-02.06

Deschênes-Rompré, Marie-Pier UP-105

Dion, Marie UP-107

Djahangirian, Orchidée UP-001

Donnelly, Bryan POD-05.06

Dovirak, Ostap UP-052

EElharram, Malik UP-024

Elhilali, Mostafa UP-007

Elias, Rami MP-02.19

Elkoushy, Mohamed POD-01.04, MP-02.07, MP-02.09, MP-02.18, UP-098

Elliott, Daniel MP-08.10

Elsawy, Mohamed MP-05.10

Elshal, Ahmed UP-061

Elterman, Dean MP-04.19, UP-063


148 CUA 2012 BANFF

FFahmy, Nader UP-076

Fairey, Adrian POD-05.04, MP-03.05

Figueroa, Victor H. MP-05.01, MP-05.14, UP-082

Finelli, Antonio UP-019

Flannigan, Ryan UP-059

Fleshner, Neil UP-102

Foell, Kirsten MP-02.05

Fortin, Israel UP-041

Fuoco, Michael UP-069

GGagnon, Louis-Olivier MP-01.14, UP-028, UP-029

Gajewski, Jerzy MP-04.17

Garcia, Francisco MP-06.02, MP-06.03

Garcia, Maurice POD-04.05

Gudeloglu, Ahmet MP-06.07, UP-101, UP-114

Gustafson, Paul MP-04.05

H-IHamidizadeh, Reza MP-02.10

Hamilton, Robert POD-02.04

Han, Kyungseok MP-09.01, MP-09.03

Heimrath, Olivier P. UP-039

Herschorn, Sender MP-04.11, MP-04.12

Hoag, Nathan UP-087

Hoy, Nathan MP-04.10, MP-05.13

Huon, Yannick UP-042

Ismail, Salima MP-03.13

Izard, Jason MP-01.16, MP-01.17, MP-07.03, MP-08.11

J-KJewett, Michael A.S. UP-013

Kaler, Kamaljot MP-08.01

Kalyanaraman, Balaji UP-110

Kanaroglou, Niki MP-05.07


CUA 2012 BANFF 149

Kapoor, Anil MP-03.09

Khambati, Aziz UP-078

Khan, Faisal MP-07.08, UP-020

Kinnaird, Adam S. POD-04.06

Klinghoffer, Zachary POD-01.05, MP-06.08

Klotz, Laurence UP-066

Kumar, Surendra UP-031

LLabouba, Ingrid MP-09.10, UP-058

Langille, Gavin MP-06.09

Lavallée, Luke MP-01.19

Lawson, Keith MP-03.07, UP-072

Lee, Jason Y. UP-104

Lee, Taehyoung UP-113

Leong, Nelson UP-051

Levine, Max A. MP-04.06

Liang, Teresa UP-088

Lobb, Ian MP-03.18

Longpre, Michelle UP-030

MMaciejewski, Conrad MP-05.12

MacLellan, Dawn MP-09.04

Mallat, Faouzi UP-079, UP-085, UP-086, UP-089, UP-094

Margel, David MP-01.02, MP-09.08, UP-025, UP-040

Massaro, Peter MP-02.20, UP-109

McKay, Jeffrey UP-073

Melnyk, Megan MP-08.04, MP-08.06

Metcalfe, Charles MP-03.15, UP-034

Metcalfe, Michael MP-03.02

Michael, Amanda UP-008, UP-115

Mickelson, Jennifer J. UP-068

Moles, Jonathan UP-065


150 CUA 2012 BANFF

Morales, Alvaro MP-07.01

Morales, Carlos MP-03.08

Moreel, Xavier UP-049

NNam, Robert POD-05.05

Narayanan, Ramkishen UP-077

Nayak, Jasmir POD-05.03, UP-011, UP-023

Nguyen, Laura MP-08.02

Nguyen, Tim MP-08.05

Nickel, J. Curtis MP-08.07, MP-08.08, UP-075

Nitti, Victor POD-04.01

North, Scott POD-02.02

O-POlesen, Jamie POD-03.02

Ordon, Michael POD-01.01, MP-03.17, MP-03.19

Patel, Premal UP-111

Pippi Salle, Joao L. MP-05.09

Poisson, Alexis UP-064

Popovic, Mihailo MP-04.04, UP-054

Pouliot, Frédéric MP-09.11

Preston, Mark A. POD-05.02, MP-01.09

Punjani, Nahid UP-002, UP-071

Punnen, Sanoj MP-01.04, MP-01.10, MP-01.15, UP-037, UP-038

RRamsay, Sophie MP-04.21

Razvi, Hassan POD-01.06

Rhee, Jonathan MP-07.06

Robinson, Michael MP-02.11, UP-093

Rocha, Joice UP-021

Romao, Rodrigo L.P. POD-03.01, UP-080, UP-081

Rourke, Keith MP-08.09

Rowe, Neal MP-01.01

Rutkowski, John UP-009


CUA 2012 BANFF 151

SSaad, Fred POD-02.01, POD-05.01

Sandhu, Gurdarshan MP-07.04, MP-07.05, MP-07.07, UP-005

Shamloul, Rany MP-06.01

Shayegan, Bobby UP-050

Sheikh, Adeel MP-05.02

Sheridan-Jonah, Anna UP-017

Siemens, D. Robert MP-01.22, UP-032

Sivalingam, Sri MP-02.04, MP-02.06, MP-02.08, MP-02.14, UP-096

Skeldon, Sean MP-01.18, MP-06.04

Spelliscy, Courtney MP-05.11

Stakhovskyi, Oleksandr MP-07.10

Stearns, Gillian MP-05.03

Steele, Stephen S. MP-04.13

Stothers, Lynn MP-04.14, MP-04.15

Suntharasivam, Thiru MP-01.05

TToren, Paul POD-02.05, MP-04.01, UP-046

Tran, Kim-Chi MP-03.21

Tse, Richard UP-014

Tu, Hin Yu Vincent UP-099

U-V-WUllah, Shahnoor UP-108

van Rhijn, Bas W.G. MP-09.09

Violette, Philippe POD-03.05

Wang, Xinmin MP-04.16

Weber, Bryce POD-03.04

Welk, Blayne MP-08.03, MP-08.12

Wildgoose, Petra MP-05.05

Wong, Carson UP-035

Wong, Lih-Ming MP-01.06, MP-01.08, UP-033


152 CUA 2012 BANFF

Y-ZYafi, Faysal A. MP-07.02

Yan, Hanmu UP-100

Yanko, Daniel MP-03.22

Yap, Stanley MP-03.04, MP-03.06

Yutkin, Vladimir MP-01.03

Zadra, Joseph POD-01.03

Zappavigna, Christopher MP-06.06, UP-016, UP-091, UP-092, UP-103

Zareba, Piotr UP-012

Zhu, Justin MP-03.20

Zorba, Orhan Ünal UP-062, UP-074, UP-090

Zorn, Kevin POD-04.02, MP-01.13


CUA 2012 : Final Programme

Documents

Transcript of CUA 2012 : Final Programme